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ABSTRACT 
Parkinson’s Disease (PD) is a progressively debilitating neurodegenerative disease that affects 
the central nervous system and leads to severe difficulties with body movements. PD occurs due 
to the selective degeneration of neurons in the region of the brain known as the substantia nigra 
pars compacta. To date PD remains an incurable disease. Currently prescribed drugs provide 
only symptomatic relief to patients. Furthermore, they have considerable side effects and are 
often ineffective in the later stages of the disease or need to be used in combination in order to be 
effective. The role of neuroprotectants as a preventative measure in PD therapy is consequently 
receiving a great deal of attention and is being subjected to extensive research.  This study 
sought to develop a novel prolonged-release drug delivery device for providing site-specific 
administration of newly researched neuroprotective agents. Nicotine was employed as the model 
neuroprotectant to incorporate in a novel reinforced crosslinked multiple-unit multi-polymeric 
drug delivery device. The study was the first of its kind to develop and employ the alkaloid for 
this purpose in a formulated delivery system. The device was intended to be one that provided 
zero-order prolonged release of the drug over a period of 1-2 months. The device was formulated 
such that its design was in keeping with the potential for implantation into the substantia nigra 
pars compacta to provide site-specific drug delivery. In order to do so, polymers, with 
biocompatible and bioerodable characteristics were selected to incorporate the drug within a 
reinforced crosslinked matrix. The study elucidated the mechanism of crosslinking of 
ionotropically crosslinked alginate spheres (gelispheres) with a variety of crosslinking agents 
through an evaluation of physicomechanical properties of the crosslinked system. The presence 
of barium in the crosslinked matrices generated densely networked gelispheres which retained 
their robustness following exposure to hydrating media and displayed promising potential for 
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entrapping drug molecules and retarding their release. The system was reinforced employing 
hydroxyethylcellulose (HEC) and polyacrylic acid (PAA). A Design of Experiments approach 
employing a Plackett-Burman screening design enabled optimisation of the proposed device in 
terms of reinforcing polymers (HEC and PAA) and crosslinking agents (barium and calcium). In 
order to further attenuate drug release rate the optimised crosslinked gelispheres were exposed to 
dilute hydrochloric acid (HCl) which significantly decreased gelisphere matrix swelling and 
erosion following exposure to simulated cerebrospinal fluid (CSF). These gelispheres were 
thereafter incorporated into a compressed release-rate modulating polymeric discs. Zero-order 
drug release was observed for a period of 50 days in simulated CSF when the optimised 
gelispheres were incorporated into compressed poly(lactic-co-glycolic) acid (PLGA) discs. 
Alternative approaches to modify drug release kinetics were also evaluated including the use of 
PLGA coatings on compressed hydroxypropylmethylcellulose-polyethylene oxide (HPMC-PEO) 
discs incorporating gelispheres and the use of crosslinked alginate-pectinate gelispheres as 
carrier systems to deliver PLGA-PLA (polylactic acid) microparticles incorporating drug. A 
Box-Behnken statistical design was employed to formulate and optimise the drug carrying 
PLGA-PLA microparticles. In both of the abovementioned cases we obtained sustained zero-
order drug release. 
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SUMMARY 
 
Configuration of Crosslinked Polyspheres for Site-Specific Delivery of Neuroprotectants 
Parkinson’s Disease (PD) is a progressively debilitating neurodegenerative disease that occurs 
due to the selective degeneration of neurons in the region of the brain known as the substantia 
nigra and leads to severe difficulties with body movements. To date PD remains an incurable 
disease. This study sought to develop a novel prolonged-release drug delivery device for 
providing site-specific administration of a newly researched neuroprotective agent, nicotine, 
incorporated in a novel reinforced crosslinked multiple-unit polyspheric drug delivery device. 
The device was intended to be one that provided zero-order prolonged release of the drug over a 
period of a few months. In order to do so, polymers, with biocompatible and bioerodable 
characteristics were selected to encapsulate the drug within a reinforced crosslinked matrix. The 
study elucidated the mechanism of gelation of ionotropically crosslinked alginate spheres 
(gelispheres) within a unique combination of reinforcing biopolymers, hydroxyethylcellulose 
(HEC) and polyacrylic acid (PAA) which was formulated employing a variety of crosslinking 
agents. A Plackett-Burman screening design enabled identification of independent factors which 
influenced the behaviour of the proposed device in terms of drug release (DR) and drug 
entrapment efficiency (DEE). In order to attenuate DR, matrix swelling and disintegration, the 
optimised crosslinked gelispheres were exposed to dilute HCl. The optimised gelispheres were 
incorporated into release-rate modulating compressed polymeric discs. Alternative approaches to 
modify drug release kinetics were also investigated including the use of PLGA coatings on 
compressed polymeric discs incorporating gelispheres and the use of crosslinked gelispheres as 
carrier systems to deliver PLGA-PLA microparticles incorporating nicotine.  
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Chapter 1  
Parkinson’s Disease – The Benefits of a Novel Drug Delivery System for 
Neuroprotective Agents 
 
‘Involuntary tremulous motion, with lessened muscular power, in parts not in action and even 
when supported; with a propensity to bend the trunk forwards, and to pass from a walking to a 
running pace: the senses and intellects uninjured.’  
 
- An Essay on the Shaking Palsy, Dr. James Parkinson, 1817 
1.1 Introduction 
Parkinson’s Disease (PD) or Paralysis Agitans was first documented in 1817 by Dr James 
Parkinson as the “shaking palsy” that afflicted his gardener who led a life of “sobriety” (Critchley, 
1955). Since then the relationship between personality and the potential for developing PD has 
been extensively investigated. The inverse relationship between the “novelty-seeking” personality 
(verses the law-abiding, contentious and cautious “reduced-novelty seeking” personality displaying 
a ‘certain intellectual and moral rigidity’ (Critchley, 1955)) and subsequent development of PD is 
widely documented (Menza et al., 1990; Menza et al., 1992; Benedetti et al., 2000). Smoking, 
alcohol, coffee, cocaine, amphetamine and opiate abuse have all been shown to have somewhat of 
a preventative effect in the onset of PD (Paulson and Dadmer, 1991; Menza et al., 1993; Fujii at 
al., 2000). As a direct paradox, to this phenomenon, currently prescribed drugs for managing this 
condition have now been demonstrated to have a link between patients seeking a “reward-seeking” 
lifestyle subsequent to initiating therapy (Uitti et al., 1989; Dodd et al., 2005; Klos et al., 2005; 
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Stocchi, 2005). Such etiological data only confirms the pathological affliction associated with PD 
by depletion of the ‘rewarding’ dopaminergic neurons in the brain.    
 
 
PD is a disease of the central nervous system (CNS) that leads to severe difficulties with body 
motions. Typical symptoms include tremor, rigidity, slowed body movements (bradykinesia), 
unstable posture and difficulty in walking (characterized by the patient’s shuffling gait). To date 
PD remains an incurable disease. The currently available pharmacological and non-
pharmacological treatments are able to offer only symptomatic relief for patients (Katzung, 2001). 
Available therapies aim to improve the functional capacity of the patient for as long as possible; 
however they do not modify the progression of the neurodegenerative process. The need for newer 
and more effective agents is consequently receiving a great deal of attention and consequently 
being subjected to extensive research. 
 
 
In neuropathological terms, PD is characterized by the presence of intracytoplasmic inclusions 
from protein aggregates called Lewy bodies (LBs) (Burke, 1998) and the depletion of pigmented 
DA-containing neurons in the region known as the substantia nigra pars compacta (Forno, 1996). 
LBs consist of a heterogeneous mixture of proteins and lipids. The lipoidal core of these inclusions 
is surrounded by the peripheral filamentous elements which can comprise a variety of proteins, 
including ubiquitin, neurofilament, various proteasomal elements, and α-synuclein, which may be 
oxidatively modified (Fahn and Cohen, 1992; Zhang et al., 2000). Approximately 80% of 
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dopaminergic neurons in the susbtantia nigra are already irreversibly destroyed when the first 
symptoms of PD become significantly visible.   
 
 
Affecting one in every 100 persons above the age of 65 years, it is the second most common 
neurodegenerative disease after Alzheimer's disease (de Rijik, et al., 2000). Apart from a 
documented relationship between personality-type, PD generally presents itself in the population as 
a sporadic condition. However an atypical presentation arising from gene defects inherited, by 
Mendelian trait have also been observed (Lev and Melamed, 2001; Vila and Przedborski, 2004). 
Among such inherited forms, abnormalities in the genes coding for the protein α-synuclein have 
been documented (Polymeropulous et al., 1997). Secondary causes of this condition include 
infection (post-encephalitic PD), drugs (e.g. antipsychotics such as haloperidol and thiordazine, 
antiemetics such as promethazine and metaclopramide (Standaert and Young, 2001)), chronic 
intoxication (among many substances, manganese and more rarely carbon bisulphide or carbon 
monoxide (Critchley, 1955)) and stroke.  
 
 
Over the past few decades a large volume of data generated from clinical studies, autopsies and in 
vitro and in vivo experimental models have been accumulated, which has allowed us to gain some 
understanding of the pathogenesis of sporadic PD. Studies that have investigated this multifactorial 
cascade have thus far been primarily, if not exclusively, studied in toxic experimental animal 
models of PD, in particular from models that have been produced by the parkinsonian neurotoxin 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Emborg, 2004).  
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Studies demonstrated that soon after the systemic administration of MPTP, its active metabolite, 
MPP+, (1-methyl-4-phenylpyridinium ion) (Srivastava et al., 1993), concentrates in the 
mitochondrial matrix, where it binds to complex I of the electron transport chain (ETC) (Gluck et 
al., 1994). This binding interrupts the movement of electrons along the ETC, leading to an 
increased production of reactive oxygen species (ROS), particularly superoxide radicals (Figure 
1.1). This MPP+-related disruption in electron flow is consequently associated with a drop in 
adenosine triphosphate (ATP) production. This phenomenon is found only in susceptible areas of 
the brain such as the ventral midbrain and striatum (Khan et al., 2005).  
 
Figure 1.1: Summary of the pathological process involved in PD (Source: Adapted from Dipiro 
et al., 2001). Abbreviations DOPAC: 3,4-dihydroxyphenylacetic acid; MAO-B: monoamine 
oxidase inhibitor B; GSH: glutathione; GSSH: glutathione disulfide; H2O2: hydrogen peroxide; 
OH. : hydroxyl free radical and OH- hydroxyl ion.  
 
In addition to aggravating mitochondrial oxidative stress and energy depletion, MPP+ also interacts 
with synaptic vesicles by binding to vesicular monoamine transporter-2 (Przedborski and Jackson-
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Lewis, 1998; Przedborski, 2005). Thus, MPP+ translocates into synaptic vesicles and stimulates the 
release of synaptic DA (Fabre et al., 1999). The resulting extruded cytosolic DA readily undergoes 
autoxidation, thus generating a burst of ROS, subjecting nigral neurons to oxidative stress (Fabre et 
al., 1999).  Some theories suggest that the oxidation of cytosolic DA could also be catalyzed by 
enzymes such as cyclo-oxygenase-2 (Teismann and Ferger, 2001). 
 
With reference to Figure 1.1, studies by Fahn and colleagues (Fahn, 1991; Fahn, 1992a; Fahn and 
Cohen, 1992b) have described the role of the oxidative pathway on dopaminergic neuronal 
degeneration and the role that antioxidants may play in the prevention of PD. Finally, the role of 
glutathione (GSH) in the degradation of DA neurons has been described by Bharath and colleagues 
(2002). They reported that age-related depletion in GSH levels may precipitate the accumulation of 
oxidizing free radicals such as hydrogen peroxide, hydroxyl ions and superoxide in the brain.  This 
depletion in GSH has been attributed to the progressive mitochondrial dysfunction in the brain 
which has a drastic impact on ATP synthesis and usage. Furthermore, it enhances the formation of 
the LBs described earlier. Figure 1.2 summarizes the role that antioxidants may play in the 
treatment of PD. 
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Figure 1.2: A schematic of free radical involvement as a common intermediary risk factor for 
many neurotoxic events in the pathogenesis of PD. Abbreviations: mtDNA: mitochondrial DNA 
(Source: Adapted from Prasad et al., 1999). 
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1.2 Current Therapies and their Limitations 
There is no cure for PD, since currently available therapies can neither arrest nor reverse the 
progression of the disease. However, the symptoms can be managed with several different drugs. 
The drugs used to treat PD either boost the levels of DA in the brain or mimic the effects of DA.  
 
Figure 1.3: Sites of action of pharmacological therapies currently prescribed for PD (Source: 
Adapted from Katzung, 2001). 
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Most patients who begin treatment with only a DA receptor agonist eventually need to add 
levodopa within a few years (Silver and Ruggieri, 1998). To minimize side effects, very low doses 
are used initially and gradually titrated up. It is significant to mention here that exposure of patients 
to the ‘gold standard’ of PD therapy (Mercuri and Bernardi, 2005), levodopa results in fluctuations 
of motor responses in approximately 30-50% of patients exposed to therapy for as little as 5 or 
more years (Hutton and Morris, 1995). The most common fluctuation experienced is the so called 
‘on-off’ phenomenon that results in an unpredictable transient loss of therapeutic effect (Riley and 
Lang, 1993). Furthermore, older patients can be particularly sensitive to the adverse effects of these 
drugs, which may cause symptoms of confusion, hallucinations, orthostatic hypotension and 
fatigue. Apart form levodopa, drugs that are currently prescribed for the management of PD 
include DA receptor agonists, selegiline, amantadine, catechol-O-methyl transferase (COMT) 
inhibitors and anticholinergics. Table 1.1 highlights the relative benefits of the currently prescribed 
therapies.  
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Table 1.1: Currently prescribed drugs for the management of PD symptoms and their limitations. 
LEVODOPA SELEGILINE AMANTADINE ANTICHOLINERGICS DA RECEPTOR AGONISTS COMT INHIBITORS 
This is the key compound in the 
treatment of PD, acting as a precursor 
of DA. When levodopa is administered 
orally it is rapidly decarboxylated and 
only a small portion of the dose enters 
the CNS unchanged. Thus a high dose 
is required for the desired effect; this 
induces nausea and vomiting in the 
sufferer. Cardiac arrhythmias are also a 
concern for patients with a history of 
heart disease. It has also been linked to 
depression, insomnia, agitation and 
anxiety (Obeso et al., 2000; Olanow et 
al., 2004; Jankovic, 2005).  In some 
cases dyskinesias can be so severe that 
they impede speech, swallowing, 
respiration, and balance (Koller and 
Hubbard, 1990).  
 
Although levodopa reduces many of the 
motor symptoms of PD, it does not 
affect non-motor symptoms (Cools, 
2005) nor is it able to halt the 
progression of the degeneration of 
dopaminergic nigral neurons. 
Fluctuations in drug response are a 
common phenomenon. For many 
patients, however, after 4 to 6 years of 
therapy, there is an ever-shortening 
duration of response to levodopa. These 
so called ‘off’ periods are marked by 
severe akinesia that can extend over 
many hours (Brotchie et al., 2005). This 
commonly requires an adjustment of the 
dose of levodopa and “drug holidays” 
to allow for continuation of the therapy 
(Forzese, 1997; Jankovic, 2000). The 
optimal period for such an intervention 
is extremely patient specific. Even in 
those patients that do respond 
favourably, subsequent recurrences and 
fluctuations in the ‘on-off’ phenomenon 
are not uncommon and in many 
instances the beneficial effects are short 
lived (Olanow et al., 2004). 
This monoamine oxidase B 
(MAO-B) inhibitor prevents the 
metabolism of DA in the body. 
As a result when used in 
combination with levodopa, it 
enhances and prolongs its 
antiparkinsonian effects. Thus 
allowing for the dose of levodopa 
to be reduced. Its main use is as 
adjunctive therapy with levodopa 
to allow a reduction in the 
fluctuating response that patients 
experience with its long term use. 
Some studies have shown that it 
may protect neuronal cells from 
the consequences of oxidative 
stress (Wadia et al., 1998, Am et 
al., 2004, Yamada and Yasuhara, 
2004, Magyar and Szende, 2004; 
Mandel et al., 2005) and 
promoting the release of neural 
growth factors (Kontkanen and 
Castrén, 1999; Mizuta et al., 
2000).  
The underlying mechanism is 
believed to be associated with 
decreased hydrogen peroxide 
(H2O2) (Magyar and Szende, 
2004). Studies suggest that 
concurrent use with levodopa 
may lead to potentiated adverse 
effects. On its own it has been 
shown to cause insomnia in 
patients when taken later during 
the day. Studies do suggest that 
Selegiline may retard disease 
progression and significantly 
delays the need for levodopa 
(Cohen and Spina, 1989; Rinne 
et al., 1991; Macleod et al., 
2005). However it has only been 
shown to have a mild therapeutic 
effect on the management of PD 
when used alone (Katzung, 
2001). 
Amantadine, an antiviral 
agent, was found by chance 
to be effective in PD. Studies 
regarding the current use of 
this agent have shown that it 
is particularly effective in 
reducing dyskinesias. These 
effects are thought to be 
mediated by its anti-
glutamate action (Stoof et al., 
1992). Amantadine is 
thought to either promote the 
release, prevent the reuptake 
or have an influence on the 
synthesis of DA. Its exact 
mechanism is however still 
unclear. However, 
amantadine has the potential 
to have an extremely 
detrimental effect on 
cardiovascular diseases and 
even induce seizures in 
susceptible patients (Factor 
and Molho, 1999). Its CNS 
effects include restlessness, 
depression, confusion and 
hallucinations (Katzung, 
2001). Due to the nature of 
PD the patients that are more 
susceptible to the disease i.e. 
mainly the elderly, find these 
side effects to be intolerable. 
 
Its main disadvantages lies in 
the fact that it is less potent 
than levodopa and its 
benefits may work only 
briefly in some patients who 
have mild symptoms of the 
disease (Factor and Molho, 
1999). 
Anticholinergic medications, 
such as trihexyphenidyl or 
benztropine, are specifically 
effective against tremor.   In 
a recent review from the 
Cochrane database, studies 
do not strongly support that 
a anticholinergic agents have 
a potentially better effect on 
tremor than on other 
outcome measures 
(Katzenschlager et al., 
2003). In addition, these 
agents have little influence 
on reducing bradykinesia or 
akinesia (Comella and 
Tanner, 1995) in patients.  
 
The adverse effects of these 
medications often limits 
their dosing. Adverse effects 
such as fatigue, drowsiness, 
confusion, agitation and 
hallucinations, particularly 
in elderly PD patients are 
common (Katzung, 2001). 
Other side effects such as 
postural hypotension, dry 
mouth, blurred vision, 
urinary retention, nausea and 
vomiting, constipation, 
palpitations and cardiac 
arrhythmias may also occur. 
Effects on memory have 
also been documented as 
well as an increased 
sensitivity to dementia 
(Comella and Tanner, 1995). 
Furthermore, abrupt 
withdrawal leads to 
precipitation of acute 
parkinsonian symptoms. 
 
DA receptor agonists can be 
divided in two main classes: the 
ergot derivatives like 
bromocriptine, pergolide, lisuride, 
cabergoline and the non-ergot 
derivatives like ropinirole, 
pramipexole, apomorphine or 
piribedil. They may be used alone 
to delay the need for levodopa, or 
may be used with levodopa to 
increase its effectiveness.  Some 
studies have suggested a 
neuroprotective effect exhibited 
by these agents (Schapira, 2002a; 
2002b; Schapira and Olanow, 
2003; Schapira, 2003). 
 
Although these agents do 
demonstrate effectiveness in 
managing symptoms when used 
alone, they are riddled with side 
effects for the patient. While the 
ergot derivatives have the 
potential to cause psychiatric 
disturbances and CVS problems 
that can progress in certain 
instances to a myocardial 
infarction and subsequent death. 
Even when administered at lower 
doses patients experience 
orthostatic hypotension,   
constipation, dyskinesias, 
confusion and insomnia (Katzung, 
2001; Wong et al.; .2003).  The 
efficacy of DA agonists used as 
monotherapy in early stage of PD 
has been demonstrated in 
numerous studies (Clarke and 
Guttmen, 2002). However, as 
disease progresses, it becomes 
essential to add levodopa, to 
achieve a better therapeutic effect 
(Wong et al., 2003).  
COMT inhibitors are used 
mainly in combination with 
levodopa. Examples of COMT 
inhibitors include entacapone 
and tolcapone.  
 
Once again the side effect 
profile cannot be dismissed. 
The incidence of sleep 
disturbances, orthostatic 
hypotension, dyskinesias, 
confusion and insomnia are 
common. Although tolcapone 
is efficacious in the control of 
motor fluctuations (Rajput et 
al., 1997), there have been 
increasing concerns about its 
safety, and in particular its 
potential hepatotoxicity (Assal 
et al., 1998) and due to this its 
use has been restricted in 
many countries. In contrast, 
entacapone has not been 
associated with changes in 
liver function.  Entacapone in 
particular, provides a valuable 
therapeutic tool for the 
management of PD patients 
with motor fluctuations 
(Gershanik et al., 2003; 
Schrag, 2005). It is also 
believed that co-
administration of levodopa 
with a COMT inhibitor in 
early PD patients may delay 
the onset of wearing off 
phenomenon by limiting any 
abrupt fluctuations in plasma 
levodopa levels (Gershanik et 
al., 2003; Schrag, 2005).  
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1.3 Neuroprotection as a Treatment Strategy for the Management of PD 
It is estimated that the loss of dopaminergic neurons in the substantia nigra pars compacta are as 
much as 70-80% by the time diagnosis is made. Given this prolonged course of progressive 
neuronal loss, strategies aimed at reducing the rate of neuronal loss or dysfunction (i.e. clinical 
neuroprotection or disease-modification) are particularly important in this disorder. Effective 
clinical neuroprotection would importantly reduce PD-related disability for thousands of patients. 
In 2001, this prompted the National Institute of Neurological Disorders and Stroke (NINDS) at the 
National Institute of Health (NIH) in the United States of America to establish the Committee to 
Identify Neuroprotective Agents for Parkinson’s disease or (CINAPS). This committee is aimed at 
identifying and conducting clinical trials of such agents that can slow the progression or prevent 
the onset of PD. In a review by Ravina and colleagues (2003), the authors sought to identify 
potential neuroprotective agents for testing in such clinical trials. They collaborated with scientist 
and clinicians from academia and industry as well as various patient and foundation groups in 
various countries to establish a broad list of potentially appropriate agents. After systematic 
reviews using the specified criteria they found 12 compounds to be attractive candidates for further 
clinical trials in PD (Table 1.2).  The criteria employed during the systematic pharmacological 
assessment of each agent are as follows: 
1. Scientific rationale 
2. Evidence of blood-brain barrier penetration 
3. Adequate safety and tolerability data  
4. Efficacy in animal models of the disease and/or preliminary efficacy data in humans or 
human clinical studies 
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Table 1.2: Agents selected by CINAPS as potential neuroprotective agents for assessment in 
clinical trials for the treatment/prevention of PD. 
Neuroprotective Agent References 
Caffeine (Chen et al., 2001; Ross and Petrovitch, 2001; 
Checkoway et al., 2002) 
 
Coenzyme Q10* (Beal et al., 1998; Shults et al., 2002; Beal, 
2004) 
 
Creatine* (Matthews et al., 1999; Tarnopolsky et al., 
2001) 
 
Estrogen (Leranth et al., 2000; Shepherd, 2001; 
Sawanda and Shimohama, 2003; Morale et al., 
2006) 
 
GM-1 ganglioside* (Schneider et al., 1998) 
 
Minocycline* (Du et al., 2001; Tomas-Camardiel et al., 
2004) 
 
Nicotine (Maggio et al., 1998; Checkoway et al., 2002;  
Bordia et al., 2006; Quik et al., 2006) 
 
Neuro-immunophilin A (Gold  and Nutt, 2002) 
 
Selegiline (Deprenyl) and rasagiline (The Parkinson Study Group, 2002; 
Maruyama et al., 2000; Maruyama et al., 
2002; Tatton et al., 2003) 
 
Ropinorole and pramipexole (Schapira, 2002) 
 
*these four compounds have been selected by CINAPS to evaluate in larger, Phase III Clinical 
Trials. Coenzyme Q10 has been under investigation since February 2005 
(www.ninds.nih.gov/funding/research/parkinsonsweb/drug_summaries).  
 
 
While many of the discussed treatment options still remain in the primary stages of their 
evaluation, they all hold an immense potential to revolutionize PD therapy. The identification of 
several compounds with neuroprotective activity in numerous animal and human studies has lead 
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the progression of PD research towards the development of drug delivery systems that can deliver 
these agents via mechanisms that can minimize side effects for patients and optimise compliance. 
The therapeutic potential for the development of such drug delivery systems for neurodegenerative 
diseases has been emphasized in a review by Popovic and Brundin (2006). They have particularly 
emphasized the need to develop systems that can provide controlled delivery in a site-specific 
manner to the brain. Particular attention has been directed at biodegradable polymeric systems. The 
review provides significant insight into the importance of the site of administration as an essential 
factor dictating the efficacy of the intended system. 
 
One of these 12 neuroprotective agents selected by CINAPS is the tobacco alkaloid nicotine (Table 
1.2). For the purposes of our study it was selected as the model neuroprotectant agent to 
incorporate into the proposed drug delivery system. It represents a unique challenge to incorporate 
into a drug delivery system intended for prolonged release due to its hydrophilicity and low 
molecular weight. 
 
1.4 Nicotine as a Neuroprotectant for PD 
The potential application of the principal alkaloid in tobacco, nicotine as a neuroprotectant in PD 
was demonstrated as far back as 1926 (Moll, 1926). More recent studies have also shown that it 
plays a role in the prevention of age-related dementias. PD has been one of the diseases given 
much attention (Morens et al., 1995; Tzourio et al., 1997; Tanner et al., 2002). The results have 
shown that nicotine does indeed have a positive impact in preventing the degeneration of neurons 
involved in PD (Gorell et al., 1999; Rusted et al., 2000; Quik, 2004). Studies have demonstrated a 
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marked reduction in cortical nicotinic receptor binding that parallels the degree of dementia in PD 
(Newhouse and Kelton, 2000; Newhouse et al., 2004). Nicotine, a nicotinic receptor stimulator 
evokes the release of DA from the striatum and therefore protects the nigrostriatal neurons from 
degeneration (Rusted et al., 2000). The mode of its addiction is also a possible identification of this 
mechanism. A study conducted by Clarke and colleagues (1988) demonstrated that nicotine’s 
ability to activate dopaminergic release in the mesolimbic cortical neurons, that mediates its reward 
effects, produces a dependant locomotor (possibly striatal) stimulation. Furthermore, it has also 
been shown that nicotine is able to act as a free radical scavenger (Quik and Kulak, 2002; Obata et 
al., 2002) and participate in iron complexation (Soto-Otero et al., 2002; Bridge et al., 2004) thus 
prevent lipid peroxidation and subsequent neuronal degeneration. Studies have shown a significant 
improvement in the patient’s mental attentiveness, body control in walking and the use of hands, 
and reducing anxiety shortly after initiating therapy (Prasad et al., 1994; White and Levine, 1999; 
Quik and Kulak, 2004). Schneider and co-workers (1998) conducted a study in non-human 
primates, which demonstrated that the co-administration of a nicotinic agonist with a lower 
levodopa dosage resulted in an improvement in parkinsonism similar to that seen with a higher 
levodopa dosage, although it led to a decline in motor complications such as dyskinesias. 
  
The mechanism of its action is under much debate and investigation. Studies have indicated that 
this action of nicotine is mediated by the activation of presynaptic nicotinic α4β2 and α7 receptors 
located on the dopaminergic nerve terminals in the corpus striatum (Quik and Jeyarasasingam, 
2000; Belluardo et al., 2000; Matsubayashi et al., 2004; McCullam et al., 2005; Quik and 
McIntosh, 2005; Bordia et al., 2006; Quik et al., 2006). It has been proposed that it acts on the 
mRNA subunits within the dopaminergic terminals in the substantia nigra pars compacta (Visanji 
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et al., 2005). It has also been shown that nicotine directly induces the neuroprotection of 
dopaminergic neurons in the substantia nigra by stimulating the release of the neurotrophic 
fibroblast growth factor-2 (FGF-2) (Maggio et al., 1998). The additional effects of nicotine in the 
brain, such as its ability to selectively stimulate glucose utilization in cerebral neurons (that in turn 
stimulates striatal, cortical and mesolimbic activity) (London, 1990), inhibit brain MAO-A 
enzymes (Fowler et al., 1998) as well as its ability to enhance the production of pituitary 
hormones, of particular significance, ACTH, which stimulates cortisone production (Fuxe et al., 
1990) may also shed light on its mechanism of action. 
 
However, this does not justify patients to smoke in order to prevent the disease. Any benefits from 
nicotine in cigarettes or other tobacco products are far outweighed by the proven harm of using 
such products. Hence, the approach taken to deliver nicotine to the patient is consequently vital and 
must be addressed. Despite the fact that the research supporting the neuroprotective effects of 
nicotine is overwhelming, designing a novel system for its modulated delivery may have many 
merits. Thus far no such system has been developed. 
 
Although transdermal patches have been effective for smoking cessation, some studies have shown 
contradictory findings regarding their use in PD.  Patients often fail to comply with this treatment 
due to the unwanted side-effects, primarily nausea and gastrointestinal disturbances. The low 
tolerability may be related to a lack of specificity of nicotine, which would directly stimulate the 
autonomic nervous system (Lemay et al., 2003; Lemay et al., 2004). Nicotine gums and sprays also 
have benefits; however are accompanied by similar side-effects as the patch. While the patch and 
gum are unaesthetic, nasal sprays often lead to nasal congestion and rhinorrhea. The patch also has 
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a notorious reputation for causing severe skin irritation indicated by reddening, pruritis and oedema 
in the area of application (Gourlay et al., 1999).  
 
Figure 1.4 summarizes the possible mechanisms by which nicotine may elicit its neuroprotective 
effects in the brain for the prevention of PD. 
 
Figure 1.4: Proposed neuroprotective mechanisms of nicotine in the brain involved in preventing 
the onset and progression of PD. 
 
For the purposes of this study nicotine has been considered as the model neuroprotectant to be 
delivered through a novel reinforced crosslinked multi-polymeric multi-unit drug delivery device. 
NEUROPROTECTIVE 
MECHANISM OF 
NICOTINE
Free radical scavenger (Xie 
et al., 2005)  
Stimulates glucose 
utilization in neurons 
Promotes cortical activity 
Stimulates the Mesolimbic 
Dopaminergic Reward 
Pathway (Clarke, 1990) 
Stimulates striatal dopamine 
release (Matsubayashi et al., 
2004) 
Directly stimulates FGF-2 
neurotrophic release in the 
substantia nigra (Maggio et 
al., 1998) 
Stimulates ACTH release 
Increases cortisone levels 
Anti-inflammatory effects  Prevents lipid peroxidation 
Indirectly stimulates 
Melatonin release, which 
is neuroprotective 
(Stankov et al., 1993) 
Iron complexation 
(Bridge et al., 2004) 
Prevents neural degeneration 
Prevents neural degeneration 
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To date, no such device exists for application in PD. Current means of delivering nicotine in pilot 
studies have demonstrated poor compliance due to the unwanted peripheral side effects (Lemay et 
al., 2003; Lemay et al., 2004).  Thus site-specific delivery would enable elimination or attenuation 
of the aforementioned side-effects if nicotine is restricted to its site of action, the CNS.  
 
1.5 Challenges Associated with Drug Delivery to the Brain 
Despite the fact that knowledge regarding the molecular biology and cellular physiology of the 
brain has advanced at a rapid pace, much remains to be learned about delivering drugs and 
pharmaceuticals for the diagnosis and treatment of central nervous system (CNS) diseases. Neural 
activity in the brain requires precise regulation of the neural microenvironment as well as basic 
physiological processes including, delivery of nutrients, removal of waste, protection from toxic 
substances circulating in the blood and maintenance and repair processes. Sites where blood comes 
into contact with neural tissue are crucial interfaces known as the blood-brain barrier (BBB) and 
are important in creating the optimal environment for efficient neural activity through a variety of 
barrier mechanisms (summarized in Table 1.3). The BBB creates the largest ‘barrier interface’ with 
respect to its surface area (12–20 m2/1.3 kg brain) in the body and has the most significant impact 
on drug delivery of neuroactive agents to the brain (Abbot et al., 2006). 
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Table 1.3: Properties of the BBB which limits delivery of neuroactive agents to the CNS (Source: Adapted from Abbot et al., 2006). 
Blood Brain 
Barrier Properties 
Tight 
junctional 
structure  
Tight junctions are a physical barrier. The tightness of the BBB appears not only from the physical complexity of its junctional structure, but also 
from the numerous transmembrane particles which, create an astomising dense network. Transmembrane proteins known as claudins, assist in sealing 
the intercellular spaces and enforce selectivity. The claudins function within a complex network of other transmembrane and cytoskeletal proteins 
linked to the actin cytoskeleton, which imposes adhesion between the junctions thus provides additional structural strength to the BBB. The result is a 
strong and restricting inter-cellular connecting region that extends around the endothelial cell margin severely restricting penetration of polar 
hydrophilic molecules through this paracellular pathway. Thus molecules employ a transcellular pathway across the brain endothelium to enter the 
BBB. 
The nature of 
the endothelial 
cell membrane 
The endothelial cell membrane influences passive drug permeability. Like all cells, the brain endothelium possesses an outer cell membrane 
composed of a lipid bilayer with embedded proteins. Small gaseous molecules such as oxygen and carbon dioxide can diffuse freely through the 
membrane, enabling oxidative metabolism of the brain and facilitating its pH regulation. The majority of drugs used to treat the CNS are lipophilic 
and thus easily diffuse through the endothelial membranes. Lipid analysis of the brain endothelium shows a high cholesterol content. The apparent 
average optimum molecular weights are approximately < 280Da and lipophilicity LogPoctanol < 2.0. However these values can vary depending on the 
therapeutic activity of the neuroactive agent.  
Uptake 
transporters  
The paracellular pathway for small molecules between the blood and brain in comparison to peripheral vasculature is severely restricted. Thus, where 
transfer is required, it must be assisted by specific transport systems known as uptake transporters which are located in the endothelial membranes. 
Many BBB transporters facilitate transfer without requiring energy by allowing solute to move down an electrochemical gradient, while others 
require energy to transport against a gradient, either actively derived from ATP or through coupling mechanisms to develop favourable concentration 
gradients. Some transporters are located on both the luminal and brain-facing membranes of the endothelium (bidirectional), while others are 
localised predominantly to one or other membrane, allowing directional (vector-mediated) transport to occur.  
Transcytosis This can either be receptor- or adsorptive-mediated. As stated previously, some uptake transporters on the brain endothelium may function 
bidirectionally, thus also permit efflux. However, in addition, several families of transporters have been identified that are capable of actively 
transporting solutes out of the brain endothelial cells (often with the consumption of ATP). They restrict the CNS entry of a number of potentially 
harmful or toxic agents circulating in the blood, and are thought to have other housekeeping functions. They have a particular significance for drug 
delivery, since they can effectively block or reduce entry of lipophilic drug molecules. 
Efflux 
transporters  
Most membrane transporters are able to transport only small molecules (< 1000Da) due to the spatial and energetic requirements of the substrate-to-
transporter docking sites and transfer mechanism. Larger molecules such as polypeptides and proteins can be transported across the BBB through 
vesicular routes. Of the two mechanisms that have been identified, one requires specific interaction with a membrane receptors followed by 
endocytosis and receptor-mediated transcytosis. The other is less specific, by which cationic molecules can bind to the surface negative charges of the 
endothelial glycocalyx and be internalised and transferred: adsorptive-mediated transcytosis. 
The enzymatic 
barrier 
Further metabolism, particularly in the cells of the BBB, specifically the brain endothelium and the choroid plexus significantly affect 
pharmacokinetics and bioavailability of neuroactive agents. Both sites express a range of Phase I, II and III enzymes. Due to the selectivity of the 
reactions, the influence of brain endothelial enzymes has to be considered exclusively for each potential neuroactive agent. 
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The ability to deliver these molecules systemically to the brain is impeded by several factors 
including their degradation and metabolism, either by relative short half-lives of the molecules, or 
metabolic degradation by the liver prior to reaching the CNS as a target site. Furthermore, the near-
impermeable BBB presents as a protective cellular barrier and is the chief site regulating molecular 
transfer between the blood and brain (Table 1.3). It is made up of tightly bound brain endothelium, 
has low passive permeability combined with a highly selective transport system, and therefore 
poses a significant obstacle for the delivery of many neuroactive factors. A number of strategies 
have been developed to circumvent the selective BBB. Some of the techniques currently available 
for the delivery of neuroactive factors to the brain for PD include:  
1. Trans-cranial brain delivery  
a. Direct infusion with stereotactic guidance 
b. Osmotic pumps 
c. Controlled- and/or sustained-release polymer systems 
2. Trans-nasal brain delivery 
3. Disruption of the BBB 
a. Carrier- or receptor-mediated transcytosis  
b. Osmotic opening 
4. Small molecule lipidization  
 
However, depending on the intended application, the systems offer various advantages and 
disadvantages with their use (Bodor 1992; Lossinsky et al., 1995; Tamai and Tsuji, 2000; Bodor 
and Buchwald, 2003; Guerin et al., 2004; Begley, 2004; Huynh et al., 2006; Siepmann, 2006; 
Popovic and Brundin, 2006; Pardridge, 2007).  
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In recent years, biopolymer based systems for the delivery of bioactive agents have gained 
considerable attention due to their established biodegradability and biocompatibility, excellent 
mechanical strength and controlled release profiles. 
 
Furthermore, controlled release systems remain in direct and sustained contact with the tissues, and 
some of them degrade in situ. In such a case, both the polymeric material itself as well as its 
degradation products must be free from toxicity. For devices implanted into the body, the classical 
retaliatory tissue response to a foreign material (e.g. an implant) leads to its encapsulation. This 
may impede diffusion of the drug to the surrounding tissue and result in failure of the device. This 
tissue response depends on different factors, in particular, on the implantation site (Fournier et al., 
2003). 
 
1.6 Implantable Therapeutic Systems 
Historically the first implantable devices formulated for therapeutic use to deliver medicaments for 
sustained and controlled release were developed by Lafarge in 1861 (Chien, 1987). Subsequently 
systems have been developed to release a variety of drugs. The development of biopolymer based 
implantable pharmacotherapeutic systems however is as recent as the late 1960s with the discovery 
of lipophilic silicone-capsules (Chien, 1987). Among the factors that were modulated to control 
drug release included the thickness and surface area of the silicone-capsules as well as the polarity 
of the entrapped medicament. This research has led to the formulation of numerous commercial 
products to provide a mechanism to administer drugs in a controlled and long-term manner. 
Gaginella and Bass (1974) employed the abovementioned silicone capsules to provide chronic 
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administration of nicotine in vivo. However, the primary disadvantage of such a system is that this 
modified silicone capsule is not biodegradable. This implies that following implantation, a second 
surgery is required to remove the device from the body. Furthermore, mechanical damage to the 
device or the empty (devoid of drug after its release) capsule can result in the accumulation of 
potentially toxic particles in the body. The development of biocompatible biodegradable polymers 
for sustained release implantable systems therefore has received significant focus. 
 
Among the various advantages described in a review by Langer (1983), implantable polymeric 
devices have the capacity to optimise drug therapy and offer the following benefits to patients: 
1. Plasma drug levels are consistently maintained within the therapeutic window;  
2. Site-specific administration which can eliminate or attenuate peripheral adverse effects;  
3. Prolonged-release systems improve patient compliance by allowing a significant reduction 
in dosing frequency;  
4. They allow for the administration of drugs with short in vivo half-lives and the achievement 
of sustained plasma levels with minimum fluctuation, predictable and reproducible release 
rates for extended durations; 
5. Implantable systems are more cost-effective long-term;  
6. They allow for dose reduction since the drug can be administered to the site of action to 
regions in the body that are poorly perfused, such as the CNS; 
 
Several advances in this area of research have been made to develop systems that display the 
ability to deliver drugs in a site-specific manner to tissues that can be activated by a variety of 
mechanisms including magnetic and electrical fields (Hsieh et al., 1981; Edelman et al., 1985; 
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Kwon et al., 1991; Furukawa et al., 2003; Zebli et al., 2005), vapour and osmotic pressure (Alzet® 
Osmotic Pump), pH (Siegel et al., 1988), enzymes (Fischel-Ghodsian et al., 1988), ultrasound 
(Kost et al., 1989; Kost, 1993), light (Mathiowitz and Cohen, 1989) and temperature (Hoffman et 
al., 1986; Bae et al., 1987; Furukawa et al., 2003; Lendlein et al., 2005; Ohya et al., 2005). 
 
1.7 Rationale and Motivation for Study 
To date PD remains an incurable disease, afflicting growing numbers of individuals. Organizations 
such as CINAPS have realised the importance of preventative treatments in the form of 
neuroprotective agents in the field of PD therapy and have devoted due attention to their potential 
role as future treatments for the disease. It is recognised that patient compliance with regards to 
drug therapy; particularly with neurodegenerative diseases is a significant concern for treatment 
success with the elderly (Grosset et al., 2005). This study aimed to develop a novel drug delivery 
system with the intent to bridge the discrepancy associated with optimising drug therapy and 
patient compliance for chronic neurodegenerative diseases such as PD. This study focused on the 
elucidation of the in vitro pharmaceutical benefits of developing a prolonged drug delivery system 
for neuroprotective agents. Nicotine was selected as the model neuroprotective agent to be 
delivered in the formulated system. A novel delivery system of this nature has thus far not been 
developed. It must be emphasised here that the device was intended to be versatile to deliver a 
range of neuroprotective molecules. Nicotine, being a small molecule with appreciable water 
solubility was a challenge to confine within the system to achieve the desired zero-order sustained 
release characteristics, hence displayed the potential that the device demonstrated for the delivery 
of other neuroprotective agents.  
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A device providing prolonged modulated release will allow patients to have as little exposure to 
dose-dependent adverse effects based on the attainment of steady-state blood levels and 
minimizing the fluctuations in plasma concentration through zero-order drug release kinetics. 
Developing a system with the capacity to provide site-specific delivery into the substantia nigra 
pars compacta in the brain would minimise peripheral accumulation of therapeutic agents and thus 
prevent unnecessary side-effects. The device would be developed employing biodegradable 
polymers so that only a single surgical minimally invasive procedure would be required.  
 
The polymeric system would need to have the capacity to deliver small molecular compounds such 
as the proposed neuroprotective agent; nicotine over a period of a 1-2 months hence necessitated 
the investigation of a unique combination of polymers reinforced with crosslinking agents to 
develop a compact network which would disintegrate gradually in situ when exposed to 
cerebrospinal fluid (CSF) in order to release nicotine. This involved an investigation and 
understanding of the following factors: 
 
1. The factors influencing the ability of the reinforced polymeric system to entrap drug (drug 
entrapment efficiency) and modulate drug release 
2. The physicomechanical properties and viscoelastic behaviour of the device when exposed to 
simulated CSF and the mechanics of its degradation.  
 
This study is the first to develop a reinforced crosslinked multi-polymeric multiple-unit device for 
the delivery of nicotine for PD therapy.  
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1.8 Aim and Objectives of This Study 
The aim of this study was to focus on the in vitro development and evaluation of a novel prolonged 
release system for newly researched neuroprotective agents. As mentioned previously, the device 
was intended to be one that provides zero-order prolonged release of nicotine over a period of 1-2 
months. The device was formulated such that its design was in keeping with the potential for 
implantation into the substantia nigra pars compacta in order to provide site-specific drug delivery. 
In order to do so, polymers with biocompatible and bioerodable characteristics were selected to 
entrap the drug within a reinforced crosslinked matrix.  
 
In order to accomplish this aim the following objectives were outlined: 
 
(i) Selection of an appropriate polymer combination based on the evaluation of the 
physicochemical and physicomechanical properties.  
(ii) Application of ionotropic gelification in accordance with Design of Experiments approach 
to assimilate a multiple-unit polymeric structure reinforced with a suitable polymer(s) and 
crosslinking agents. 
(iii) In vitro evaluation of the polymeric device in terms of its textural rigidity, gelation 
mechanism, erosional capacity and dissolution behaviour. 
(iv) Elucidation of the molecular assemblage through enthalpic techniques and Fourier 
transform infrared (FTIR) spectroscopy. 
(v) Kinetic modelling of drug release. 
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1.9 Synopsis of Dissertation 
This dissertation is structured such that it provides a logical approach to present the research 
conducted in keeping with the aforementioned aims and objectives, while highlighting the various 
avenues investigated to modify nicotine release during the study. 
 
The First Chapter provides an overview of Parkinson’s disease, the lack of any effective treatments 
for the disease and the limitations of currently prescribed therapies. Studies being conducted on 
newer treatment options such as the use of neuroprotective agents are also discussed. Particular 
emphasis has been placed on the role of the alkaloid nicotine, which was employed as the model 
neuroprotectant for the proposed drug delivery system. An overview of the challenges associated 
with drug delivery to the brain elaborated on the hurdles that were considered when developing the 
reinforced crosslinked multi-unit device. Implantable devices previously and currently developed 
for site-specific delivery of neuroactive agents highlighted the rationale for the proposed study. 
The chapter summarizes the aims and objectives of the study which were achieved.  
 
Chapter Two discusses the properties of alginate, the biopolymer selected to develop the drug 
delivery system. The influence of various formulation parameters on the physicomechanical and 
physiochemical properties of ionotropically crosslinked alginate spheres (gelispheres) were 
evaluated employing textural analysis. The influence of monomeric ratios within the copolymer 
and crosslinking agents, namely, zinc, calcium and barium was evaluated to select the appropriate 
alginate grade to incorporate nicotine. 
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Chapter Three presents the three phase approach adopted for the development and optimisation of 
the reinforced multi-polymeric gelispheres. An overview of the two polymers, 
hydroxyethylcellulose (HEC) and polyacrylic acid (PAA) which were incorporated into the 
alginate gelispheres as reinforcing agents is provided. Three crosslinked agates are discussed, 
namely zinc, calcium and barium. Studies demonstrated that zinc-crosslinked gelispheres 
generated formulations which disintegrated easily following exposure to simulated cerebrospinal 
fluid (CSF) (0.1M PBS; pH 7.4; 37ºC; 50rpm), hence it was not employed for the second phase of 
the study. The first phase elaborates on the role of the aforementioned crosslinked agents and the 
influence of post-curing exposure to dilute hydrochloric acid (HCl) on the erosional properties of 
the multi-polymeric gelispheres. The second phase involved adoption of a Design of Experiments 
approach through a Plackett-Burman screening design to elucidate the influence of 5 independent 
formulation variables, namely the concentrations of the three polymers; alginate, HEC and PAA 
and the crosslinking agents, barium (primary crosslinker) and calcium on the drug entrapment 
efficiencies and drug release behaviour of the gelispheres. The final phase involved conducting 
optimisation studies of the multi-polymeric gelispheres following which the optimised system was 
exposed to dilute HCl post-curing in order to attenuate the rate and extent of gelisphere swelling 
and erosion following exposure to simulated CSF. FTIR and enthalpic techniques were employed 
to elucidate the interactions between the polymers and nicotine on a molecular level. While the 
multi-polymeric barium-calcium-crosslinked system developed exhibited characteristics whereby it 
retained its integrity for durations which, far exceeded the native alginate gelispheres studied in 
Chapter Two, zero-order release was not achieved. Thus approaches to further prolong drug release 
were investigated.  
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Chapter Four investigates the incorporation of the optimised gelispheres from Chapter Three into 
compressed external polymeric matrices (discs). Three polymers were selected to formulate the 
discs, namely hydroxypropylmethylcellulose (HPMC), polyethylene oxide (PEO) and poly(lactic-
co-glycolic) acid (PLGA). Various polymer blends were formulated to elucidate the degradation 
and erosional behaviour of the compressed discs following exposure to simulated CSF. Drug 
release studies demonstrated zero-order release for 50 days from PLGA discs incorporating 
optimised gelispheres. Finally, kinetic analysis of drug release from the multi-units was undertaken 
employing FDA-recommended f1 and f2 similarity and difference factors.  
 
Chapter Five presents the results for the study which investigated the first alternative approach 
employed to modify nicotine release. This involved formulating PLGA-coated compressed 
polymeric discs, which incorporated calcium-crosslinked alginate-HEC gelispheres. 
 
Chapter Six investigates the role of crosslinked alginate and pectin gelispheres as a means to 
deliver a polylactic acid (PLA) and PLGA microparticulate system incorporating nicotine. A Box-
Behnken statistical design was employed to formulate the microparticles through an oil-in-oil 
(O/O) phase separation process. Three factors were evaluated, namely polymer type, stirring time 
and concentration of the surfactant, Span 80. Artificial Neural Networks (ANN) was also 
employed using a Generalized Feed Forward algorithm, as a simultaneous optimisation technique. 
Optimised microparticles were incorporated into alginate-pectinate gelispheres (double 
entrapment) to formulate a polyspheric crosslinked system.  
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The concluding chapter emphasises significant parameters regarding the multi-polymeric multi-
unit systems developed and provides recommendations for future studies in terms of the versatile 
means of adapting the developed system for alternative neuroprotectant agents. 
 
1.10 Potential Benefits of This Study 
The development of the proposed reinforced crosslinked multi-unit device providing prolonged 
site-specific delivery of neuroprotectants such as nicotine will enable PD patients to receive 
preventative treatments through a means that will provide the various benefits. The most 
significant advantages of the system include enhanced patient compliance and improved 
therapeutic success. Elderly patients form the majority of those afflicted with the disease. It has 
been widely established that compliance to treatments in this patient group is a significant hurdle 
with regard to therapeutic success (Dipiro, 1999). Through the use of a prolonged release device 
we can provide patients with administration at extended intervals and enable them to achieve the 
optimal benefits of the treatment. Furthermore the attainment of sustained drug levels of the 
administered neuroprotectants will enable improved therapeutic success, since it will maintain drug 
concentrations at the site of action (the brain) within the therapeutic window. This translates into 
better product tolerability and minimization of unnecessary peripheral adverse effects. 
 
Developing the proposed device also enables the formulation of a unique polymeric drug delivery 
system and the formulation of technology that is entirely novel in this field. This study allows the 
elucidation of new mechanisms of interaction between a composite crosslinked multi-unit multi-
polymeric device and biodegradable matrix reinforcers. The developed system serves as a platform 
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for the future development of and formulation of novel crosslinked prolonged release implant for 
the encapsulation of newly studied and/or developed neuroprotectants. Finally due to the fact that 
the proposed system seeks to employ simple formulation procedures which expose the 
incorporated molecules to minimal degradative factors, such as extremes of temperature and pH 
implies that a variety of bioactive molecules or entities (such as proteins and cells) can be delivered 
through the proposed system. Such a versatile platform can provide a means of delivering 
bioactives through ideal zero-order release. 
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Chapter 2  
Elucidation of the Properties of Crosslinked Alginate Gelispheres as a Platform 
for Drug Delivery through Physicomechanical Analysis 
 
2.1 Introduction 
The polyanionic algal polysaccharide alginate was employed to formulate the proposed drug 
delivery system. Alginate is a biocompatible and biodegradable glycosidic copolymer which 
undergoes instantaneous crosslinking in the presence of divalent cations by a process known as 
ionotropic gelation. This process has been widely used commercially since the conditions under 
which gelispheres are formulated are mild, usually conducted at room temperature and in an 
aqueous medium. This rapidly occurring process is both simple and cost-effective, therefore allows 
for easy scale-up and large-scale manufacture. Crosslinked alginate spheres, referred to as 
gelispheres, have found wide application in the field of pharmaceutical drug delivery. The term 
‘gelisphere’ was coined by Pillay and coworkers (2002). It refers to an ionically crosslinked 
polymeric spherical matrix, prepared by ionotropic gelation. Such an entity has the capacity to 
undergo a process known as gelation, which involves the polysaccharide polymer imbibing water 
from a surrounding hydrating medium (e.g. physiological fluid or buffers) swelling, and 
undergoing polymeric disentanglement and resulting in subsequent matrix degradation. 
 
Alginate is a natural polysaccharide extracted from a variety of brown seaweed, each of which 
produces a variant of the copolymer with specific characteristics dependant on its monomeric 
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constituents. Alginates differ in terms of their viscosity and the ratio of monomeric units, namely 
the 1,4-linked sugars, β-D-mannuronic acid (M) and its C-5 epimer α-L-guluronic acid (G). These 
units are arranged in homopolymeric blocks (GG and MM) interspersed with regions where the 
monomers alternate (MG) (Smidsrød and Draget, 1996; Draget et al., 2002). The chemical 
structures of the polymer and its constituent monomers are represented in Figure 2.1. 
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Figure 2.1: Chemical structure of alginate and its monomers mannuronic acid (M) and guluronic 
acid (G). (Source: Draget et al., 2003). 
 
Alginate undergoes instantaneous crosslinking in the presence of divalent cations such as calcium 
and zinc (Yotsuyanagi et al., 1987), but not with magnesium or other monovalent cations 
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(Sutherland, 1991).  The resultant matrix represents a hydrogel i.e. a polymeric network capable of 
absorbing, swelling and retaining large quantities of water within their hydrated matrices without 
rapid dissolution or loss of their three-dimensional networks (Hoffman, 2002). Gelling induced by 
specific cations is indicative of an interaction between the crosslinking ions that produces a 
conformational change in the polymer. G-units exist as associated crystalline aggregates in the 
form of a two-dimensional ribbon-like structure. The ‘ribbon’ contains electronegative cavities, 
which when interacting with divalent cations, entrap them within the cavities in an ‘egg-box’ 
arrangement (Grant et al., 1973) (Figure 2.2).  This association allows for the formation of a three-
dimensional gel network with intra-polymeric bonding occurring in conjunction with cation 
stabilization of G-chains.  
 
Figure 2.2: Chemical structure of alginate and its monomers guluronic acid (G) and mannuronic 
acid (M) in an ‘egg-box’ arrangement when crosslinked with divalent cations (depicted by the red 
circles in the diagram) (Source: FMC BioPolymer Novamatrix, CRS Conference, 2005). 
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M-units have a unique mechanism of interaction between their carboxyl groups and the divalent 
crosslinking cations; however they produce weaker bonds (Draget et al., 2003).  The physical 
properties of the developed hydrogel are consequently a direct function of factors such as the 
monomeric composition, sequential structure, molecular mass, nature of crosslinking agent, the 
presence of chelating agents that bind with crosslinking ions, concentration of non-gelling ions and 
the presence of a strengthening polycationic coat (Kong and Mooney, 2003). Studies have 
indicated that a general trend of superior mechanical strength is demonstrated by G-rich alginates 
due to preferential binding of divalent crosslinking cations such as calcium to these monomeric 
units (Smidsrød and Skjåk-Bræk, 1990; Kuo and Ma, 2001). The GG-block exhibits a high 
selectivity for crosslinking cations depending on the structural orientation of the GG-blocks in the 
polymeric substrate which in its stereo-chemical orientation provides a cavity like space for cations 
to sit in easily in a thermodynamically stable stereo-orientation. The cations and water molecules 
utilize the area in accordance with the fast developing crosslinking polymeric matrix and determine 
the final stereo-chemical orientation of the resultant filled cavity (Draget et al., 2003). This is 
illustrated in Figure 2.3. The larger size of the crosslinking cation generates a smaller space for 
hydrated ion clusters and therefore fewer water molecules can be accommodated within the filled 
cavity (Draget et al., 2003). Thus it provides more stability to the polymeric backbone. This is 
discussed in greater detail in later sections.  
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Figure 2.3: A calcium ion packed in a GG pocket between two alginate strands. Crosslinking 
between the carboxyl ends of the saccharide units alters the stereochemistry of the two approaching 
pockets considerably. (Source: Adapted from Al Musa et al., 1999). 
 
The development of novel crosslinked gelisphere systems of alginate has been viewed as a possible 
means to deliver a variety of pharmaceuticals (Gombotz and Wee, 1998). Alginates are an ideal 
medium for pharmaceutical delivery. In particular site-specific delivery to mucosal tissue for 
localized action is a possibility due to the fact that alginates are bioadhesive. Commercially 
available preparations of alginate films and fibres have exploited this characteristic and have found 
extensive application as protective surgical wound dressings (Gilchrist and Martin, 1983). 
Moreover, it is biocompatible, biodegradable and freely permeable to small molecules, such as 
oxygen, nutrients and small proteins (Gombotz and Wee, 1998; Leonard et al., 2004) which is an 
ideal environment to entrap and deliver among other pharmaceutical products, viable cells 
(Gombotz and Wee, 1998; Krasaekoopt et al., 2004). Other commercial uses of alginates are listed 
in Table 2.1. 
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Table 2.1: Commercial uses of alginates. (Source: Whistler et al., 1953). 
Commercial Use Examples of Applications in Field 
Medical Sulphonated alginic acid is an anticoagulant, 
pharmaceutical drug delivery, surgical uses, 
dental impression material 
 
Cosmetics Water soluble colloids in lotions, toothpastes 
and ‘grease-free’ creams  
 
Food Ice cream stabilizer, cheeses, whipping cream, 
thicken soups and sauces etc. 
 
Other Used to remove small quantities of metals 
from solution. This property allows it to be 
used to soften water 
 
 
Furthermore, the conditions under which gelispheres are formulated are mild, usually conducted at 
room temperature and in an aqueous medium. This rapidly occurring process is both simple and 
cost-effective. It has been successfully employed for the delivery of sensitive drugs (Badwan et al., 
1983; Hari et al., 1996; Tonnesen and Karlsen, 2002; Ueng et al., 2005), proteins (Kim and Lee, 
1992; Xing et al., 2003; Leonard et al., 2004), DNA (Smith, 1994; Alexakis et al., 1995), living 
cells (Smidsrød and Skjak-Braek, 1990; Orive et al., 2002; Koch et al., 2003; Serp et al., 2005), 
spermatozoa (Torre et al., 2000) and genes (You and Peng, 2005). 
 
Drug release from alginate gelispheres is directly related to matrix pore size if present and the rate 
at which matrix degradation occurs when the system is exposed to hydration. The mechanical 
transformation incurred by the polymeric matrix following exposure to hydration further 
determines the rate at which drug release occurs over time. Such data allows for the prediction of 
the duration for which the gelispheres will be intact within the body subsequent to administration 
(Bajpai and Tankhiwale, 2006).  
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While most alginate delivery systems have focused their attention on employing zinc and calcium 
as a biocompatible crosslinking agents that can adequately interact with the polymer; more recent 
studies have demonstrated the potential offered by agents such as barium on controlling drug 
delivery through its unique mechanism of interaction with the polymer (Bajpai and Sharma, 2003). 
While the choice may seem controversial due to potential biocompatibility problems, as has been 
pointed out in a study conducted by Bajpai and Sharma (2003), the barium released from alginate 
matrices (a process known as sequestration which occurs through an exchange with sodium ions in 
buffer/physiological fluids such as cerebrospinal fluid (CSF) which, discussed in the following 
chapter), when exposed to physiological environments, it immediately interacts with phosphate 
ions to form barium phosphate, thus preventing any interaction with body tissues. This study aimed 
to establish the influence of barium, calcium and zinc on the physicomechanical properties of 
crosslinked alginate gelispheres in their unhydrated and hydrated states in order to elicit their 
potential role in pharmaceutical delivery systems.  
 
The influence of hydration on the swelling behaviour and subsequent degradation of the 
gelispheres is a direct function of their mechanical strength. Since our aim was to develop a system 
that has prolonged release kinetics, we sought to establish the most thermodynamically stable 
stereo-orientation possible within the crosslinked system by employing a range of crosslinking ions 
and varying monomeric ratios. The influence of the crosslinking agents, namely barium, calcium, 
zinc and various combinations of these three cations on the mechanical properties of alginate 
gelispheres were assessed in both the hydrated and unhydrated states.  
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The following sections detail the study conducted to evaluate the physicomechanical and 
physiochemical properties of native ionotropically crosslinked alginate gelispheres following 
exposure to hydration. This study investigates the influence of the monomeric constitution of the 
polymer (G/M ratio) and crosslinking agents, namely barium, calcium and zinc on the textural 
and erosional properties of the matrix.  
 
2.2 Materials and Methods 
2.2.1 Materials  
Six different grades of sodium alginate with varying G/M-ratios were analysed in this study. These 
included TIC Pretested® TICA-alginTM 200 powder, TICA-alginTM 400, TICA-alginTM HG-400, 
TICA-alginTM 900 which were donated by TIC Gums (Belcamp, MD, USA), Protanal® LF 10/60 
were donated by FMC BioPolymer (Haugesund, Norway) and ISP Manugel® DMB (ISP 
Corporation, CA, USA).  The constituent ratios of monomeric units are detailed in Table 2.2. 
 
Table 2.2: Alginates of varying G/M-ratios.  
Alginate  
Designation  
Commercial  
Alginate 
Guluronic acid  
(%) 
Mannuronic acid  
(%) 
A1 TICA-alginTM 200 45 55 
A2 TICA-alginTM 400 45 55 
A3 TICA-alginTM HG 400 60-65 35-40 
A4 TICA-alginTM 900 45 55 
A5 Protanal® LF 10/60 65-75 25-35 
A6 Manugel® DMB 69 31 
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The crosslinking agents employed included barium chloride, calcium chloride and zinc gluconate 
which were purchased from Rochelle Chemicals (Gauteng, South Africa).  
 
2.2.2 Preparation of Alginate Gelispheres  
Ionotropic gelation was employed to formulate the gelispheres. Briefly a 1%w/v solution of alginate 
dispersion was prepared in 100mL double deionized water (Millipore® filter with pore size 
0.22μm). The crosslinking solution was composed of either 2%w/v barium chloride, calcium 
chloride, zinc gluconate or binary combinations (2%w/v each) of the salts prepared in 200mL 
double deionized water. A 23-gauge syringe was employed to titrate the alginate solution dropwise 
into the gently vortexed crosslinking solution.  A 24-hour curing period was employed following 
which the gelispheres were removed and washed with 3x500mL deionized water. The gelispheres 
were subsequently dried in ambient conditions under an extractor for 48 hours. The dried 
gelispheres were then analysed for their mechanical properties.   
 
2.2.3 Textural Analysis of Unhydrated Gelispheres 
A Texture Analyser (TAXT.plus Stable Micro Systems®, Surrey, UK) was employed to conduct 
textural analysis on the gelispheres. Data acquisition was performed at 200 points per second.  
Resilience, matrix hardness (deformability modulus) and matrix fracture energy of the crosslinked 
gelispheres were assessed according to their G and M content. The association of the monomers, 
i.e. GG, GM, MM blocks and their interaction with the crosslinking cations on the mechanical 
properties was also examined. Samples with an identical G/M ratio were compared according to 
differences in viscosity. Typical parameters are listed in Table 2.3. 
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Table 2.3: Parameter settings for measurement of the physicomechanical properties of gelispheres. 
Test Parameter Fracture Energy and Deformability Modulus Matrix Resilience 
Pre-test speed 1.0 mm/s 1.0 mm/s 
Test speed 0.5 mm/s 0.5 mm/s 
Post-test speed 1.0 mm/s 1.0 mm/s 
Target mode Force 50% Strain 
Target force 40 N - 
Trigger force 0.5 N 0.5 N 
Load cell 5 kg 5 kg 
 
The force-time profile was employed for the determination of matrix resilience. This refers to the 
ability of a gelisphere to recover upon application of deforming stress to its original state of 
equilibrium. This was calculated as the ratio of the areas under the compression and decompression 
curve (Figure 2.4a). A force-distance profile generated for the gelispheres was employed to obtain 
the area under the curve (AUC) which enabled the evaluation of the energy needed to rupture the 
gelisphere matrix, i.e. the fracture energy (Nm) (Figure 2.4b) while the gradient to the peak force, 
known as the deformability modulus (N/mm) (Figure 2.4c) corresponds to the hardness of the 
gelisphere matrix.  
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Figure 2.4: Typical textural profiles generated for crosslinked alginate gelisphere matrices (a) 
matrix resilience (%); (b) fracture energy (Nm) and (c) deformability modulus (N/mm). 
(c) 
(b) 
(a) 
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2.2.4 Textural Analysis of Hydrated Alginate Gelispheres 
Gelispheres were immersed in 15mL double deionised water in glass vials and agitated at 50rpm in 
a shaker bath (Labline® Instruments, IL, USA) maintained at 37°C. Samples (N=10) were removed 
and analysed for four 24 hours intervals and evaluated for the above stated parameters (Table 2.3) 
employing a texture analyser. Texture Exponent® for Windows Version 3.2 (Stable Micro 
Systems®, UK) was used to facilitate fully integrated data acquisition. 
 
2.2.5 Analysis of Alginate Gelisphere Erosion  
Gelispheres of known weight were immersed in 15mL deionized water maintained at 37°C and 
agitated at 50rpm in a shaker bath (Labline® Instruments, IL, USA). At predetermined periods of 
times samples were extracted and dried in ambient conditions under an extractor for 48 hours to 
allow complete removal of water from the matrix. Samples were then re-weighed and the loss of 
matrix was computed.  Studies were conducted in triplicate. The % of the gelisphere matrix eroded 
after hydration was calculated employing Equation 2.1. 
 
MEt = (W0 – Wt) x 100                                                                                                      Equation 2.1 
                 W0                                                                                    
 
Where:  
MEt = Matrix erosion at time t hours (%); 
Wt = Mean weight of gelispheres after t hours of exposure to hydration; and 
W0 = Mean weight of gelispheres at time t0 
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2.3 Results and Discussion 
2.3.1 Textural Analysis of Unhydrated Alginate Gelispheres  
Textural analysis demonstrated that the both the G/M-ratio and nature of crosslinking agent had a 
significant impact on the robustness of unhydrated gelispheres. It is important to define the 
implication of the terms compact and porous with respect to the crosslinked matrices here. 
Compact refers to the formation of a matrix which is densely networked. They are resistant to 
applied mechanical stress, thus display high fracture energy and deformability moduli. Such a 
network has the capacity to entrap a significant amount of drug (discussed further in Chapter 3) 
and contain it for longer durations of time following exposure to hydrating medium. Thus the 
formation of such a matrix is beneficial for generating gelispheres capable to providing sustained 
drug release, which is the intended purpose of the drug delivery device for the study. A porous 
matrix on the other hand has a patent structure, hence demonstrates the ability to recover more 
easily after an applied mechanical stress, which confers to a high matrix resilience. These matrices 
are not suitable for entrapping drug molecules of a small molecular weight, since it permits ready 
entry of water molecules in the matrix, allowing the entrapped drug to be rapidly released.  
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Figure 2.5: Profiles depicting the relationship between, (a) matrix resilience (%) (SD<1.23%), (b) 
deformability modulus (N/mm) (SD<3.45N/mm) and (c) fracture energy (Nm) (SD<0.0004) of 
unhydrated gelispheres crosslinked with zinc, calcium, barium and various binary combinations of 
the cations (N=5). 
 
 (c) 
 (a) 
(b) 
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2.3.1.1 Influence of G/M-Ratio on the Textural Properties of Unhydrated Alginate 
Gelispheres 
G-rich alginates employing calcium as a crosslinking agent produced more robust gelispheres in 
comparison to zinc-crosslinked gelispheres. This was due to the fact that calcium selectively has a 
greater affinity for G-units in alginate (McDowell, 1977; Aslani and Kennedy, 1996). Hence, G-
rich gelispheres crosslinked with calcium demonstrated higher fracture energies. However their 
resilience and deformability modulus were lower than the corresponding zinc-crosslinked 
gelispheres. For instance, A5 demonstrated a deformability modulus of 71.42N/mm for calcium-
crosslinked matrices, while this value declined to 56.96N/mm with zinc-crosslinked matrices.  
 
Alginates with lower G/M-ratios demonstrated that zinc ions were less selective with regard to 
their affinity for the monomeric units within the polymer. They produced more robust gelispheres 
due to more extensive crosslinking within the polymer network. For example A2 has a 
deformability modulus of 91.23N/mm when crosslinked with zinc ions whereas a significantly 
lower modulus of 67.17N/mm was obtained for calcium-crosslinked matrices. However, zinc-
crosslinked G-rich alginate gelispheres (i.e. A5 and A6) demonstrated significantly lower 
resilience, deformability moduli and fracture energy than their calcium-crosslinked counterparts 
(Figure 2.5a-c). This was due to the weaker bonds produced between the small cation and G-units.  
Barium also demonstrated selective binding with G-rich alginates A5 and A6, thus generating 
gelispheres which displayed high deformability moduli, 188.76N/mm and 167.50N/mm 
respectively. This is discussed further in the next section.  
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2.3.1.2 Influence of Crosslinking Agent on the Textural Properties of Unhydrated Alginate 
Gelispheres 
Divalent calcium ions have an ionic radius of 114pm with an atomic volume of 29.9cm3/mol, 
while divalent zinc ions have smaller ionic radii of 88pm with, an atomic volume of 9.2cm3/mol 
(Ionic Information of Calcium, 2004; Ionic Information of Zinc, 2004). Thus they prove to be a 
greater challenge to destabilize from within their highly stable crosslinked G-unit pockets. Hence 
the crystal structure of the zinc-crosslinked gelispheres succumbed to the pressure of applied 
mechanical stress more easily causing collapse of the matrix. 
   
Figure 2.6: Spatial arrangement of (a) zinc (b) calcium and (c) barium ions.  
(Source: http://www.scescape.net/~woods/elements/zinc.html 2004; 
http://www.scescape.net/~woods/elements/calcium.html 2004; 
http://www.scescape.net/~woods/elements/barium.html 2004). 
 
Calcium ions in their divalent states are present as an ordered rigid hexagonally close-packed shape 
(Figure 2.6). The zinc ions in comparison are arranged in a distorted hexagonally close-packed 
shape (Ionic Information of Calcium, 2004; Ionic Information of Zinc, 2004). This implies that 
zinc due to its smaller atomic radius (almost a third of that of divalent calcium ions) and distorted 
structure has the capacity to insert itself into sites where the larger calcium ions cannot. Divalent 
barium ions have an even larger ionic radius at 149pm and atomic volume of 39.24cm3/mol (Ionic 
Information of Barium, 2004). These Ba2+ ions exist in a body centred cubic structure as a 6-
(a) (b) (c) 
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coordinate octahedron (Figure 2.7). Their observed interaction with alginate was thus very 
different from calcium and zinc ions. The chelated structure formed as result of the alginates’ G-
unit interaction with the cations was thermodynamically more favourable, since due to its larger 
ionic radius it produced a more compact arrangement with ‘smaller voids’ (Al Musa et al., 1999). 
Ba2+
H2O H2O
H2O H2O
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O O
G
OO
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Figure 2.7: The interaction of divalent barium ions with carboxylic acid groups on alginate G-
units and water molecules (octahedral arrangement) within the polymeric matrix. (Source: Adapted 
from Briceño et al., 2002).  
 
The results demonstrated that there is an inverse relationship between matrix resilience (which 
confers to matrix porosity) and fracture energy (which confers to matrix hardness) for gelispheres 
crosslinked with calcium and zinc. It is postulated that this emerges from the fact that the 
application of a deforming force on the gelispheres compresses the loose matrices and thus 
indicated that a porous sponge-like matrix was present. Thus the fracture energy was in fact 
indicative of the energy needed to maximally compress the gelispheres which subsequently led to 
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rupture of the matrix. Barium-crosslinked gelispheres demonstrated low matrix resilience and 
fracture energy however their deformability moduli exceeded those of the calcium and zinc-
crosslinked counterparts by between approximately 49-121N/mm and 36-102N/mm respectively 
for the various alginates. This indicated that barium-crosslinked gelispheres were brittle in nature, 
as opposed to the amorphous porous matrices of the calcium and zinc-crosslinked gelispheres.  
Gelispheres produced by a Ba/Ca combination were less porous than those produced by a Ba/Zn 
combination, indicated by the lower resilience and high fracture energies of Ba/Ca-crosslinked 
gelispheres. Conversely, Ba/Zn-crosslinked matrices demonstrated higher resilience and G/M ratio 
dependant behaviour on fracture energy, indicated by the lower fracture energies demonstrated by 
G-rich alginates, A5 and A6.  
 
On the other hand, zinc imparted an amorphous character particularly to M-rich Ba/Zn-crosslinked 
gelispheres.  For example, the M-rich alginate A1 had an unhydrated matrix resilience of 48.80% 
when crosslinked with Ba/Zn, while this value declined to 15.57% when crosslinked with the 
Ba/Ca combination. This occurred with Ca/Zn-crosslinked matrices also. While the calcium ions 
selectively bound with G-units; zinc ions could bind with both G- and M-units (McDowell, 1979). 
The zinc ions could not be displaced by the calcium ions from their stable locations within the 
polymeric network. The smaller atomic size of the divalent zinc ions implied that they could fit 
into smaller electronegative polymer pockets. However, this also implied that the resultant 
structure was more porous due to the presence of larger ‘voids’ between the polymeric chains. The 
resilience values for unhydrated M-rich alginates, i.e. A1-A4 were approximately 10-20% higher 
for zinc-crosslinked gelispheres, versus their calcium-crosslinked counterparts. With regards to the 
combination of Zn/Ca/Ba, a dominant effect of calcium and barium was observed.  
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2.3.2 Textural Analysis of Hydrated Alginate Gelispheres 
 The results generated for hydrated gelispheres over a period of 96 hours provided significant 
insight into the mechanism of hydration and subsequent disentanglement of the gelisphere 
matrices. The gelispheres eroded completely after 96 hours.  
 
The hydrated gelisphere matrices underwent gelation when exposed to aqueous medium as a result 
of the polymeric network undergoing chain relaxation (Figure 2.8). This increased the viscoelastic 
properties of the gelispheres and resulted in a decrease in matrix rigidity and resilience. As the 
gelispheres become hydrated the matrix initially swelled to accommodate the water molecules 
diffusing into the gelispheres and adopted its new porous structure. Once water had penetrated the 
core of the gelispheres, the ‘egg-box’ structure broke and they began to lose weight and finally 
eroded. It has been postulated that dissociation of the crosslinking cations initially occurs at the site 
of M-unit binding (Al Musa et al., 1999). As mentioned earlier, the cations bind to the 
electronegatively charged carboxylic acid (–COO-) groups of the M-units. Hence, once the cations 
were dissociated from these locations an electrostatic repulsive force was generated between the 
electronegative groups resulting in chain relaxation, increased water uptake and gel swelling. 
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Figure 2.8: Schematic illustration of the hydration mechanism and erosion of ionically crosslinked 
gelispheres.  
 
Apparent ‘increases’ in robustness (indicated by peaks in the resilience profiles) resulted due to the 
unique hydration mechanism of the gelispheres. The gelispheres absorbed water and sequentially 
formed peripheral layers of hydrated crosslinked polymer, while the central core remained 
unhydrated. As the peripheral layers reached maximal hydration and ruptured, the subsequent layer 
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became exposed to water molecules and in turn underwent hydration. Therefore hydration occurred 
in concentric layers within the gelispheres (Figure 2.9).  
Time (hours)
0 20 40 60 80
M
at
rix
 R
es
ili
en
ce
 (%
)
0
10
20
30
40
50
A1
A2
A3
A4
A5
A6
 
Time (hours)
0 20 40 60 80
M
at
rix
 R
es
ili
en
ce
 (%
)
0
10
20
30
40
50
A1
A2
A3
A4
A5
A6
 
Time (hours)
0 20 40 60 80
M
at
rix
 R
es
ili
en
ce
 (%
)
0
10
20
30
40
50
A1
A2
A3
A4
A5
A6
 
Figure 2.9: Contd. on pg 75 
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Figure 2.9: Matrix resilience (%) of hydrated alginate gelispheres crosslinked with (a) calcium, (b) 
zinc, (c) barium, (d) calcium and zinc, (e) calcium and barium, (f) barium and zinc, (g) calcium, 
barium and zinc over a period of 96 hours (N=3; SD<3.18%).  
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Figure 2.10: Contd. on pg 77 
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Figure 2.10:  Deformability modulus (N/mm) of hydrated alginate gelispheres crosslinked with (a) 
calcium, (b) zinc, (c) barium, (d) calcium and zinc, (e) calcium and barium, (f) barium and zinc, (g) 
calcium, barium and zinc over a period of 96 hours (N=3; SD<5.42N/mm).  
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Figure 2.11: Contd. on pg 79 
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Figure 2.11: Fracture energy (Nm) on hydrated alginate gelispheres crosslinked with (a) calcium, 
(b) zinc, (c) barium, (d) calcium and zinc, (e) calcium and barium, (f) barium and zinc, (g) calcium, 
barium and zinc over a period of 96 hours (N=3; SD<0.0005). 
 
2.3.2.1 Influence of the Co-ordination Number of Crosslinking Agent on Matrix Hydration 
The rate and extent of chain relaxation and water uptake was markedly decreased as the degree of 
crosslinking increased. This was reflected in the physicomechanical properties undergoing a 
generalized decline over time when exposed to hydration. When exposed to hydration zinc-
crosslinked gelispheres demonstrated slower rates of chain relaxation and matrix degradation. This 
was due to the fact that water penetrated these gelispheres more slowly and to a lesser degree over 
time in comparison to the calcium-crosslinked spheres. Upon hydration, calcium ions have a 
(f) (g) 
(d) (e) 
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greater propensity to attract oxygen atoms in water molecules due to the fact that they possess 
higher co-ordination numbers (7-9) in the crystal structure (Cambridge Structural Database, 
Version 5.25, 2004). Zinc ions bind with lower co-ordination numbers (4-6) in the crystal state 
(Cambridge Structural Database, Version 5.25, 2004) and therefore do not have as significant a 
water attracting power as calcium. Hence when exposed to water the crystal lattice of the zinc-
crosslinked matrix underwent chain relaxation and subsequent degradation more slowly. 
Furthermore, due to the more extensive polymeric binding with zinc ions, the matrix did not 
collapse when it was dissociated from G-unit bound sites, as was the case with calcium-crosslinked 
matrices. Over time zinc-crosslinked gelispheres also indicated overall higher initial deformability 
moduli than their calcium-crosslinked counterparts. Unhydrated zinc-crosslinked gelispheres had 
deformability moduli 10-30N/mm higher than calcium-crosslinked gelispheres. Upon hydration, 
the corresponding values for zinc-crosslinked gelispheres at any given point in time were higher by 
approximately 2-20N/mm than hydrated calcium-crosslinked gelispheres.  
 
2.3.2.2 Influence of G/M-Ratio on Matrix Hydration 
The degree of chain relaxation over time varied with the different grades of alginates, such that 
some alginates (e.g. M-rich A4) underwent polymeric relaxation to the core almost immediately, 
while others (e.g. G-rich A5) retained an unhydrated core up to 24-72 hours. The G-rich alginate 
A5 crosslinked with calcium had an unhydrated deformability modulus of 71.78N/mm, which 
declined to 36.23N/mm after 24 hours exposure to hydration. However, after 72 hours exposure to 
hydration however, it ‘increased’ to 71.60N/mm. This indicated that although hydration of the 
peripheral layers of the gelisphere did occur, the unhydrated core was not exposed to water until 72 
hours, where-after hydration of the core occurred rapidly when the deformability modulus declined 
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to 36.75N/mm. Correspondingly apparent ‘increases’ in the observed fracture energy required to 
rupture gelispheres were greater at 24 and 48 hours following hydration due to swelling of the 
gelispheres. Thus anomalous results were obtained as the probes broke through the hydrated layers 
of the gelispheres and approached the rigid crosslinked unhydrated core.  
 
Zinc-crosslinked alginates with low G/M-ratios allowed the formation of more rigid gels upon 
hydration. This can be explained in terms of the fact they possess a greater capacity for interaction 
with the zinc cation. The unhydrated gelispheres formulated with alginates the low G/M-ratio 
alginates A1-A4 crosslinked with zinc, possessed initial deformability moduli in the region of 
85.00-91.23N/mm. Upon hydration, relatively M-rich alginates such as A3 and A4 crosslinked 
with zinc retained an unhydrated core until 96 hours. Hence although an initial decline 
(approximately 10%) in resilience could be seen after 72 hours, at t=96 hours the resilience 
‘increased’ by approximately 9% to reveal the unhydrated rigid zinc-crosslinked core.  
 
2.3.2.3 The Influence of G-Unit Selectivity for Crosslinking Agents on Matrix Hydration 
Gelispheres prepared by employing a Ca/Zn combination of crosslinking agents demonstrated 
results that were a direct function of G-ratio and polymer molecular weight. While for relatively 
M-rich alginates such as A1, the effect was that the combined crosslinking resulted in a weakening 
of the unhydrated matrix in comparison to gelispheres prepared with only zinc as the crosslinking 
agent. Upon subsequent hydration the matrix of the Ca/Zn combination gelisphere remained more 
robust through the 96 hours. At the 96th hour when the unhydrated core was exposed to hydration, 
the deformability moduli for calcium, zinc and Ca/Zn combination were observed to be 
48.55N/mm, 50.82N/mm and 66.44N/mm respectively. This phenomenon can be explained in 
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terms of the combined effects of thermodynamically more stable binding of calcium ions with 
electronegative cavities of G-units with the extensive binding within the matrix provided by zinc 
ions and M-units. Water molecules therefore not only had to dissociate stable zinc-M-unit bonds, 
but also destabilize the large calcium ions from their G-bound cavities in the matrix.  When 
unhydrated Ca/Zn-crosslinked gelispheres were exposed to hydration, a rearrangement of 
crosslinking cations within the polymeric cavities allowed the matrix to acquire a 
thermodynamically stable arrangement that was more compact than the individually crosslinked 
matrices. For G-rich alginate A6 this phenomenon was clearly synergistic. The deformability 
moduli of the unhydrated spheres crosslinked with a Ca/Zn combination of cations was greater 
(87.15N/mm) than either calcium or zinc-crosslinked gelispheres (62.02N/mm and 74.43N/mm 
respectively). Furthermore, it was observed to be the larger value (53.03N/mm) (more robust 
gelisphere) of the three over the 96 hours subsequent to hydration (31.05N/mm and 42.29N/mm 
for calcium and zinc-crosslinked gelispheres respectively).   
 
2.3.2.4 Barium as a Matrix Re-inforcer for G-rich Alginates 
It was observed that barium had a significant impact on the hydration dynamic of the polymeric 
matrices. As mentioned earlier, barium imparted a brittle character to the matrices due to its more 
compact binding mechanism with the polymer. The gelispheres were therefore less resilient and 
demonstrated higher deformability moduli. The interaction of Ba/Ca combination-crosslinked 
gelispheres with water molecules was similar to that shown by barium-crosslinked gelispheres. 
However the interaction with zinc ions produced an interesting phenomenon. Resilience underwent 
a sharp decline in the first 24 hours following which it stabilized for the next 72 hours. The average 
decline in resilience of Ba/Zn combination-crosslinked gelispheres observed in the first 24 hours 
 83
was 34.79% (SD<5%). This decline was not as large when all three cations are employed to 
crosslink the matrix. For the first 24 hours the decline was 20.42% (SD<4%). This phenomenon 
was also seen in the deformability modulus values for the respective gelispheres. Sharp declines 
were observed, in particular over the first 24 hours. While high values were prevalent for all 
unhydrated gelispheres which had barium as one of the crosslinking agents, the initial decline after 
exposure to hydration was significant. Fracture energy indicated a notable deviation. Following 
hydration, the abovementioned gelispheres demonstrated higher fracture energies. This can be 
explained in terms of the fact that zinc within matrices could easily be displaced from M-bound 
units with penetrating water molecules. The selectively G-unit-bound barium ions proved to be 
greater challenge to displace. The brittle Ba/Zn crosslinked gelispheres therefore demonstrate low 
deformability moduli (in the region of 57.36-32.32 N/mm) throughout the study.  
 
2.3.3 Erodibility of the Crosslinked Alginate Gelispheres   
Crosslinked water-soluble polymeric matrices such as those generated in this study undergo 
erosion through a very unique mechanism. The generation of water-soluble entities from the initial 
water-insoluble matrix that leads to the eventual degradation of the matrix involves a stepwise 
process. Theoretically it has been stated that ‘as long as the crosslinks (within the three-
dimensional polymeric network) remain intact, it is insoluble, and, when placed in an aqueous 
medium it can swell only to the extent allowed by the crosslink density’ (Heller, 1987). Thus the 
process of matrix erosion is dependant upon two mechanisms, namely: 
1. Cleavage of the crosslinks;  
2. Cleavage of the water-soluble polymeric backbone. 
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Cleavage of polymeric bonds within such a matrix results in chain disentanglement and the 
formation of pores in the structure. These ‘pores’ hold the penetrating water, causing the matrix to 
swell. This swelling allows the influx of more quantities of water and results in the ionisation of 
the polymer causing subsequent dissolution into the aqueous medium. The process culminates in 
the loss of the integrity of the matrix and its degradation. 
 
2.3.3.1 Influence of G/M Ratio and Crosslinking Agent on Matrix Erosion 
Results indicated that matrix erosion over time was maximally observed with calcium-crosslinked 
gelispheres (approximately 39.90 - 59.17% gelisphere mass was lost within 48 hours of exposure 
to hydration). Zinc and barium-crosslinked matrices remained comparatively more intact for a 
longer period of time. In comparison, at 48 hours zinc-crosslinked gelispheres underwent between 
11.87 - 24.89% matrix erosion, while barium-crosslinked gelispheres underwent only 20.81 -
28.40% erosion. As stated previously, the slower rates of hydration of the central core of the 
gelispheres with these matrices implied that the matrix remained intact for a longer duration. The 
various combination-crosslinked matrices demonstrated a general trend of slower rates of 
hydration over the first 24 hours after which the rate of matrix degradation increased exponentially. 
This was due to the destabilizing effect of calcium ions on the matrix and their greater affinity for 
water molecules that caused the gelispheres to swell and lose their integrity at a faster rate. 
Observed differences between the various M-rich alginates of varying molecular weight were not 
significantly vast. However, gelispheres crosslinked with only calcium indicated that the rate of 
matrix degradation and erosion was a function of G-ratio in the polymer. Although barium ions 
possess a greater water-attracting potential (due to its higher coordination number), it formed 
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chelates with the alginate G-units which were less porous. This implied that water molecules had 
greater difficulty penetrating the matrix and to force chain disentanglement. Thus the profile of 
barium-crosslinked gelispheres imitated that of zinc. The compact barium-crosslinked alginate 
structure retained its integrity for a longer duration of time.   
 
Table 2.4 indicates the range of matrix erosion for the various alginates crosslinked with 
combinations of cations were as follows. 
 
Table 2.4: Range of matrix erosion for the various alginate gelispheres crosslinked with various 
combinations of divalent cations after 24 hours of exposure to hydration.  
Crosslinking 
Cations 
Mean Matrix Erosion (%) 
(t=24 hours) 
Standard Deviation for 
Matrix Erosion (%) 
(t=24 hours) 
Ca/Zn 13.42 4.50 
Ba/Ca 56.76 3.39 
Ba/Zn 52.71 2.95 
Ba/Ca/Zn 55.35 3.06 
 
 
The differences between the rates of matrix erosion of gelispheres crosslinked with various 
combinations of the three cations were not vast. The exception to this rule was Ca/Zn combination-
crosslinked gelispheres. The Ca/Zn-crosslinked gelispheres underwent an exponential rise in 
matrix erosion after 24 hours. By the 96th hour, gelisphere matrices were between 38.12 - 65.86% 
eroded. In comparison, at 96 hours, the other gelispheres underwent little, if any change following 
their initial 24 hour degradation. This can be explained in terms of the fact that once zinc was 
initially removed from its M-unit chelated sites, the matrix became significantly more porous and 
open to the entry of water molecules. Thus following the first 24 hours exposure to hydration, 
subsequent entry of water molecules into the matrix and degradation was much more rapid. The 
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presence of barium imparted a significant degree of robustness to the alginate matrices. Barium-
crosslinked matrices retained their integrity for a prolonged period of time. Initially the matrix 
eroded rapidly due to the ions rapid displacement from weakly bound M-unit bound regions. 
Subsequent disintegration is prevented due to tightly bound G-unit bound components of the 
matrix, which were difficult to displace.   
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Figure 2.12: Contd. on pg 88 
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Figure 2.12: Matrix erosion (%) of gelispheres following hydration crosslinked with (a) calcium, 
(b) zinc, (c) barium, (d) calcium and zinc, (e) calcium and barium, (f) barium and zinc, (g) calcium, 
barium and zinc over a period of 96 hours (N=3; SD<4.52%).  
 
2.4 Concluding Remarks 
The results indicated that the different crosslinking agents interacted with varying intensity with 
monomeric units of the polymer, thereby generated gelispheres with significantly different 
mechanical characteristics. The study demonstrated that the relative monomeric (G/M) ratio within 
the alginates significantly influenced the degree of crosslinking and subsequently the 
physicomechanical behaviour of formulated gelispheres. Textural analysis of the different matrices 
indicated that that the robustness of crosslinked matrices declined over time when exposed to 
(d) 
(g) (f) 
(e) 
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hydration through a gradual process of concentric hydration whereby the peripheral layers of the 
matrix become hydrated first.  
 
Overall textural analysis of the crosslinked gelisphere matrices indicated that incorporation of 
barium imparted a brittle character to the crosslinked matrices due to the formation of densely 
compact crosslinked polymeric networks. The presence of zinc in crosslinked matrices produced 
porous and therefore resilient gelispheres which interacted more significantly with the M-rich 
alginates. Zinc-crosslinked gelispheres possessed porous networks that demonstrated little change 
in matrix resilience despite indicating a slight decline in matrix hardness following exposure to 
hydration over time due to dislocation from M-unit bound sites within the polymeric network. The 
calcium matrices demonstrated intermediate mechanical characteristics and imparted greater 
robustness to gelispheres with high G/M-ratios due to their preferred chemical affinity for G-units 
within alginate networks.  In terms of matrix erosion it was observed that zinc-crosslinked 
gelispheres demonstrated the most rapid rates of erosion due to the formation of porous matrices 
that allowed easier entry of water molecules into the polymeric networks. Calcium and barium in 
particular demonstrated selectivity for G-rich alginates, imparting them with significantly more 
compact crosslinked matrices. Matrix erosion occurred least significantly with zinc and barium-
crosslinked matrices. Calcium-crosslinked gelispheres remained most intact over time following 
hydration. It was also observed that the most significant degradation of gelisphere matrices 
occurred within the first 24 hours of exposure to hydration. 
 
In view of the rapid matrix erosion rates, it was established that in order for the system to survive 
simulated CSF, the system required further reinforcement. This was achieved by the addition of 
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further polymers into the gelisphere matrix (discussed in the following chapter). Barium-
crosslinked gelispheres demonstrated beneficial properties in terms of their capacity to generate 
denser compact matrices which allowed minimal penetration of hydrating media and indicated 
slower rates of degradation. These compact matrices are ideal for entrapping small molecules such 
as nicotine, the proposed model neuroprotectant into their cavities and preventing rapid drug 
release. 
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Chapter 3  
Evaluating the Role of Hydroxyethylcellulose and Polyacrylic Acid on the 
Modifying Drug Release Rates of Crosslinked Alginate Gelispheres  
 
‘……scientific research was much like prospecting: you went out and you hunted, armed with 
your maps and your instruments, but in the end your preparation did not matter, or even your 
intuition. You needed your luck, and whatever benefits accrued to the diligent through sheer, 
grinding hard work.’ 
 
- The Andromeda Experiment, Michael Crichton, 1969. 
 
3.1 Introduction 
Advances in producing high-performance polymer-based compositions is predominately the 
utilization of new mixtures of polymers and mixtures of polymers with reinforcing components, 
rather than from new polymer compositions. Multi-polymeric systems resulting from the 
combination of two or more miscible polymers can under certain circumstances result in the 
development of systems that have superior properties than either system alone. The development 
of strong interfacial adhesion, either though the development of covalent bonds or secondary 
bonds, such as dipole interactions or the significantly stronger hydrogen bonds may result in a 
system with properties demonstrating synergy between the components to bring about superior 
mechanical strength, easier processability and wider commercial applicability.   
 
As outlined in Chapter 2, the ability of alginate to react with crosslinking cations is a direct 
function of the average length of G-units within the polymer. During initial studies the 
combination of a high G-content alginate (A5 from Chapter 2) with numerous biodegradable 
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polymers was evaluated to produce a polymeric system that had superior robustness and delayed 
degradation kinetics than the conventional calcium-crosslinked alginate systems currently 
employed for drug delivery.  
 
The following polymers were evaluated as reinforcing agents for the crosslinked alginate 
gelispheres during preformulation: 
• Cellulosic ethers including hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC); 
and hydroxypropylmethylcellulose (HPMC); 
• Polyesters including polylactic acid (PLA) and poly(lactic-co-glycolic) acid (PLGA) of 
varying viscosities; 
• Poly(acrylic acid) (PAA); 
• Pectin with varying degrees of methoxylation; and 
• Polyvinyl alcohol (PVA) of various molecular weights 
 
Results demonstrated that although gelispheres generated by ionotropic gelation as discussed in 
Chapter 2 employing various polymer blends, none were able to retard nicotine release sufficiently 
beyond 2 hours when exposed to simulated cerebrospinal fluid (CSF). Furthermore, being a 
polyanionic polymer, alginate is known to degrade in the presence of an alkaline pH (physiological 
pH 7.4) due to interactions between carboxylic acid groups in the polymer and the surrounding 
alkaline medium that induces ionization of the polymer (which confers to enhanced solubility) and 
subsequently polymer degradation. Hence it was concluded that induction of an interaction 
between the free carboxylic acid groups, particularly those of the M-units (since G-units have a 
 93
significant and selective interaction with crosslinking ions employed in gelation) with another 
species, degradation could be retarded. 
 
The polymer that demonstrated the most promising results was the cellulosic ether, 
hydroxyethylcellulose (HEC). This hydroxylated cellulosic ether is a non-ionic water-soluble 
polymer. Its physiochemical properties are discussed in more detail in the following sections. 
 
Cellulose is the most abundant naturally occurring polysaccharide. Being a polysaccharide it is a 
biodegradable and biocompatible polymer composed of polymerised sugar monomers. It is 
arranged predominately as linear 1,4-β-D’-glycosidic linked β-D-glucospyranose units that have 
the capacity to arrange themselves in closely formed arrangements through the formation of strong 
secondary hydrogen bonds and numerous other primary and secondary valence attachments. The 
resulting huge molecular structure is one that is rigid and poorly water soluble. It forms the main 
constituent of structural components in plants. Celluloses have very high molecular masses and 
due to their size and strong associative forces demonstrate poor water solubility.  
 
Figure 3.1: The chemical structure of cellulose composed of linear 1,4-β-D’-glycosidically-linked 
β-D-glucospyranose units. (Source: Ludwig, 2005). 
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Each anhydroglucose unit in the cellulose molecule has three reactive hydroxyl groups (depicted 
by (*) in Figure 3.1). Cellulosic ethers such as hydroxyethylcellulose (HEC) (Figure 3.2) are 
prepared by the action of ethylene oxide or ethylene chlorhydrin on alkali cellulose (cellulose 
treated with sodium hydroxide). This reaction occurs in two steps first, whereby ethylene oxide 
reacts at the hydroxyls (*) in the cellulose chain and subsequently ethylene oxide polymerizes to 
form a side chain. The polymer employed in this study has two units of ethylene oxide groups and 
a degree of substitution of 1.5, i.e. two units of hydroxyls substitutes in two units of ethylene oxide. 
These polymers are more soluble in water and alkaline solutions than native cellulose and insoluble 
in organic solvents. The hydroxyl groups attached to the ethyl groups imply that the polymeric 
chains are branched hence, do not associate as significantly as native cellulose (Whistler et al., 
1953). Its application in the pharmaceutical industry includes formulation of controlled-release 
dosage forms (Alvarez-Fuentes et al., 2004; Andrews and Jones, 2006), as a binder and coating 
agent in tablets (Wade and Weller, 1994), and as a bioadhesive in muco-adhesive patches and 
implants (Dayal et al., 2005; Andrews and Jones, 2006).  
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Figure 3.2: The chemical structure of the cellulosic ether hydroxyethylcellulose (HEC).  
(Source: Ludwig, 2005). 
 
Initial studies indicated that the interaction between alginate and various celluloses and polyesters 
indicated extremely rapid matrix degradation and drug release rates. The interaction occurring 
between alginate and HEC was however exceedingly promising in this regard.  
 
Recent studies employing combinations of the alginate and HEC to develop membranes have 
indicated concurring results of the presence of a synergistic interaction between the polymers 
(Naidu et al., 2005; Kalyani et al., 2006). The membranes developed have been applied in the field 
of chemical, petrochemical and the pharmaceutical industry. However no study thus far has 
employed the alginate-HEC combination in a crosslinked gelisphere matrix for the purpose of 
achieving sustained drug release. 
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Alginate salts such as sodium alginate undergoes gelation below a pH of 3 to form alginic acid. 
This fibrous precipitate of alginic acid demonstrates some significant physicochemical and 
physicomechanical properties which differ from its predecessor (Stanford, 1883; 1884; 1885; 
1886). According to typical X-ray diffraction (XRD) profiles (Figure 3.3), it is observed that 
sodium alginate is not a flat molecule, like most celluloses, which have a typical fibre period of 
10.0Å (Whistler et al., 1953). Alginate is an amorphous polymer with a fibre period of 
approximately 15.0Å. Alginic acid and sodium alginate have polymeric arrangements that differ in 
the skew symmetry and the conformation of the pyranose rings that lead to different 
physiochemical properties. Alginic acid has a fibre period of 8.7Å (Whistler et al., 1953), 
indicating that it is superiorly three-dimensional with a significantly greater negative rotation 
within the molecule. It demonstrates greater stability to hydration in comparison to its salt but is 
capable of absorbing approximately 200 to 300 times its weight of water and salts to the extent 
of 60% of its own weight (Hoagland and Lieb, 1915). It is insoluble in cold water and only mildly 
soluble in hot water and is significantly resistant to acidic degradation, however degrades in hot 
alkaline solutions after several days (Stanford, 1883; Percival and McDowell, 1967). In the 
unhydrated state it is rigid and extremely resistant to the action of solvents. As a colloid alginic 
acid may be considered an irreversible gel.  
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Figure 3.3: X-ray diffraction (XRD) profile observed for the G-rich sodium alginate (FMC 
BioPolymer) selected for further studies. 
 
 
 98
Polyacrylic acid (PAA) is also called a polyelectrolyte since each monomeric unit has an ionizable 
carboxylic acid group (Figure 3.4). PAA has the unique ability to absorb significant amounts of 
water significantly exceeding its own weight. For this study the PAA Carbopol® 934 was 
employed to coat the reinforced gelispheres. It is a lightly crosslinked branched chain polymer of 
polyacrylic acid. It has a high molecular weight of approximately 3 MDa and a pKa between 5.35 
and 7.2 (Mortazvi and Smart, 1995; Riley et al., 2001). At a low pH, the degree of dissociation of 
the carboxylic acid groups is low and the polymer adopts a coiled conformation, while at a high 
pH, the chain expands as a result of intra-polymeric electrostatic repulsions. The polymer appears 
more hydrophobic when the chain is in a compact conformation. It has been employed in the field 
of pharmaceutical drug delivery due to its unique muco- and bioadhesive properties (Cuña et al., 
2001; Baloğlu et al., 2003). 
CH2CH
COOH
 
Figure 3.4: The chemical representation of the monomer in Carbopol® 934; the covalently 
crosslinked branched chain polymer employed to coat the crosslinked reinforced alginate 
gelispheres. (Source: Ludwig, 2005). 
 
Its equilibrium swelling is highly affected by various factors including pH and ionic strength of the 
hydrating medium. In aqueous media with a physiological pH of 7.4, Carbopol® 934 exists as 
swollen gel particles. Inter-particulate contact is a prerequisite for gel formation. In the presence of 
cations the negatively charged carboxylic groups are shielded, resulting in less repulsion between 
the polymer chains. Polyacrylic acids appear to have an especially strong affinity for divalent 
cations such as zinc and calcium (Kriwet and Kissel, 1996; Lueßen et al., 1996). Complexation of 
the divalent cations with the polymer is dependant on the accessibility (which corresponds to the 
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degree of pH dependant ionisation) of carboxylic acid groups. It has also been suggested that 
divalent ions such as calcium may bridge adjacent carboxylic acid groups in the polymer (Kriwet 
and Kissel, 1996), which would influence the rheological properties by permitting the formation of 
more entangled networks within the hydrated gels.   
 
Crosslinked systems have received much focus as a means of achieving prolonged release in drug 
delivery. The phenomenon of crosslinking or the formation of covalent bonds between individual, 
often heterogeneous polymeric chains allows the formation of macro-networks (illustrated in 
Figure 3.5) that have significantly greater dimensional stability, increased thermal and chemical 
resistance than either of the individual polymer systems (Rosen, 1993; Painter and Coleman, 
1997). Thus their capacity to retard and significantly prolong drug release confers them suited for 
controlled release. The degree of crosslinking is a function of numerous factors, including the type 
of crosslinking agent employed, the concentration, crosslinking reaction time, polymer viscosity 
and molecular mass and concentration of the polymers (Al Musa et al., 1999). 
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Figure 3.5: Schematic illustrating the mechanism of crosslinking of alginate G-units with divalent 
calcium ions.   
 
Previous studies have focused on employing divalent and trivalent ions as crosslinking agents for 
hydrophilic polymers. In terms of drug delivery, this interaction has been evaluated in particular 
between the pectins and alginates (Cohen et al., 1997; Pillay and Fassihi, 1998; Miyazaki et al., 
2000; Nokhodchi and Tailor, 2004; Pillay et al., 2005). The formation of crosslinks within the 
polymeric matrices leads to the formation of covalent bonds which causes precipitation of the 
insoluble hydrogel. Such crosslinking processes increase the rigidity of the polymer and reduce 
their swelling in solvents. This generally causes it to have a reduced permeability and release of 
incorporated drugs from polymeric matrices (Badwan et al., 1983, Al Musa et al., 1999). 
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The following sections discuss the physiochemical properties of the model neuroprotectant 
nicotine employed for the study. The three phase approach (discussed in detail further on) 
adopted for the formulation and optimisation of the multi-polymeric ionotropically crosslinked 
gelispheres is presented. Formulations are evaluated employing a combination of textural 
analysis, drug release studies, drug entrapment efficiency, enthalpic techniques and FTIR to 
elucidate the factors that mediated their physicomechanical behaviour on a molecular level.   
3.2 Materials and Methods 
Nicotine ((-)-1-methyl-2-(3-pyridyl)-pyrolidine) was purchased from Sigma Pharmaceuticals 
(Sigma Pharmaceutical Group; MA, USA). The polymers that the gelispheres comprised of 
included: Sodium alginate which was donated by FMC BioPolymer (Drammen, Norway) and 
hydroxyethylcellulose (HEC), which was donated by Hercules Inc., Natrosol® Pharm (Wilmington, 
DE, USA). The crosslinking agents employed were zinc sulphate, calcium chloride and barium 
chloride which were donated by UniLab, Saarchem (Pty.) Ltd. (Krugersdorp, Republic of South 
Africa).  
 
3.2.1  Physiochemical Properties of Nicotine  
Nicotine or (-)-1-methyl-2-(3-pyridyl)-pyrolidine is a bicyclic alkaloid with a pyridine ring and a 
pyrrolidine ring. The molecule possesses a chiral carbon (depicted in Figure 3.6), therefore exists 
in two enantiomeric forms. In nature, nicotine only exists in the S-enantiomer, which is levo-
rotatory.  
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N
N
CH3
3-(1-Methyl-pyrrolidin-2-yl)-pyridine
 
Figure 3.6: The 2-dimensional representation of the S-enantiomer of nicotine. The (*) indicates 
the location of the chiral carbon. (Source: Armstrong et al., 1998). 
 
 
It is a weak base with a pKa of 8.0 and is soluble in both lipids and water. Native nicotine exists as 
a pale yellow pungent liquid. At physiological pH of 7.4, 31% of nicotine exists in the unionized 
form, hence can readily diffuse through biological membranes, including the BBB. The chemical 
properties of nicotine are briefly summarized in Table 3.1. 
Table 3.1: The chemical properties of nicotine. (Source: CRC Handbook, 2004). 
Property Nicotine 
Formula C10H14N2
Molecular weight 162,234 g.mol-1
Melting point -7.9°C
Boiling point 247°C
Basicity (pKa) 8.0
Ionization (pH 7.4) 69%
Aqueous solubility of tartarate salt (21ºC) 50mg/mL
 
A typical Fourier Transform Infrared (FTIR) spectrum of nicotine (Figure 3.7) indicates the 
following peaks that characterize its various chemical groups: 
• Between 2700 and 2390 cm-1 indicates C-H stretching.  
• The peak at 1647 cm-1 indicates an aromatic C=N double bond stretching.  
• The peak at 1691 cm-1 aromatic C=C double bond stretching.  
• The peaks at 717 cm-1 and 896 cm-1 correspond to the out of plane bending  
* 
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Figure 3.7: FTIR spectra of nicotine.  
 
 
The hydrogen tartarate salt of nicotine (nicotine hydrogen tartarate or NHT), was employed for 
this study. It is a crystalline substance and is an extremely stable substance compared to the 
nicotine base, which is known to be highly unstable (Place et al., 1992). Upon exposure to aqueous 
medium, NHT dissociates to form tartrate ions and nicotine (Place et al., 1992). Figure 3.8a 
depicts the typical DSC profile obtained. The first distinct endothermic peak observed at 91.54ºC 
corresponds to the heat of fusion of the solid crystalline powder of the tartarate salt of nicotine. 
The second peak observed at 183.60ºC corresponds to the point when it is liberated from its salt 
and exists as pure nicotine in the liquid form. The peak seen at 207.09ºC corresponds to the 
temperature beyond which the liquid nicotine loses its crystalline properties and becomes an 
isotropic liquid.  
 
A typical X-ray diffraction profile (XRD) (Figure 3.8b) indicates the presence of a significant 
peak at an angle of 17.95 2-Theta degrees which it is proposed corresponds to the pyrrolidine 
Wavenumber cm-1
%
 Transm
ittance 
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ring. Smaller peaks observed at 22.49 and 27.08 2-Theta degrees correlate to the pyridine ring 
and methyl group respectively.  
0.00 100.0 200.0 300.0 400.0
Temp [C]
-10.00
-5.00
0.00
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Acquisition Date 05/09/19
Lot No: N1
Sample Name: projekN
Sample Weight: 2.909[mg]
Operator: Wilna Liebenberg
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Figure 3.8: Typical (a) DSC and (b) X-ray diffraction (XRD) profile observed for the model 
neuroprotectant nicotine. 
 
(b) 
 106
3.2.2  Standard Curve for Nicotine 
 
Figure 3.9: UV spectrum for nicotine (WinASPECT, Version 1.6.13.0, 2002, Analytik Jena AG, 
Germany). 
  
 
The maximum UV absorption of nicotine occurs at a wavelength of 261nm (Figure 3.9). To 
generate the standard curve for nicotine three dilutions of nicotine were prepared in 0.1M PBS with 
a pH of 7.4 (Figure 3.10).  
 
It was observed that the polymers employed to formulate the gelispheres, namely alginate and 
HEC, absorbed at a wavelength of 261nm. Since this interfered with an evaluation of nicotine 
absorbance at the same wavelength an alternative one was selected where the absorbance of 
nicotine was sufficiently significant but would not invite the same interference from the polymers.  
Hence samples were evaluated at 245nm to avoid interference from the constituent polymers with 
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nicotine UV absorption. Figure 3.10 indicates the calibration curve generated for nicotine at a 
wavelength of 245nm. 
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Figure 3.10: Standard curve for nicotine at a wavelength of 245nm in 0.1M PBS at pH 7.4.   
Three Phase Approach Employed to Develop and Optimise the Crosslinked Multi-
Polymeric Gelispheres 
The study was divided into three phases. Phase I comprised of 12 formulations. Six of these 
formulations contained drug, while the remaining did not. Two polymers were employed, alginate 
and HEC in a fixed concentration ratio of 2%w/v:1%w/v. These were denoted as the Alg-HEC 
gelispheres. These gelispheres were crosslinked with three cations namely, zinc, calcium and 
barium. Half of each set of formulations was exposed to dilute hydrochloric acid (HCl) to establish 
its effect on the swelling and drug release kinetics of the gelispheres. Based on the results, it was 
concluded that barium and calcium would be employed for further study, due to rapid degradation 
observed for zinc-crosslinked gelispheres. Phase II comprised a Plackett-Burman screening design 
y = 3.4868x 
R2 = 0.9863 
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to identify the influence of 5 independent formulation variables, namely, the concentrations of the 
three polymers, alginate, HEC and PAA and crosslinking agents, barium (primary crosslinker) and 
calcium on the dependant factors, drug entrapment and drug release from the gelispheres (Alg-
HEC-PAA gelispheres). Based on these findings, Phase III sought to optimise the crosslinked 
system based on the abovementioned parameters and expose the optimised system to dilute HCl. 
Within the distinct phases, studies were conducted to establish the scientific rationale which 
resulted in the observed physicomechanical behaviour of the developed systems.  
 
3.2.3 PHASE I: Elucidating the Effect of Crosslinking Agent and Post-Curing Exposure to 
Dilute HCl on Multi-Polymeric Reinforced Gelispheres  
3.2.3.1 Formulation of Crosslinked Reinforced Alg-HEC Gelispheres 
Ionotropic gelation was employed to formulate the gelispheres. A dispersion comprising 2%w/v 
alginate and 1%w/v HEC (the reinforcing agent) in their native forms were prepared in double de-
ionised water (Millipore® filter; pore size 0.22µm) and subsequently homogenized employing a 
vortex mixer (Lab Mixer-Emulsifier®, England). The dispersion employed the stated 
concentrations based on the fact that this resulted in a dispersion which was viscous enough to 
permit the generation of suitable gelispheres with adequate robustness. 1%w/v nicotine was 
incorporated into the polymeric solution. Drug-free formulations were also prepared. The 
polymeric solution was titrated at a rate of 5mL/minute through a 23-gauge hypodermic syringe 
into a gently vortexed (VELP® Scientifica Microstirrer, Germany) crosslinking solution 
comprising either of 2%w/v barium chloride, calcium chloride or zinc sulphate. The crosslinked 
alginate-HEC (Alg-HEC) gelispheres were gently agitated for an additional 30 minutes in the 
crosslinking solution and thereafter washed with 3x500mL de-ionized water. Formulations were 
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then exposed to dilute HCl subsequent to curing (Stanford, 1883; Bajpai and Sharma, 2004) to 
evaluate the effect of precipitating alginic acid in the crosslinked system on the swelling and 
hydration dynamics of the gelispheres.  
 
Briefly, the gelispheres were immersed in 300mL of a gently vortexed (VELP® Scientifica 
Microstirrer, Germany) solution of 2M HCl for 15 minutes. Formulations were allowed to dry 
under an extractor at ambient conditions (21ºC) for 72 hours. The gelispheres were subsequently 
stored in a refrigerator at -5◦C until further analysis. Table 3.2 summarizes the various formulations 
prepared during Phase I to evaluate the role of crosslinking agent and exposure to dilute HCl post-
curing on drug entrapment efficiency, drug release and gelisphere erosion. 
 
Table 3.2: Crosslinked Alg-HEC gelispheres prepared for Phase I.  
Formulation 
Number Crosslinking Solution Post-curing Treatment 
1 Barium chloride (2%w/v)  - 
2 Barium chloride (2%w/v) Exposed to HCl 
3 Calcium chloride (2%w/v) - 
4 Calcium chloride (2%w/v)  Exposed to HCl 
5 Zinc sulphate (2%w/v) - 
6 Zinc sulphate (2%w/v)  Exposed to HCl 
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Figure 3.11: Schematic illustrating the methodology employed to formulate and analyse the Alg-
HEC gelispheres. 
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3.2.3 PHASE II: Formulation and Evaluation of Reinforced Multi-Polymeric Gelispheres 
Employing a Design of Experiments Approach 
3.2.4.1 Formulation of Alg-HEC-PAA Gelispheres in Accordance with a Plackett-Burman 
Screening Design 
The study aimed to elucidate new mechanisms of interaction between the various components of 
the developed reinforced crosslinked multi-polymeric device (Chapter 1). In order to understand 
the influence of various processing factors on the properties of the nicotine-loaded crosslinked 
gelispheres a Design of Experiments approach was adopted. This entailed the use of the Plackett-
Burman screening design (Plackett and Burman, 1946). The formulation variables evaluated 
included, evaluation of the influence of the concentrations of alginate, the reinforcing agent HEC, 
and the crosslinking ions barium and calcium. The influence of a third biodegradable hydrophilic 
polymer PAA on the properties of the matrix was also evaluated. PAA was included in the 
crosslinking solution, and not in the polymer dispersion. The responses of these factors were 
evaluated on both the physicochemical and physicomechanical level. Equation 3.1 was employed 
to screen responses in accordance with this statistical design. 
Response = b0 + b1[Alginate] + b2[HEC] + b3[PAA] + b4[CaCl2] + b5[BaCl2] 
Equation 3.1 
Where, b1 – b5 represent the coefficient constants for the concentrations of Alginate, HEC, PAA, 
CaCl2 and BaCl2 respectively.  
 
Nicotine-loaded multi-polymeric gelispheres were formulated according to a Plackett-Burman 
(PB) statistical design template (Table 3.3) that allowed various combinations and permutations of 
polymers and crosslinking agents to be formulated employing ionotropic gelation as described 
previously in Section 3.3.4.1. These gelispheres are referred to as the Alg-HEC-PAA gelispheres.  
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Table 3.3: The Plackett-Burman design template employed to optimise drug-loaded Alg-HEC-
PAA gelispheres indicating the various combinations and permutations of polymers (alginate, HEC 
and PAA) and crosslinking agents (calcium and barium) that were employed.   
Formulation 
Number 
Alginate 
(%w/v) 
HEC  
(%w/v) 
PAA 
(%w/v) 
CaCl2 
(%w/v) 
BaCl2 
(%w/v) 
1 2.5 1.00 0.5 2 2.00 
2* 2.0 0.75 1.0 1 1.25 
3 2.5 0.50 1.5 0 0.50 
4 1.5 0.50 0.5 0 0.50 
5 1.5 1.00 1.5 0 2.00 
6 2.5 1.00 1.5 0 2.00 
7 1.5 0.50 0.5 2 2.00 
8 2.5 0.50 0.5 0 2.00 
9 1.5 0.50 1.5 2 2.00 
10 1.5 1.00 1.5 2 0.50 
11 2.5 1.00 0.5 2 0.50 
12 2.5 0.50 1.5 2 0.50 
13* 2.0 0.75 1.0 1 1.25 
14 1.5 1.00 0.5 0 0.50 
* centrepoints 
3.2.4 Determination of Drug Entrapment Efficiency  
Evaluation of the drug entrapment efficiency (DEE) was conducted in triplicate on 200mg of 
nicotine-loaded gelispheres. The gelispheres were agitated with the aid of a homogenizer (VELP® 
Scientifica Microstirrer, Germany) in 500mL PBS (0.1M; pH 7.4) for 72 hours under ambient 
conditions. A 5mL aliquot was removed and centrifuged (Minor® Centrifuge, MSE, England) for 
15 minutes at 5000rpm. The clear supernatant was subsequently filtered through a Millipore® filter 
(0.45μm pore size) in order to remove any contaminants or residual polymer. Thereafter they were 
analysed by UV spectroscopy (WinASPECT, Version 1.6.13.0, 2002, Analytik Jena AG, 
Germany), at a wavelength of 245nm employing a Beckman® DU 650 Ultraviolet 
Spectrophotometer (Germany).  
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Equation 3.2 was employed to determine the DEE of the gelispheres. 
 
% DEE =      (Actual Drug Entrapment)      x 100                                                             Equation 3.2 
                 (Theoretical Drug Entrapment)  
 
 
The theoretical drug entrapment was calculated as a ratio of the amount of nicotine incorporated 
into the polymeric dispersion and the combined amount of drug and polymers in the dispersion. 
 
3.2.5 Evaluating In Vitro Drug Release Characteristics of Alg-HEC and Alg-HEC-PAA 
Gelispheres 
In vitro drug release studies were performed in triplicate on 100mg of nicotine-loaded crosslinked 
Alg-HEC and Alg-HEC-PAA gelispheres. An environment which simulated CSF was provided to 
conduct drug release studies. In order to achieve this, the gelispheres were immersed in 100mL 
0.1M phosphate buffered saline (PBS) of pH 7.4, maintained at 37°C in sealed 100mL glass jars 
that were placed in a shaker bath (Labex, Stuart SBS40®, South Africa) and agitated at 50rpm.  At 
3 hour intervals 5mL samples of the solution were removed, following which they were 
centrifuged (Minor® Centrifuge, MSE, England) for 15 minutes at 5000rpm. The clear supernatant 
was subsequently filtered through a Millipore® filter (0.45μm pore size) in order to remove any 
contaminants or residual polymer. Samples were analysed by UV spectroscopy at a wavelength of 
245nm. An equal volume of drug-free PBS was replaced into the glass bottles to maintain sink 
conditions.   
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3.2.6 Textural Analysis of Hydrated of Alg-HEC and Alg-HEC-PAA Gelispheres 
The Texture Analyser (TAXT.plus, Stable Micro Systems®, Surrey, UK) was employed to conduct 
textural analysis of the gelispheres (N=5). The texture analyser was fitted with a 10mm cylindrical 
steel probe and a 40kg load cell was used. Matrix resilience, deformability modulus and fracture 
energy of the crosslinked Alg-HEC gelispheres were assessed in both the unhydrated and hydrated 
state. Typical test parameters are indicated in Section 2.2.3 (Chapter 2). Data acquisition was 
performed at 200 points per second.  
 
In order to determine the effect of hydration, the gelispheres were immersed in 100mL simulated 
CSF (PBS 0.1M; pH 7.4 37°C; 50rpm) in a shaker bath (Labex, Stuart SBS40®, South Africa). 
Samples were analysed at 1, 2, 3, 6, 9 and 12 hours. Studies were conducted in triplicate.   
 
3.2.7  Analysis of Gelisphere Volume Changes following Hydration  
An Olympus Stereo Microscope, Model SZX-D2-200, equipped with an Olympus SZX-TR30 
camera (Tokyo, Japan) was used to evaluate changes in the surface morphology and volume of the 
gelispheres over time following exposure to hydration. AnalySIS Version 3.2 (Soft Imaging 
Systems, Japan) was employed to evaluate the images. The mean of three mutually perpendicular 
diameters of the gelispheres were measured and sphere volume (Vs) calculated employing 
Equation 3.3. 
Vs = 4πr3                                                                                                                             Equation 3.3 
        3  
 
Where, r is the radius of the gelispheres (mm). 
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The change in gelispheres diameter following exposure to hydration was evaluated to establish the 
degree of swelling and the mechanism of matrix degradation. Studies were conducted in triplicate. 
 
3.2.8 Thermal Analysis of Alg-HEC and Alg-HEC-PAA Gelispheres  
Thermal analysis of the Alg-HEC gelispheres was performed employing differential scanning 
calorimetry (DSC). Differential scanning calorimetry is a technique employed to evaluate the 
influence of applied heat and analyze thermal transitions of polymeric systems. A linear 
temperature gradient at a rate of 5˚C per minute was used from 25 - 400˚C (Perkin Elmer Pyris-1). 
Approximately 5mg of the samples were placed within crimped aluminium pans and subjected to 
analyses. 
 
3.2.9 Analysis of Polymer-Polymer and Drug-Polymer Interactions Employing FTIR 
Spectroscopy  
Fourier Transform Infrared (FTIR) studies were conducted on pure nicotine and the native 
polymers, namely Alginate and HEC and the crosslinked multi-polymeric gelispheres at 21°C 
(Nicolet Impact 400D; Nicolet Instrument Corporation, Oreland, Pennsylvania, USA). Samples of 
20mg were mixed with 2g of potassium bromide and triturated. From this mixture, 150mg was 
compressed with 8 tons force in a Beckman® Hydraulic Press (Beckman Instruments, Inc., 
Fullerton, USA) to produce transparent discs. The discs were inserted into the spectrophotometer 
cell and transmittance profiles generated.   
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3.2.10 Analysis of Changes in Surface Morphology of Hydrated Alg-HEC-PAA 
Gelispheres 
An Olympus® Stereo Microscope (Model SZX-D2-200) fitted with an Olympus® SZX-TR30 
camera (Tokyo, Japan) was employed to evaluate transitions in surface morphology of the Alg-
HEC-PAA gelispheres over 50 hours following exposure to simulated CSF as described in Section 
3.2.6. 
 
Scanning Electron Microscopy (SEM) was also employed to view changes in surface morphology 
of the Alg-HEC-PAA gelispheres at an enhanced magnification. Dried samples of the gelispheres 
were coated with a thin layer of colloidal graphite. Thereafter they were mounted onto aluminium 
stubs and coated with a thin layer of gold-palladium under an electrical potential of 20keV. 
Samples were viewed in the FE-SEM (JEOL JSM-840, Tokyo, Japan) at various magnifications 
employing probe currents between 60-30 nanoamps. 
 
3.2.12 PHASE III: Formulation Optimisation Studies  
3.2.12.1 Statistical Optimisation of Alg-HEC-PAA Gelispheres  
Drug release profiles generated from formulations from the PB Design indicated first-order 
kinetics with a burst effect. Optimisation was carried out through the application of a Design of 
Experiments response optimiser function employing Minitab Software (Release 14, Minitab Inc., 
USA) that allows simultaneous optimisation of responses. Optimised formulations were 
maximized for DEE and minimized for drug release at t=1 hour to achieve a minimal burst effect.    
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3.2.12.2 Precipitating Alginic Acid in Optimised Formulations as a Means to Retard 
Gelisphere Swelling 
As discussed in the previously, exposure of gelispheres to dilute HCl resulted in matrices that 
swelled at a slower rate and therefore retarded drug release effectively. The optimised formulation 
from the PB template was exposed to 300mL 2M HCl post-curing as discussed in Section 3.2.2 
and analysed for drug release, drug entrapment and swelling behaviour.   
 
3.3 Results and Discussion 
3.3.1 PHASE I: Elucidating the Effect of Crosslinking Agent and Post-Curing Exposure 
to Dilute HCl on Multi-Polymeric Reinforced Gelispheres  
3.3.1.1 Analysis of Physicomechanical Properties of Drug-free Alg-HEC Gelispheres  
Evaluating the physicomechanical properties of drug-free formulations provided insight into the 
nature and possible mechanism of inter-polymeric interactions as well as elucidation of the 
influence of the crosslinking ions on the robustness of the gelisphere matrices.   
 
The stereomicrographs in Figure 3.13 depict the changes within the matrices following hydration.  
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Figure 3.12: (a) Fracture energy (Nm) (SD<0.001Nm), (b) Deformability modulus (N/mm) 
(SD<7.11N/mm) and (c) Matrix resilience (%) (SD<0.54%) of drug-free unexposed Alg-HEC 
gelispheres and (d) Fracture energy (Nm) (SD<0.0014Nm), (e) Deformability modulus (N/mm) 
(SD<4.334N/mm) and (f) Matrix resilience (%) (SD<1.40%) of drug-free HCl-exposed Alg-HEC 
gelispheres, over a period of 12 hours following exposure to simulated CSF (N=5).  
(d) (a) 
 (c) (f) 
 (b) (e) 
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Upon exposure to PBS the gelispheres undergo typical ‘concentric-hydration’ that results in the 
transient increases in fracture energy of the gelispheres (discussed in Chapter 2). This phenomenon 
was particularly evident with matrices exposed to dilute HCl post-curing. While unexposed zinc 
and calcium-crosslinked matrices virtually disintegrated by the 9th hour to PBS exposure (indicated 
by the negligible fracture energies at t=9 hours), those crosslinked with barium remain significantly 
more intact (fracture energy at t=9 hours was approximately 8.80 x 10-3 Nm). HCl-exposed 
matrices remain unchanged from their initial state of equilibrium achieved within the first hour of 
exposure to PBS. As expected the deformability moduli for all formulations declined following 
exposure to PBS, with the most significant change occurred within the first hour of exposure. 
Unexposed matrices experienced a decline in the deformability modulus (hardness) after the first 
hour of exposure to PBS of between 87.64 - 85.19%, while the decline observed for HCl-exposed 
matrices was smaller, between 67.03 - 69.96%.  
 
With regards to the porosity of the matrices, HCl-exposed matrices did not indicate any significant 
change following the decline observed within the first 3 hours of exposure to PBS. The matrix 
resilience of unexposed gelispheres declined by approximately 18.30% within the first hour of 
exposure to PBS, while that of HCl-exposed matrices declined by only 2.65% and 4.42% for zinc 
and barium-crosslinked matrices respectively. For calcium-crosslinked matrices, this increased by 
3.87% within the same period of time (t=3 hours). This may be due to the capacity of divalent 
calcium ions to attract and accommodate more water molecules within crosslinked G-units due to 
their higher co-ordination number (Chapter 2, Section 2.3.2). Barium ions, on the other hand did 
not offer sufficient space within the crosslinked pockets due to their large atomic size, despite 
comparative water attracting capacity. Zinc ions were too small to develop sufficiently crosslinked 
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pockets within the polymer, hence allowed the matrix to unravel more rapidly following initial 
water penetration.   
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Figure 3.13: Stereomicrographs (Magnification x16) indicating changes in surface morphology of 
drug-free Alg-HEC gelispheres crosslinked with (a) BaCl2, (b) CaCl2, (c) ZnSO4, (d) BaCl2/dil. 
HCl, (e) CaCl2/dil. HCl, and (f) ZnSO4/dil. HCl, following exposure to simulated CSF over a 
period of 12 hours.  
 (a) 
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 (d) 
 (e) 
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3.3.1.2 Analysis of Physicomechanical Properties of Drug-loaded Alg-HEC 
Gelispheres  
3.3.1.2.1 Unhydrated Drug-loaded Alg-HEC Gelispheres 
The unhydrated gelispheres revealed the nature of the drug-loaded matrices prior to 
exposure to simulated CSF (0.1M PBS; pH 7.4; 37ºC; 50rpm). Textural analysis indicated a 
general trend of higher matrix robustness among gelispheres exposed to dilute HCl (Figure 
3.14a-c). Calcium and barium-crosslinked matrices were robust and compact, while zinc-
crosslinked matrices were porous.  
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Figure 3.14: Textural analysis indicating the (a) Fracture energy (Nm) (SD<0.0001Nm), 
(b) Deformability modulus (N/mm) (SD<3.15N/mm) and (c) Matrix resilience (%) 
(SD<1.96%) of unhydrated drug-loaded Alg-HEC gelispheres crosslinked with various 
crosslinking agents (N=5). 
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Results were congruent with those obtained in Chapter 2, however it is essential to indicate 
here that a general trend of lower matrix resilience, higher deformability modulus and 
fracture energy were observed for the corresponding matrices that employed only A5 (G-
rich alginate, Chapter 2) as the polymeric framework of the gelispheres, in comparison to 
the multi-polymeric system developed in this study. Furthermore, all formulations exposed 
to dilute HCl post-curing demonstrated correspondingly higher values for fracture energy 
and matrix resilience and lower values for deformability modulus. This conferred to greater 
robustness of the gelispheres, which in turn had a positive impact on retarding matrix 
degradation and drug release kinetics.  
 
With regards to matrix porosity, matrix resilience of HCl-exposed gelispheres was higher 
by approximately 2.30% - 5.55% than their unexposed counterparts. This implied that the 
porosity of the unexposed matrices decreased when dried following curing. The nature of 
water loss with HCl-exposed gelispheres occurred through an alternative mechanism, such 
that it lead to a contraction of the matrix and thus resulted in a lower matrix porosity. The 
HCl-exposed matrices were significantly brittle in comparison to the unexposed 
gelispheres. Fracture energies were higher by 7.94 - 26.69 x 10-4 Nm. The deformability 
moduli declined by 12.24 - 58.36N/mm following exposure to dilute HCl post-curing.  
 
As discussed in Chapter 2 the crosslinking ions with larger ionic radii, such as barium, 
enabled a greater degree of ‘networking’ of the polymeric matrix and therefore permitted 
the matrices to be more compact. The adjacent polymeric strands within the matrix were 
drawn closer together due to the larger cationic radii. Thus the order of matrix compactness 
 124
was as follows: Zinc<Calcium<Barium. This phenomenon was observed to concur for all 
matrices regardless of exposure to dilute HCl. Following exposure, the variation between 
the robustness was most significant with zinc-crosslinked matrices. The hardness of zinc-
crosslinked matrices increased by 58.44N/mm. In comparison, the difference between 
barium-crosslinked matrices exposed to dilute HCl and the unexposed was 12.24N/mm. 
 
3.3.1.2.2 Textural Analysis of Hydrated Drug-loaded Alg-HEC Gelispheres  
Textural analysis of nicotine-loaded gelispheres indicated the presence of more compact 
matrices entrapping the drug that eroded at a slower rate from drug-free gelispheres. It is 
proposed that the presence of secondary dipole-dipole interactions between lone pairs of 
nitrogen ions in the heterocyclic rings in nicotine may interact with carboxylic acid and 
hydroxyl groups of the polymers, thus generating a superiorly compact network which was 
more resistant to degradation.  
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Figure 3.15: Changes in the physicomechanical properties observed in the (a) Fracture 
energy (Nm) (SD<0.0006Nm), (b) Deformability modulus (N/mm) (SD<9.87N/mm) and 
(c) Matrix resilience (%) (SD<3.4%) of drug-loaded Alg-HEC gelispheres and (d) Fracture 
energy (Nm) (SD<0.0004Nm), (e) Deformability modulus (N/mm) (SD<10.32N/mm) and 
(f) Matrix resilience (%) (SD<1.27%) of drug-free HCl-exposed Alg-HEC gelispheres, 
following exposure to simulated CSF, to over a period of 12 hours (N=3).  
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Results demonstrated that when nicotine was incorporated into the polymeric matrix, the 
behaviour of the gelispheres concurred with drug-free formulations. Following hydration, 
the gelispheres attracted solvent molecules into the matrix thus allowing water molecules to 
enter the crosslinked pockets within the network. Hence the gelispheres exhibited a greater 
fracture energy value since, energy was accommodated within the voids of the matrix. With 
the exception of barium-crosslinked gelispheres the fracture energies of hydrated 
gelispheres declined appreciably after t=3 hours of exposure to PBS. Barium-crosslinked 
gelispheres retained higher fracture energies up to t=6 hours before any significant decline 
was observed. Transient increases in fracture energy and deformability moduli 
demonstrated the typical concentric mechanism of matrix degradation discussed in Chapter 
2.  HCl-exposed matrices demonstrated a significantly greater and sustained fracture energy 
for the corresponding crosslinking ions verses unexposed formulations. HCl-exposed 
barium-crosslinked demonstrated the highest fracture energies over time. This indicated the 
presence of significant interaction between the two polymers and the large divalent barium 
ions that enabled the generation of formulations significantly resistant to degradation, 
which correlated with the rate of drug release observed (discussed further in Section 
3.3.1.7). 
 
Deformability moduli declined appreciably within the first hour of exposure to simulated 
CSF. The most appreciable decline was observed in unexposed zinc-crosslinked matrices. 
In contrast the HCl-exposed zinc-crosslinked matrices demonstrated the least decline in 
matrix hardness i.e. deformability modulus. This discrepancy was approximately 
44.41N/mm, and the most significant among the gelispheres. This phenomenon was 
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interesting since the initial (unhydrated) deformability moduli for the unexposed 
gelispheres was greater, while following hydration, the decline experienced was also 
significant. Thus it was observed that exposure of the gelispheres to PBS resulted in a rapid 
influx of water and ion exchange into the matrix that allowed an increased rate of 
degradation. In contrast, the rate of water penetration and ion exchange (sequestration) for 
the HCl-exposed matrices was retarded by the reduced interaction between water molecules 
and the unionized alginate (alginic acid).  
 
Initially observed higher values for matrix resilience were sustained for the HCl-exposed 
matrices throughout the hydration study. However, the porosity of the HCl-exposed 
matrices was found to be a function of the nature of crosslinking agent employed. As 
observed previously, zinc-crosslinked matrices generated more porous matrices, followed 
by calcium and then barium. With regards to unexposed matrices, barium demonstrated 
significantly increased porosity following t=6 hours of exposure to PBS. When combined 
with the high values for fracture energy and deformability modulus at the same time, it was 
concluded that this was primarily due to an increased uptake in water i.e. gelispheric 
swelling (Figure 3.15 and 3.16) and not due to matrix degradation.  Unexposed zinc-
crosslinked matrices appeared to disintegrate appreciably by t=9 hours of exposure to PBS, 
indicating that ions had a very minimal interaction with the polymers and were unable to 
retain the structural properties of the matrix for a sustained period of time. 
  
 
 
 128
 
          t=0h                      t=2h                     t=3h                       t=6h                          t=9h                   t=12h 
 
          t=0h                      t=2h                     t=3h                       t=6h                          t=9h                   t=12h 
 
          t=0h                      t=2h                     t=3h                       t=6h                          t=9h                   t=12h 
 
          t=0h                      t=2h                     t=3h                       t=6h                          t=9h                   t=12h 
 
          t=0h                      t=2h                     t=3h                       t=6h                          t=9h                   t=12h 
 
          t=0h                      t=2h                     t=3h                       t=6h                          t=9h                   t=12h 
Figure 3.16: Stereomicrographs (Magnification x16) indicating changes in surface morphology of 
nicotine-loaded Alg-HEC gelispheres crosslinked with (a) BaCl2, (b) CaCl2, (c) ZnSO4, (d) 
BaCl2/dil. HCl, (e) CaCl2/dil. HCl, and (f) ZnSO4/dil. HCl, following exposure to simulated CSF, 
to over a period of 12 hours. 
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3.3.1.3 Swelling Behaviour of Hydrated Alg-HEC Gelispheres 
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Figure 3.17: Change in volume (mm3) of hydrated crosslinked Alg-HEC gelispheres drug-free 
(ND) (a) unexposed to dilute HCl and (b) exposed to dilute HCl and drug-loaded gelispheres (c) 
unexposed to dilute HCl and (d) exposed to dilute HCl following exposure to simulated CSF, over 
a period of 12 hours (N=3; SD<5.34%).  
 
 
Since both alginate and HEC are hydrogels, they have the capacity to take up water when exposed 
to hydration. When exposed to simulated CSF, the gelispheres undergo sequestration and gradually 
(a) 
(c) 
(b) 
(d) 
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expanded in gelisphere volume until sufficient polymeric relaxation occurs to cause the matrix to 
erode and disintegrate. Exposure to dilute acid prevented the uptake of water and subsequent 
matrix degradation significantly. The matrices imbibed sufficient water that allowed for a 201.15% 
- 329.14% increase in volume, following which an ‘equilibrium hydrated gelisphere volume’ was 
maintained for the remainder of the 50 hours. Due to the nature of the alginate employed, i.e. G-
rich, the selectivity of the polymer for the crosslinking ions had a significant impact on the degree 
of crosslinking in the polymer. As observed from textural analysis, the greater affinity of the G-
units towards calcium and barium ions resulted in the formation of more compact matrices.  An 
increase in the degree of crosslinking had a predictable effect on the swelling behaviour. With such 
a large degree of physical restriction in the hydrogel network, water uptake decreased markedly, 
and the swelling rate also decreased. In general unexposed zinc-crosslinked gelispheres increased 
in volume to the greatest degree over the 50 hours. Barium-crosslinked gelispheres generally 
indicated slower rates of water uptake and matrix swelling over the 12 hours. The decline in 
volume for calcium-crosslinked gelispheres with drug after t=6 hours indicated that matrix erosion 
occurred.  
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Figure 3.18: Flowchart illustrating the process of hydration and subsequent chain disentanglement 
following hydration of the polymeric matrix. 
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3.3.1.4 Evaluation of Drug-Polymer Interactions Employing FTIR Spectra 
FTIR spectra of nicotine, sodium alginate, nicotine/alginate, calcium/alginate; with and without 
nicotine are shown in Figure 3.19a-c. FTIR spectrum of sodium alginate revealed various distinct 
peaks of alginate: hydroxyl at 3364.03cm−1, carbonyl at 1627.34cm−1, and carboxyl and 
carboxylate at about 800 to 1400cm−1 (Figure 3.19a). However, the physical mixture of nicotine 
and sodium alginate showed the peaks attributable to both nicotine and sodium alginate. The 
distinct peak at 1255.54cm−1 (Figure 3.19b) indicates the aromatic N-H stretching in the nicotine 
molecule. The broad peak observed at 1426.76cm−1 (Figure 3.19b) corresponds to O-H bending in 
the alginate molecule. It is proposed that hydroxyl groups in the alginate monomers, most likely in 
the G-pockets housing the nicotine molecules, interact with lone pairs on the nitrogen atoms which 
form part of the nicotine pyridine aromatic ring. This confirms the interaction of nicotine with 
alginate at the molecular level (Figure 3.20). With the addition of calcium to the dispersion, more 
distinct peaks were observed between 2700 and 230cm-1 (Figure 3.19c) (which confer to C-H 
stretching) indicate a possible ionic interaction with nicotine molecules within the crosslinked G-
pockets. Boarder peaks at in the region of 1380 - 1500cm-1 indicated enhanced bending of 
hydroxyl groups in alginate, corresponding to interactions with interactions of the carboxylic acid 
groups with divalent calcium ions. 
 133
 
 
 
Wavenumber cm-1
Wavenumber cm-1
(a) 
(b) 
%
 Transm
ittance 
%
 Transm
ittance 
 134
 
 
Figure 3.19: FTIR spectra for (a) native alginate, (b) alginate/nicotine and (c) calcium-crosslinked 
alginate incorporating nicotine indicating the interactions between the alginate, calcium and 
nicotine. 
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Figure 3.20: Proposed mechanism of interaction of nicotine with alginate monomers at a 
molecular level. 
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3.3.1.5 Evaluating Changes in Surface Morphology of Unexposed and HCl-Exposed 
Gelispheres following Hydration 
The scanning electron micrographs (SEM) indicated the changes in surface morphology of 
unexposed and HCl-exposed gelispheres following exposure to simulated CSF. 
 
Unhydrated unexposed gelispheres possessed diameters approximately in the range of 2-3mm and 
demonstrated spherical to elongated morphology. Their surface indicated the presence of pores on 
the surface in the region of approximately 0.5 - 10µm (Figure 3.21a). Their surface appears 
generally smooth and indicated the presence of small rectangular crystalline structures, possibly 
due to the presence of residual crosslinking salts on the surface. Following hydration, the 
gelispheres underwent polymeric disentanglement and degradation. Hence the dried gelispheres 
indicated a significantly smaller diameter between 0.7 - 1.5mm. A porous surface was observed, 
which conferred with matrix degradation and increased matrix resilience following hydration 
(Figure 3.21b). Pores appeared enlarged and ‘clogged’ with crystalline structures. It was proposed 
that crystalline structures observed on their surface were as a result of sequestered crosslinking 
ions. These crystals were smaller in size. This porous matrix permitted the small nicotine 
molecules to rapidly diffuse out of the matrices and conferred to the rapid drug release rates 
observed (Figure 3.21b). 
 
Unhydrated HCl-exposed gelispheres possessed diameters of approximately 3mm. Their surfaces 
appeared irregular and coarse (Figure 3.21c). Minute crystalline particles (residual crosslinking 
salts) were also observed on the surface. The gelispheres were approximately spherical. Surfaces 
also appeared porous and undulated. SEMs indicated that precipitation of alginic acid had occurred 
throughout the matrix, due to the homogeneity of the matrix. This is expected, since hydrogen ions 
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are sufficiently small to rapidly penetrate the entire crosslinked matrix during the 15 minute period 
for which the gelispheres are exposed to dilute HCl post-curing. Following exposure to simulated 
CSF, the pores enlarged and the matrix underwent degradation in a manner similar to that 
previously observed with unexposed gelispheres however, the matrix appeared to remain more 
intact and less porous. This conferred to the slower rates of drug release observed for HCl-exposed 
gelispheres. 
   
 
   
 
Figure 3.21: Scanning electron micrographs of unhydrated drug-loaded (a) unexposed barium-
crosslinked (Magnification 1300x; 30 nanoamps) and (b) HCl-exposed barium-crosslinked 
gelispheres and hydrated (Magnification 300x; 30 nanoamps) (c) unexposed barium-crosslinked 
and (Magnification 1300x; 30 nanoamps) (d) HCl-exposed barium-crosslinked (Magnification 
6500x; 30 nanoamps) gelispheres following exposure to simulated after 50 hours. 
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 (c) (d) 
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3.3.1.6 Evaluation of the Drug Entrapment Efficiency of Alg-HEC Gelispheres 
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Figure 3.22: Drug entrapment efficiency (%) (where, Formulation 1:BaCl2, 2:BaCl2/dil. HCl, 
3:CaCl2, 4:CaCl2/dil. HCl, 5:ZnSO4, 6:ZnSO4/dil. HCl) of nicotine within crosslinked Alg-HEC 
gelispheres following exposure to simulated CSF over a period of 50 hours (N=3; SD<2.89%). 
 
 
Initial studies indicated that approximately 29% - 38% of the incorporated nicotine was lost into 
the crosslinking solution during the 30 minute curing period. This is due to the extremely high 
aqueous solubility of nicotine (50mg/mL, 21ºC) and combined with the fact that it is significantly 
ionised at a pH of 7.4 (approximately 69%). This ‘leaching’ phenomenon observed implied that the 
curing time had to be kept to a minimum. The DEE for matrices exposed for an additional 15 
minutes to aqueous dilute HCl solution permitted further ‘leaching’ of nicotine into the medium 
and resulted in an approximate 21.82% - 12.64% loss of nicotine indicated by the lower DEE 
(Figure 3.22). For HCl-exposed formulations, maximal loss is observed with formulations 
crosslinked with barium and least with zinc-crosslinked gelispheres. However it is interesting to 
note that unexposed barium-crosslinked matrices demonstrated the highest DEE values. It is 
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proposed that this is due to the fact that while the barium ions significantly crosslink the matrices 
to entrap a substantial quantity of nicotine, since drug release was primarily controlled by 
diffusion, according to Fick’s Law, the concentration gradient was greater, which resulted in a 
greater efflux post-curing.  
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3.3.1.7 Elucidation of In Vitro Drug Release from Crosslinked Alg-HEC Gelispheres  
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Figure 3.23: % Drug release profile of nicotine from (a) unexposed Alg-HEC gelispheres 
crosslinked with zinc, calcium and barium and (b) Alg-HEC gelispheres exposed to dilute HCl 
following curing, over a period of 50 hours in simulated CSF. The four phases (Ia, IIa, Ib and IIb) 
of release are also depicted (N=5; SD<0.96%).  
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Polymers such as alginate and HEC are significantly amorphous in nature (indicated by XRD 
profiles, Figure 3.4) hence the rate of drug dissolution is expected to follow this swelling process. 
The presence of crosslinking within the polymeric matrix imparts a significant degree of 
entanglement and retards the rate of solvent penetration (Heller, 1987).  
 
 
The presence of secondary inter-polymeric hydrogen bonds between the constituent polymers 
allows for a more densely entangled network thus the movement of an incorporated drug is 
hindered significantly. Due to the nature of the hydrophilic polymers employed to generate the 
matrix, it is expected that the process of matrix degradation will primarily consist of bulk erosion 
i.e. the process of hydrolysis throughout the polymeric matrix, the phenomenon of ‘concentric 
hydration’ as was observed in Chapter 2 indicated the presence of a second mechanism, that of 
surface erosion. Prolonging the phase of surface erosion and retarding bulk erosion kinetics may 
allow for the development of a reservoir-like system that could delay the rate of drug release. 
However, nicotine being highly hydrophilic compound with a small molecular weight (162.23 
g.mol-1) diffused rapidly out of polymeric matrices as soon as it was exposed to hydrating medium. 
It has an aqueous solubility of approximately 50 mg per millilitre of water (21ºC), which is 
enhanced at physiological temperature. Correlating this with mechanism of matrix erosion for 
crosslinked water-soluble polymers incorporating a drug within a three-dimensional framework 
such as the one generated, as described in Chapter 2, Section 2.3.3, compounds such as nicotine 
rapidly move out of these polymeric matrices, independent of the rate of matrix erosion (Heller, 
1987). 
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Nicotine appeared to have the least affinity for zinc-crosslinked matrices. Both the HCl-exposed 
and unexposed zinc-crosslinked gelispheres allowed for rapid first-order release of nicotine (Figure 
3.23).  Approximately 58.85% of entrapped nicotine was leached within the first hour of exposure 
to simulated CSF from unexposed while, 43.29% was leached from HCl-exposed zinc-crosslinked 
gelispheres. There was little variation between the drug-release profiles of barium and calcium-
crosslinked gelispheres, regardless of exposure to dilute HCl. All formulations demonstrated 
typical release profiles that had four distinct phases of drug release (Figure 3.23).  The first phase 
was the initial burst effect (Ia), which resulted in drug release between the range of 31.43% - 
58.85% of entrapped drug being released within the first hour of exposure to PBS. This is followed 
by a second phase (IIb) of zero-order kinetics, where a linear phase of drug release is observed.  
This was followed by a second phase of burst release (Ib) after 12 hours of exposure to simulated 
CSF. Finally, a second phase of zero-order release allows the remainder of drug to be released 
from the matrices (IIb).  
 
From a mechanistic point of view, the schematic illustrates the phenomenon of ‘sequestration’ 
(Figure 3.24). This is described by an exchange between monovalent sodium ions in the simulated 
CSF and the divalent ions that crosslink the polymeric matrix. This exchange of ions leads to chain 
disentanglement and an influx of water molecules. This caused the matrix to swell and 
subsequently caused matrix degradation into smaller non-toxic water-soluble entities.   
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Figure 3.24: Schematic illustrating the mechanism of sequestration. 
 
This phenomenon related to drug release as the influx of water molecules dissolves the entrapped 
nicotine, which is a very hydrophilic and small molecule. Hence, as soon as this occurred the 
encapsulated nicotine rapidly diffused out of the matrix. It was observed that matrices crosslinked 
with a greater ratio of calcium allowed this process to occur more rapidly.   
 
3.3.1.8 Elucidation of Polymer-Polymer Interactions Employing FTIR Studies 
FTIR spectra of HEC indicated the presence of -OH, -COOH and –CH groups. The presence of an 
interaction occurring between the two polymers and divalent cations guluronic acid residues 
forming the hydrogen bonds and bond stretching is evident due to the shifts observed in absorption 
peaks of –OH and –COOH groups, indicated by the broad band observed between 1550 - 1720cm-1 
and the peak at 1886.26cm-1.  
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Figure 3.25: FTIR spectra of (a) HEC and (b) HEC and alginate. 
 
The formation of secondary hydrogen bonding between the hydroxyl groups on HEC and 
carboxylic acid groups (illustrated in Figure 3.25), whether in the ionized or unionised state results 
in strong inter-polymeric bonds that were resistant to degradation. The presence of fewer sites 
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%
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within the polymer to interact with interpenetrating water molecules prevented accelerated 
degradation. The presence of unionised carboxylic acid groups, as in the case of precipitated 
alginic acid, (resulting from exposure to dilute HCl post-curing) further prevented interaction 
between the polymer and water molecules.  It is proposed that this interaction occurred more 
significantly between the carboxylic acid groups on the M-units in alginate and HEC due to the 
fact that the crosslinking divalent actions employed have selectivity for G-units. The fact that drug 
release was observed to be more rapid from zinc-crosslinked gelispheres can be explained in these 
terms. As observed from Chapter 2, due to its smaller ionic size, zinc is the least selective for G-
units of the three ions employed. This implies that zinc ions interacted with comparatively more 
M-units within the polymeric matrix. These M-units therefore were unable to form significant 
hydrogen bonds with HEC. Thus it was postulated that the degree to which the matrix was 
reinforced was not as significant as for Ba2+ and Ca2+. Hence the relative rate of degradation and 
consequent translation to drug release kinetics was more rapid for zinc-crosslinked matrices.  
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Figure 3.26: Schematic illustrating the proposed mechanism of hydrogen bonding (H-bonds) 
forming between alginate M-units and HEC resulting in a reinforced gelisphere matrix. 
HEC Alginate 
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3.3.1.9 Analysis of Native and Crosslinked Polymer Thermal Transitions Employing 
Differential Scanning Calorimetry 
The glass transition temperature (TG) for the polymers was calculated employing Differential 
Scanning Calorimetry (DSC). The G-rich alginate was dehydrated at approximately 98.93ºC 
indicated by the endothermic peak in the DSC profile (Figure 3.27a). Endothermic peaks at 
approximately, followed by an exothermic peak indicating decomposition of the biopolymer 
between 230ºC - 270ºC. This resulted in the formation of Na2CO3 and a carbonized residue. 
Decomposition of the carbonaceous material occurred above 300°C.  
 
The DSC profile for HEC (Figure 3.27b) indicated two distinct endothermic peaks. The first peak 
between 40°C - 115°C indicated a phase of water loss (dehydration) from the polymer. This 
temperature range was smaller in magnitude which indicated that dry HEC possessed a smaller 
water content than alginate. The second endothermic peak corresponded to the thermal transition 
relating to polymer melting. 
 
The crosslinked gelispheres indicated four distinct phases of thermal transition (Figure 3.27c). It is 
proposed that that the first endothermic peak between 50°C - 74°C corresponded to dehydration of 
the matrix. The second endothermic peak between 170°C - 250°C corresponded to the phase 
whereby alginate and HEC break the secondary hydrogen bonds binding them. The second phase 
corresponded to endothermic peaks between 250°C - 310°C which correlated with dissociation of 
crosslinking ions from guluronic and mannuronic acid residues within the alginate molecule. The 
final endothermic peak corresponded with melting and matrix decomposition. 
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Figure 3.27: Typical DSC profiles obtained for the G-rich Alginate (FMC BioPolymer) and (b) 
HEC (Hercules Inc., Natrosol® Pharm) selected for formulating the proposed drug delivery system 
and (c) the unexposed calcium-crosslinked Alg-HEC gelispheres. 
 
3.3.2  PHASE II: Formulation and Evaluation of Reinforced Multi-Polymeric Gelispheres 
Employing a Design of Experiments Approach 
3.3.2.1 Alg-HEC-PAA Gelisphere Yield – Evaluation of Reaction Efficiency 
The efficiency of a reaction can be measured in numerous ways. The most common method 
employed is though the calculation of the percentage yield. No reaction proceeds with 100% yield 
efficiency due to factors such as the formation of by products, incomplete conversion of the 
starting materials, loss upon formulation of the reaction mixture, and upon isolation and 
purification of the desired end product. The % gelisphere yield was calculated employing Equation 
3.5 to establish the influence of formulation parameters on the efficiency of the crosslinking 
reaction. 
(c) 
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% Gelisphere Yield =     (Actual Gelisphere Yield)     x 100                                           Equation 3.5 
                                     (Theoretical Gelisphere Yield) 
 
 
Results indicated that larger polymeric concentrations (both alginate and HEC) resulted in higher 
gelisphere yield (Table 3.4). The presence of calcium in the formulation also enhanced % 
gelisphere yield.  
 
Table 3.4: Gelisphere yield efficiency (%w/w) for the Alg-HEC-PAA formulations. 
*centerpoints 
 
 
 
Formulation Number  Gelisphere Yield Efficiency (% w/w) 
1 74.67 
2* 98.42 
3 73.70 
4 63.52 
5 57.46 
6 67.75 
7 71.49 
8 68.12 
9 72.66 
10 76.62 
11 76.97 
12 78.92 
13* 98.42 
14 80.29 
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3.3.2.2 Evaluation of the Drug Entrapment Efficiency (DEE) of Alg-HEC-PAA Gelispheres 
DEE for the Alg-HEC-PAA gelispheres ranged between 18.75% - 53.67% (Table 3.5). Higher 
entrapment efficiencies were observed with formulations composed of a higher alginate and HEC 
concentration and both crosslinking ions produced compact matrices. This was due to the fact that 
the greater degree of polymer interaction and crosslinking that occurred within the gelisphere 
resulted in an increased restriction for nicotine molecules from leaching out of the matrix during 
formulation. An increased concentration of the polymers allowed the formation of more secondary 
hydrogen bonds, resulting in a denser crosslinked polymeric network. The presence of both barium 
and calcium ions increased the degree of crosslinking within the matrix, accentuating the density of 
the gelisphere. The final system was therefore one that could effectively retain the incorporated 
nicotine and achieve higher DEE. 
 
A higher concentration of PAA resulted in gelispheres with higher nicotine entrapped within their 
matrices due to the fact that the polymer formed a mechanical barrier around the crosslinked 
gelispheres, and thus prevented ‘nicotine-leaching’ during curing. 
 
According to statistical analysis (discussed further under Section 3.4.6) the concentration of 
alginate in the formulation had the most significant impact on DEE in comparison to all other 
factors. There was a direct correlation between the quantity of nicotine entrapped within the 
matrices and the %w/v of alginate employed in the formulation. This is due to the fact that alginate 
is the polymer that undergoes crosslinking with the cations resulting in the development of the 
network that restricts nicotine within the matrix.  Hence, the greater the quantity of polymer 
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(alginate) to undergo crosslinking, the denser the developed crosslinked matrix, and the greater the 
degree of nicotine entrapment. 
 
Table 3.5: Response outcomes for the Alg-HEC-PAA formulations (N=3). 
*centerpoints 
 
3.3.2.3 Elucidation of In Vitro Drug Release from Alg-HEC-PAA Gelispheres 
All formulations demonstrated first-order drug release kinetics. The concentration of both 
polymeric constituents had a synergistic and significant effect on retarding drug release. Higher 
concentrations of both polymers allowed for an attenuated burst-effect (Figure 3.28). Formulations 
prepared with lower alginate and HEC concentrations demonstrated drug release exceeding 90% 
within the first hour (Figure 3.28). In comparison, formulations with higher alginate HEC 
concentrations were able to retard drug release in the first hour to 34%. This indicated significant 
interaction between the polymeric components in determining matrix integrity, which impeded 
drug release. The matrices generated thereof possessed a greater degree of polymeric chain 
Formulation 
Number 
Drug Entrapment Efficiency 
(%) 
Drug Release (%) 
at 1 hour 
1 40.73 50.51 
2* 40.03 65.05 
3 53.67 56.46 
4 34.03 90.22 
5 29.01 74.43 
6 47.37 52.60 
7 38.68 34.05 
8 26.14 84.29 
9 18.75 73.29 
10 30.75 58.01 
11 41.23 51.78 
12 32.91 61.61 
13* 40.03 65.05 
14 24.91 88.35 
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entanglement assisted by the formation of inter-polymeric secondary hydrogen bonds. This in turn 
impeded the movement of water molecules into the matrices, which resulted in polymeric 
relaxation and subsequent matrix degradation and nicotine release. 
 
Higher concentrations of PAA were observed to have a mildly positive effect on retarding drug 
release (discussed further in Section 3.4.6). This was due to the formation of a mechanical barrier 
around the gelispheres that prevented the ready interaction and subsequent penetration of water 
molecules in the surrounding medium with the polymeric matrix.   
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Figure 3.28: % Drug released over a period of 50 hours from the Alg-HEC-PAA gelispheres 
following exposure to simulated (N=3; SD<3.55%). 
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3.3.2.4 Thermal Analysis of Alg-HEC-PAA Gelispheres  
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Figure 3.29: Typical differential scanning calorimetry (DSC) profiles of (a) Formulation 2, (b) 
Formulation 4 and (c) Formulation 7. 
 
Three formulations were selected to conduct DSC analyses. Selection was based on concentration 
of polymers and crosslinking ions, so that a variety of combinations could be observed. Typical 
DSC profiles for the Alg-HEC-PAA gelispheres indicated an enhanced endothermic peak in the 
region of 160ºC - 180ºC indicating complex de-polymerization, primarily of alginate.  The 
schematic in Figure 3.26 illustrated the possible chemical groups that result in the abovementioned 
interaction causing the enhanced thermodynamic stabilisation of the multi-polymeric entity. This 
stabilisation contributed towards the reduced degradation of the gelispheres. Figure 3.29 indicates 
the DSC profiles obtained for three formulations with sufficiently different compositions to 
illustrate the influence of formulation parameters on the thermal stability of the gelispheres. For 
(c) 
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Formulation 2 (2%w/v Alginate, 0.75%w/v HEC; 1%w/v PAA, 1%w/v CaCl2 and 1.25%w/v BaCl2) 
(centerpoint), two distinct endothermic peaks are observed at 166.75ºC and 175.36ºC (Figure 
3.29a). It is postulated that these corresponded to loss of water molecules from the matrix and the 
breaking of secondary hydrogen bonds between alginate and HEC. These endothermic peaks were 
shifted higher in Formulation 4 (1.5%w/v Alginate, 0.5%w/v HEC; 0.5%w/v PAA, 0%w/v CaCl2 and 
0.5%w/v BaCl2)  to 169.46ºC and 179.56ºC (Figure 3.29b). Hence an enhanced interaction, as is 
observed when a greater of crosslinking occurred due to the presence of higher concentrations of 
both crosslinking ions as in Formulation 7 (1.5%w/v Alginate, 0.5%w/v HEC; 0.5%w/v PAA, 2%w/v 
CaCl2 and 2%w/v BaCl2) (Figure 3.29c) to generate the matrix, allowed for enhanced stabilisation. 
This is further validated by the reduced burst effect observed when these formulations are exposed 
to simulated CSF (Figure 3.28).  Exothermic peaks between the region of 250ºC – 350ºC indicate 
polymeric relaxation. 
3.3.2.4 Evaluation of Physicomechanical Properties of Alg-HEC-PAA Gelispheres   
Alginate and Ba2+ concentrations had the most significant impact on the formation of compact and 
robust gelispheres. Textural analysis indicated that matrix resilience and therefore the porosity of 
the Alg-HEC-PAA gelispheres gradually increases over time. Formulations generated with higher 
concentrations of alginate and barium demonstrated minimal changes in matrix resilience 
(porosity) over time hence remained intact for a longer duration of time following hydration. The 
porosity of the matrices correlates directly with the surface area available for the matrix to interact 
with solvent molecules which promotes matrix degradation and drug release. Hence lower and 
sustained matrix resilience indicates an increased capacity to maintain the integrity of the matrix 
and retard nicotine release. 
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The results indicated that the gelispheres swelled in concentric layers with the peripheral layers 
becoming hydrated first. This demonstrated a deviation from the expected bulk hydration kinetics 
expected with hydrophilic polymers employed to generate the matrices. Instead it was observed 
that surface hydration and erosion preceded bulk erosion. It was observed that a transition occurred 
in the basic physicochemical nature of the matrices which was adequate to significantly affect its 
degradation behaviour. The profiles for fracture energy confirmed this phenomenon by indicating 
transient increases in fracture energy when the texture analyser probe came in contact with the 
central unhydrated crosslinked core of the matrix (Figure 3.30b).  
 
With regard to deformability moduli, there is a general decline of between 69.97% - 92.58% 
following exposure to hydration as water penetrated the matrix and resulted swelling (Figure 
3.30c). Thereafter, a thermodynamic equilibrium was achieved and stabilized the system until 
complete matrix degradation occurred.  
 
As mentioned previously, HEC functioned as a matrix reinforcer by forming strong secondary 
hydrogen bonds with alginate (discussed further on). This interaction was sufficiently significant to 
enhance matrix robustness, retard drug release and decrease the matrix porosity (indicated by 
smaller resilience following exposure to simulated CSF) (Figure 3.30a). Upon hydration HEC 
aided the maintenance of the matrix and prevented water penetration, therefore delaying matrix 
degradation. 
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Figure 3.30: Changes observed in the (a) Matrix resilience (%) (SD<0.72%) (b) Fracture energy 
(Nm) (SD<0.0001Nm) and (c) Deformability modulus (N/mm) (SD<11.67N/mm) of Alg-HEC-
PAA gelispheres over 50 hours following exposure to simulated CSF (N=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
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Table 3.6: Response Outcomes for Textural Analysis of unhydrated (t=0hr) and hydrated (after 9 hours of exposure to simulated CSF 
gelispheres of the Alg-HEC-PAA Formulations. 
Matrix Resilience (%) Deformability Modulus (N/mm)  Fracture Energy (Nm) (10-2) Formulation 
Number t=0hr t=9hr t=0hr t=9hr t=0hr t=9hr 
1 12.05 20.13 15.04 121.47 0.617 2.89 
2* 16.73 18.43 13.89 121.48 0.643 2.20 
3 19.58 28.37 12.93 213.48 0.370 6.96 
4 10.37 41.66 29.17 224.84 0.510 3.73 
5 20.60 22.84 19.03 174.83 0.450 2.08 
6 7.08 3.54 17.78 226.90 0.470 3.13 
7 12.25 8.17 71.88 70.98 1.370 2.47 
8 7.38 88.86 23.25 166.10 0.511 1.95 
9 11.83 16.39 28.47 104.76 0.652 1.97 
10 20.52 17.19 16.70 73.01 1.130 2.42 
11 12.06 16.41 14.56 111.05 0.785 3.13 
12 12.56 13.44 18.23 205.13 0.717 2.77 
13* 10.37 18.39 13.89 121.48 0.489 2.20 
14 20.05 18.08 19.73 121.97 0.617 1.06 
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3.3.3  PHASE III: Formulation Optimisation Studies 
3.3.3.1 Statistical Analysis of the Alg-HEC-PAA Gelispheres  
Main effects plots are employed in conjunction with an analysis of variance. A main effect occurs 
when the mean response to a defined outcome changes across the levels of an input parameter. 
These plots are employed to examine the level means for each parameter and compare them to 
level means for other parameters. They are also employed to evaluate the comparative influence of 
several parameters on the responses. The response mean is plotted along the x-axis against the 
overall mean effect of the parameter on the response. Significant (vertical) deviation from the 
response mean i.e. upon varying the level of a given parameter indicates the presence of a greater 
magnitude of the main effect. The gradient of the response provides an indication of the 
magnitude, since it relates to its distance from the mean response. 
 
Interaction plots are also employed in conjunction main effects plots to display the two-way 
interactions input parameters and to evaluate the relative potency of effects across parameters. An 
interaction occurs when the change in response of an input parameter from the one level of another 
differs from the change in response at the same two levels of a second parameter. That is, the effect 
of one factor is dependent upon a second factor. Parallel lines indicate an absence of interactions, 
conversely deviation from such a presentation indicates the presence and magnitude of interaction 
between the parameters. 
 
The PB design was analysed in terms of two responses, DEE, and % drug release (DR) occurring 
at t=1 hour.  
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Figure 3.31a: Main effects plots indicating the influence of input parameters on (i) % drug release 
t=1 hour (i.e. the burst effect) and (ii) % DEE (where, Carb refers to PAA).  
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(ii) 
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Figure 3.31b: Interaction plots correlating the pair-wise influence of input parameters (iii) % drug 
release t=1 hour and (iv) % DEE. The red lines indicate the upper limits of the parameters, while 
the black lines indicate the lower limits. 
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The concentration of alginate had the most significant impact on drug release from the crosslinked 
formulations. Higher concentrations of alginate had a dramatic impact in permitting slower rates of 
drug release, indicated by a minimal burst effect within the 1st hour of exposure to simulated CSF, 
and matrix degradation following hydration, as well as % DEE (Figure 3.33a-c).  
 
High concentrations of calcium in the gelispheres also had a very significant impact on retarding 
drug release. The smaller cations interpenetrated the crosslinked polymer network during 
formulation and resulted in a denser system in the central portions of the matrix thus, allowing the 
formation of a more homogenously crosslinked matrix. It did not however influence % DEE 
substantially. 
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Figure 3.32: Response surface plots correlating % drug entrapment efficiency (DEE) and the 
influence of (a) polymer concentration (alginate and HEC) and (b) the concentration of 
crosslinking ions, barium and calcium and (c) % drug release (DR) at t=1 hour (i.e. the burst effect) 
and the influence of alginate and HEC concentration. 
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PAA provided a mechanical barrier to hydration by coating the gelispheres, hence retarded drug 
release and matrix degradation when employed in higher concentrations. It is proposed that due to 
its high molecular weight (3 MDa), it did not penetrate the crosslinked matrix during formulation, 
hence it did not form part of the matrix. Furthermore, it prevented nicotine leaching from the 
matrices during curing, allowing for a greater entrapment efficiency. It indicated the presence of an 
interaction with both crosslinking agents in the formation of compact matrices capable of 
entrapping a significant amount of nicotine and retarding drug release (Figure 3.32c-d). 
 
Table 3.7: Summary of results for % drug release (DR) t=1 hour (i.e. the observed burst effect) 
and drug entrapment efficiency (DEE) for Alg-HEC-PAA gelispheres. 
Parameter % DR at t=1 hour % DEE 
|R| 0.847 0.747 
R2 0.717 0.558 
R2 adjusted 0.540 0.282 
Standard Error 10.88 7.922 
R2 for Prediction 0.008 0.132 
Durbin-Watson d 2.908 1.267 
First Order Autocorrelation -0.466 0.357 
Coefficient of Variation 16.813 22.260 
 
 
 
Results indicated that only the concentration of alginate in the formulation was significant in 
determining burst effect drug release (%DR at t=1 hour) and % DEE, since it demonstrated p-
values which were less than 0.005. 
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Table 3.8: Summary of results for % drug release (DR) t=1 hour (i.e. the observed burst effect) for 
Alg-HEC-PAA gelispheres. 
Analysis of Variance for % DR at t=1 hour 
Source SS SS% MS F F Signif df 
Regression 2393.4 72 478.68 4.046 0.03962 5
Residual 946.45 28 118.31   8
  LOF Error 945.23 28(100) 135.03 111.2593 0.07287 7
  Pure Error 1.214 0(0) 1.214   1
Total 3339.8 100       13
 
% DR 1hr = b0 + b1*[Alginate] + b2*[HEC] + b3*[PAA] + b4*[CaCl2]+ b5*[BaCl2] 
Parameter Coefficient P value Std Error -95% 95% t Stat 
b0 95.26 0.001 18.21 53.27 137.26 5.231
Alginate -25.52 0.000 6.280 -40.01 -11.04 -4.065
HEC 17.63 0.198 12.56 -11.33 46.59 1.404
PAA 1.954 0.764 6.280 -12.53 16.43 0.311
CaCl2 -1.132 0.728 3.140 -8.373 6.108 -0.361
BaCl2 5.147 0.254 4.187 -4.507 14.80 1.229
 
Table 3.9: Summary of results for % DEE for Alg-HEC-PAA gelispheres. 
Analysis of Variance for % DEE 
Source SS SS% MS F F Signif df 
Regression 633.96 56 126.79 2.020 0.180 5
Residual 502.07 44 62.76   8
  LOF Error 239.56 21(48) 34.22 0.1304 0.972 7
  Pure Error 262.51 23(52) 262.51   1
Total 1136.0 100       13
 
% DEE = b0 + b1*[Alginate] + b2*[HEC] + b3*[PAA] + b4*[CaCl2]+ b5*[BaCl2] 
Parameter Coefficient P value Std Error -95% 95% t Stat 
b0 11.05 0.429 13.26 -19.53 41.64 0.833
Alginate 13.72 0.01708 4.574 3.173 24.27 3.000
HEC 4.149 0.662 9.148 -16.95 25.24 0.454
PAA -3.261 0.496 4.574 -13.81 7.286 -0.713
CaCl2 -0.864 0.715 2.287 -6.138 4.409 -0.378
BaCl2 -1.513 0.633 3.049 -8.544 5.519 -0.496
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3.3.3.2 Formulation and Evaluation of Optimised Gelispheres  
Two formulations were generated from optimising the formulations by maximizing % DEE and 
minimizing drug release at t=1 hour (burst effect). The formulations were identical and employed 
high concentrations of alginate, HEC and PAA as well as calcium and differed only in the 
concentration of barium employed to crosslink the matrices (Table 3.10).  
 
Table 3.10: Optimised formulations developed. 
Optimised 
Formulation 
Number 
Alginate 
(%w/v) 
HEC 
(%w/v) 
PAA 
(%w/v) 
CaCl2 
(%w/v) 
BaCl2 
(%w/v) 
1 2.5 1.00 1.5 2 2.00 
2 2.5 1.00 1.5 2 0.50 
 
As observed previously, greater concentrations of barium employed to crosslink the matrix 
negatively impacted on DEE, however resulted in a reduced burst effect of drug release from the 
matrices. 
 
Results indicated that the formulation crosslinked with a greater concentration of barium 
(Formulation 1), resulted in a moderately compromised DEE (Table 3.11), due to the fact that 
barium ions occupied greater space within G-pockets of the alginate molecule. The presence of 
higher quantities of alginate and HEC conferred to superior DEE due to extensive crosslinking. 
 
Table 3.11: Drug entrapment efficiency (%) for optimised formulations (N=3; SD<0.08%).  
Optimised Formulation 
Number 
Drug Entrapment Efficiency  
(%) 
1 50.13 
2 52.22 
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Drug release kinetics demonstrated minimal difference, however as observed from previous 
results, reduced burst effects were observed for Formulation 1, which employed a higher 
concentration of barium to crosslink the matrices. The more compact matrices demonstrated 
desirable DEE and were selected to be exposed to dilute HCl in order to reduce the degree of 
matrix swelling with the intention to further attenuate the burst effect. 
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Figure 3.33: % Drug release from optimised formulations exposed to simulated CSF over 50 
hours (N=3; SD<2.06%). 
 
3.3.3.3 Elucidating the Effect of Precipitating Alginic Acid on Optimised Gelispheres  
As observed previously, the influence of exposure of gelispheres to dilute HCl caused the 
precipitation of alginic acid within the crosslinked polymeric structure. Thus significantly retarded 
the rate at which the matrices swelled and underwent erosion and directly impacted the rate of drug 
release from the gelispheres. Reducing the extent of the burst effect was the primary goal of this 
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study.  The optimised Formulation 1 from Section 3.4.3.2 was exposed to dilute HCl to reduce the 
extent of matrix swelling and erosion as observed previously during preliminary studies (Section 
3.3). The formulations were subsequently evaluated for drug release and DEE. 
 
As expected the resulting formulation, demonstrated a significant reduction of approximately 
8.07% in DEE (Table 3.12). This correlates with the prolonged period of exposure of the 
gelispheres to an aqueous environment beyond the 30 minute curing time that permits drug 
‘leaching’.  
 
Table 3.12: Drug entrapment efficiency (%) for unexposed optimised formulation 1 and HCl-
exposed optimised formulation (N=3; SD<1.15%). 
Formulation Drug Entrapment Efficiency (%) 
Unexposed optimised gelispheres 50.13 
HCl-exposed optimised gelispheres 41.16 
 
 
In this instance drug release studies were conducted over a period of 120 hours to assess the 
behaviour of the gelispheres over a prolonged period of time. It was observed that drug release 
kinetics were more sustained in comparison to those generated in previously, where it was 
observed that almost 100% of the entrapped drug was released from zinc-crosslinked gelispheres 
within 12 hours. 
 
Results indicated that the release profile for gelispheres exposed to dilute HCl followed first-order 
kinetics, with a minimal burst effect (it declined by approximately 3.76%). Over the following 50 
hours, the release profiles have minimal variation, an average of 3.26% lower drug release was 
observed for HCl-exposed optimised gelispheres (Figure 3.34). After 50 hours, the unexposed 
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gelispheres underwent a significant degree of matrix erosion that caused a surge in drug release. 
The HCl-exposed optimised gelispheres however, maintained their steady state of drug release 
even after 50 hours. 
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Figure 3.34: % Drug release from unexposed optimised formulation and HCl-exposed optimised 
formulation to over 120 hours to simulated CSF (N=3; SD<0.83). 
 
 
3.4 Concluding Remarks 
The most significant revelation from this study was the effect of exposure to dilute HCl 
precipitated alginic acid within the crosslinked matrices and significantly retarded gelisphere water 
uptake (swelling) (due to lower ionisation of the polymer and thus, lower aqueous solubility) and 
drug release rates. HCl-exposed gelispheres also displayed significantly greater robustness i.e. 
higher fracture energies, deformability moduli and resilience versus unexposed gelispheres. The 
influence of crosslinking agents in order of that which imparted greatest robustness over the 12 
hour testing period was barium>calcium>zinc. The rates of drug release observed in formulations 
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crosslinked with the various cations were in the order, barium<calcium<zinc, and inversely 
correlated with the swelling behaviour of gelispheres. The initial 12 hours demonstrated first-order 
release and was followed by a second phase of zero-order release. Drug entrapment efficiency was 
found to be in the order barium>calcium>zinc and declined by approximately 21.81% - 12.64% 
upon exposure to dilute HCl post-curing due to ‘leaching’ of nicotine into solution.  
 
While results demonstrated lower DEE for HCl-exposed gelispheres, the most significant findings 
indicated that HCl-exposed gelispheres underwent a significantly lower degree of matrix swelling 
and released nicotine at a slower rate in comparison to unexposed matrices. This property was 
significantly beneficial and the discrepancies sufficient to warrant it being an approach that may 
have potential in developing compact gelispheric matrices that underwent minimal expansion 
following exposure to CSF.  Both barium and calcium demonstrated significantly robust matrices 
that retained their structure following exposure to hydration for longer durations of time. Their 
selectivity for the guluronic acid monomer resulted in the development of matrices that were 
significantly more compact than their zinc-crosslinked counterparts. 
 
Statistical optimisation of the generated multi-polymeric Alg-HEC gelispheres employing barium 
as the primary crosslinking agent system indicated that the interaction between alginate and HEC is 
significantly synergistic in producing a highly compact gelisphere matrix when crosslinked with 
both barium and calcium ions. This interaction is unique and demonstrated superior drug 
entrapment and release kinetics than conventional alginate calcium-crosslinked systems. Exposure 
to dilute HCl post-curing further retarded drug release, but more importantly reduced the rate of 
swelling and degradation of the gelispheres. Although these results were exceedingly promising, 
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there was still a need to further retard drug release and alter the release kinetics to achieve zero-
order release. In order to achieve this, the HCl-exposed optimised gelispheres were incorporated 
into an external polymeric matrix formulated as a prolonged release drug delivery system. 
Optimisation and evaluation of the parameters of formulation of these novel multi-unit compressed 
polymeric discs is discussed in the Chapters 4 and 5. 
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Chapter 4  
Modulation of Nicotine Release via Formulation of a Compressed External 
Polymeric Matrix Incorporating Crosslinked Gelispheres 
 
4.1 Introduction 
Chapter 3 revealed that a significant modulation of drug release kinetics could be achieved from 
calcium-barium crosslinked alginate gelispheres when the reinforcing polymers, HEC and PAA 
were incorporated into the matrix. Exposure of the gelispheres to dilute HCl post-curing led to a 
further attenuation of drug release rates as well as matrix swelling. However, drug release was 
rapid and followed first-order release. This Chapter explicates the studies conducted to further 
modify the release of nicotine. The optimised gelispheres were incorporated into an external 
polymeric matrix formulated as compressed polymeric discs with the aim of modulating drug 
release to achieve prolonged zero-order release. Optimising formulation variables of the 
compressed polymeric discs through a variety of mechanisms was explored. The following 
sections discuss properties of the polymers selected to develop the proposed system and evaluate 
the studies that have been conducted in recent times in the arena of site-specific drug delivery via 
compressed biodegradable polymeric discs with particular emphasis on prolonged release systems.   
 
Three polymeric materials with sufficient compressibility and adequate safety data regarding 
biocompatibility and safety were selected to develop the external compressed matrices 
incorporating the crosslinked gelispheres developed in Chapter 3. They were: 
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 Hydroxypropylmethylcellulose (HPMC) 
 Polyethylene oxide (PEO) and 
 Poly(lactic-co-glycolic) acid (PLGA) 
 
Generally, parenteral prolonged zero-order release systems have the capacity to minimize dose-
related side-effects by achieving constant and sustained plasma-levels. This is particularly 
important for drugs with narrow therapeutic indices. A dose reduction resulting from the avoidance 
of fluctuations in plasma drug levels, as well as the enhancement of patient compliance by 
reducing the frequency of administration, are further potential benefits (Pillay and Fassihi 1999).  
 
The use of compressed hydrophilic polymeric discs are among the most popular means of 
achieving controlled drug release due to the simplicity and cost-effectiveness of their formulation 
and manufacturing and versatile applicability to deliver compounds with range of solubilities 
(Williams et al., 2002; Durig and Fassihi, 2002; Jamzad et al., 2005).  Numerous factors influence 
the rate of drug release from such matrices. The most significant factor being the properties of the 
polymer employed to generate the matrices (Jamzad and Fassihi, 2006). The simplest form is 
known as a monolithic system that is formulated by simply incorporating the pharmaceutical active 
into a hydrophilic polymer (Li et al., 1989; Durig and Fassihi, 2002).  
 
HPMC and PEO (FDA approved) are both hydrophilic biopolymers that undergo simultaneous 
swelling and dissolution when exposed to hydration. Both polymers have been used extensively to 
formulate controlled-release drug delivery systems (Maggi et al., 2000; Jamzad and Fassihi, 2006). 
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Depending on the solubility of entrapped of incorporated drugs within monolithic matrices of such 
polymers, the actives diffuse out into the bulk medium preceding or following erosion of the 
polymer (Ju et al., 1995; Skoug et al., 1993; Tahara et al., 1995). The mechanisms relating to the 
swelling of hydrophilic polymeric matrices has been the subject of significant research (Doelker, 
1993; Gao et al., 1996; Narasimhan and Peppas, 1997; Colombo et al., 1999). In particular, there 
have been several studies which have attempted to relate molecular characteristics of the swelling 
process including aspects such as polymeric chain extension, disentanglement and solvent 
accommodation to macroscopic characteristics such as drug release (Peppas, 1983; Kim and 
Fassihi, 1997; Pillay and Fassihi, 1999). Other formulation factors which influence the drug release 
rate from hydrophilic matrices include the quantity of drug loading, drug-polymer ratio, drug 
particle size and molecular mass, polymer viscosity and molecular weight, presence and nature of 
formulation excipients and release modulators (Pillay and Fassihi, 1999; Pillay and Fassihi, 2000; 
Jamzad et al., 2005). In a study conducted by Maggi and colleagues (2000), high molecular weight 
hydrophilic polymers were employed to formulate compressed polymeric matrices. Their study 
demonstrated that the degree of water uptake significantly impacted the rate of matrix degradation 
and erosion. This directly influenced the rate of drug (diltiazem hydrochloride) release. As was 
anticipated, higher viscosity grades of each polymer displayed slower hydration rates by 
demonstrating a greater degree of resistance to erosion verses the corresponding lower viscosity 
polymers. The rate of drug release was significantly dependant on the rate and extent of polymer 
gelation and swelling over time. 
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Figure 4.1: The chemical structures of (a) hydroxypropylmethylcellulose (HPMC), (b) 
polyethylene oxide (PEO) and (c) poly(lactic-co-glycolic acid) (PLGA). (Source: Ludwig, 2005). 
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Yoo et al. (2004) evaluated the role of the biodegradable polyester poly(lactic-co-glycolic acid) or 
PLGA as a carrier to administer a prolonged release formulation for site-specific delivery of the 
antibiotic gentamicin sulphate for the prevention of osteomyelitis in the form of compressed 
discs for controlled delivery. The system had the advantages of being only moderately aqueous 
soluble for controlled drug diffusion, being biocompatible as well as non-toxic and biodegradable. 
The FDA approved polymer is naturally biodegraded to glycolic acid and lactic acid (both 
components of Krebs cycle) in vitro and in vivo (Bhardwaj and Blanchard, 1998; Choi et al., 
2002). Consequently, no surgical intervention or procedures are required for their removal 
following implantation. Other studies have employed compressed PLGA controlled release discs 
for delivery of a variety of pharmaceutical agents (Wang et al., 2002; Choonara et al., 2006). 
Biocompatibility studies performed indicated that it is considerably well tolerated when 
implanted into the CNS (Fournier et al., 2003). A review by Fournier et al. (2003) established that 
regardless of the drug carrier shape (whether it is on the form of a rod, microspheres, or granules) 
or the implantation site, the CNS tissue response to implanted PLGA drug delivery devices is only 
a moderate and non-specific inflammatory reaction due to the mechanical trauma of implantation. 
The biodegradable polyanhydride, poly(bis(p-carboxyphenoxy)propane-sebacic acid) (pCPP:SA) 
has been widely studied as a means to deliver anti-neoplastic agents to the brain in the form of 
compressed  discs (Brem et al., 1994; Walter et al., 1994; Williams et al., 1997; Yuan et al., 
1999a, Yuan et al., 1999b; Yuan et al., 1999c; Pradilla et al., 2005). Recent studies (Storm et al., 
2002; Frazier et al., 2003) have investigated the release, biodistribution, and efficacy of anti-
neoplastic agents from these compressed discs implanted intracranially in vivo in rat models. 
Results have been extremely promising displaying that the systems permitted site-specific drug 
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release and resulted in a therapeutic effect with little or no systemic toxicity, and prolonged 
survival in the rat models.  
 
The subsequent sections present the study conducted to establish the pertinent aspects involved 
in the development and evaluation of the properties of an external polymeric matrix (disc) for 
incorporating the optimised gelispheres from the previous chapter in order to achieve attenuated 
drug release. The properties of the three polymers, namely HPMC, PEO and PLGA are evaluated 
in their powdered and compressed forms. The degradation and erosional behaviour of the discs 
following exposure to simulated CSF are also conducted to elucidate their influence on drug 
release. Finally kinetic modelling is undertaken to understand the predominant mechanisms 
involved in controlling drug release. 
 
4.2 Materials and Methods 
Low molecular weight (50/50) polylactic-co-glycolic acid (PLGA) with an inherent viscosity of 
0.32-0.44dL/g in CHCl3 at 30◦C (Resomer® L 503) was donated by Birmingham Polymers Inc. 
(Bioabsorbable Polymers, MA, USA), hydroxypropylmethylcellulose (HPMC) USP 2208 
(MethocelTM K4M, MW ~ 86,000 Da; methoxyl 23%, hydroxypropoxyl 8.4%, with an average 
moisture content of 3.4%w/w) was donated by Dow Chemical Company and polyethylene oxide 
(PEO) PolyoxTM WSR 303 (MW ~7 MDa and average moisture content of 0.22%w/w) was donated 
by Union Carbide (USA). 
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4.2.1  Evaluation of Powder Flow Properties and Compressibility of Polymers  
For highly soluble compounds, diffusion is the primary mechanism of drug release from polymeric 
matrices. Hence, drug release is a function of the porosity of a compressed polymeric disc can be 
modulated by a variety of factors including compression force, the size, shape and adhesion 
between the powder particles (van Veen et al., 2005).  Modulating these characteristics can allow 
for the development of entities which have the capacity to undergo controlled bioerosion with  
prolonged release capability (Wise, 1984). 
 
The rheological properties of powders can be evaluated employing a range of tests that provide an 
indication of the nature of forces present between the surfaces of solid particles.  
 
4.2.1.1 Carr’s Compressibility Index (CCI) of Polymers Employed to Formulate External 
Compressed Matrices 
Carr (1965) evaluated inter-particulate cohesive properties with angle of repose measurements and 
studied the effects of packing geometry of solids with bulk and tap density measurements. He 
established that the density of a powder is dependant upon the degree of particle packing and that 
the powder density changes as the powder consolidates. The degree of consolidation is unique to 
the powder and ratio of these densities is related to inter-particulate friction. Carr’s Compressibility 
Index (CCI) (Equation 4.3) is employed to measure the underlying phenomena of inter-particle 
interactions between powders.  The higher the CCI for any given powder after the application of 
mechanical stress, the lower its bulk density. The application of mechanical stress (tapping) allows 
for the expulsion of entrapped air within the powder and indicates good compressibility, or more 
accurately, consolidation characteristics.  
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Samples of accurately weighed powder (3g) were loaded into a 20mL graduated glass measuring 
cylinder. The initial volume (V0) was recorded.  The contents were tapped and powder volume 
recorded following 2, 8, 16, 30 and 60 taps (Vt). The fluff and apparent density was calculated 
employing Equation 4.1 and 4.2 respectively. 
 
Fluff Density = W/V0  g/mL                                                                                              Equation 4.1 
 
Tapped Density = W/Vt  g/mL                                                                                           Equation 4.2 
 
Where, W (g) is the weight of powder employed to conduct the test. 
 
Carr’s Compressibility Index (CCI) (%) was calculated employing Equation 4.3.  
% CCI = (Tapped Density – Fluff Density)/Tapped Density × 100                                 Equation 4.3 
 
4.2.1.2 Evaluation of Angle of Repose (φ) of Polymers Employed to Formulate External 
Compressed Matrices 
A static heap of powder, when only gravity acts upon it, will tend to form a conical mould. The 
angle to the horizontal cannot exceed a certain value. This is known as the angle of repose (φ) 
(AR). If any particle temporarily lies outside this ‘limiting’ angle, it will slide down the adjacent 
surface under the influence of gravity until the gravitational pull is equated by the friction caused 
by inter-particulate forces.  A higher value for AR indicates poor flowability and indicates high 
inter-particle interaction.  
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To evaluate the angle of repose (φ) an adapted fixed-funnel and free-cone method was employed 
(Carr, 1965). This involved attaching a conical funnel to a retort stand with the bottom orifice 
(diameter 7mm) at 10cm height above the surface. A sample of powder (3g) was placed into the 
funnel while keeping the orifice closed. The centerpoint and a graduated set of axes was marked on 
a piece of paper and placed beneath the funnel.  The contents of the funnel were allowed to flow 
out of the orifice and the angle that the side of the conical heap made with the horizontal plane was 
recorded as the angle of repose (φ) and calculated employing Equation 4.4: 
 
tan φ = 2h/D                                                                                                                      Equation 4.4 
 
Where,  
h = powder height at centerpoint (mm) and  
D = diameter of powder bed (mm) 
 
4.2.2  Formulation of Compressed Polymeric Discs Incorporating Gelispheres   
Briefly, 500mg of the dry polymer mixture comprising either HPMC, PEO or PLGA, and various 
binary combinations and gelispheres equivalent to 20mg of entrapped nicotine (approximately 
100mg gelispheres) and subsequently compressed into discs using a Beckman® Hydraulic Press 
(Beckman Instruments, Inc., Fullerton, USA) applying a pressure of 8 tons. Flat-faced punches 
with a diameter of 10mm were employed to compress the discs. Table 4.1 summarizes the 
investigated disc compositions.  
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Table 4.1: Investigated polymer compositions for the external matrix.  
Formulation  
Number 
HPMC  
(mg) 
PEO  
(mg) 
PLGA  
(mg) 
F1 500 - - 
F2 - 500 - 
F3 - - 500 
F4 250 250 - 
F5 250 - 250 
F6 - 250 250 
F7 166 166 166 
 
4.2.3 Evaluation of In Vitro Drug Release Characteristics of the Compressed Polymeric 
Discs Incorporating Gelispheres   
In vitro drug studies were performed in triplicate as described in Chapter 3, Section 3.3.8 over a 
period of 50 days for each disc. 
 
4.2.4  Evaluation of Friability of External Polymeric Matrices  
Friability analysis evaluated the ability of the compressed polymeric discs to withstand 
mechanical damage. The friability of the discs was measured employing a Roche® Friabilator 
(Hoffman la Roche, Basel, Switzerland). The discs were accurately weighed prior to being 
placed into the friabilator (N=3). A rotation time of 4 minutes and 20 minutes at 25rpm was 
used. Discs were removed and loose particles brushed off the surface and re-weighed. The 
percentage weight loss was calculated (Equation 2.1, Chapter 2).  
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4.2.5 Textural Analysis: Evaluation of Brinell Hardness Number (BHN) of Compressed 
Polymeric Discs 
The change in the mechanical properties of the discs following exposure to simulated CSF was 
assessed by measuring the Brinell Hardness Number (BHN). The BHN is an indication of the 
force required to indent the surface of the disc and is a measure of the hardness of the surface of 
the compressed polymeric discs.  
 
The TA.XTplus Texture Analyser (TA) (Stable Micro Systems®, Surrey, UK) was employed to 
generate a force-distance profile for discs exposed to simulated CSF (0.1M PBS; pH 7.4; 37°C; 
50rpm) at predetermined time intervals. The input parameters employed are listed in Table 4.2. 
 
Table 4.2: Typical test parameters employed for analysis of the Brinell Hardness Number (BHN) 
of compressed polymeric matrices exposed to simulated CSF. 
Test Parameter BHN (N/mm2) 
Pre-test speed 1.0 mm/s 
Test speed 0.5 mm/s 
Post-test speed 1.0 mm/s 
Target mode Distance  
Trigger type Auto (force) 
Trigger force 0.5 N 
Load cell 5 kg 
 
The textural analyzer was fitted with a 3.175mm ball-tipped steel probe and inserted into the 
discs the probe was inserted into the discs to a depth of 0.25mm at a speed of 0.5mm per second 
and removed as indicated by the test parameters listed in Table 4.2. BHN (N/mm2) was 
calculated employing the following equation, 
BHN =               2F                                                                                                       Equation 4.5 
              πD[ D - (D2 – d2)1/2 ]    
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Where, 
D = Diameter of ball probe (3.175mm)  
d = Depth of indentation (0.25mm)  
F = Force (Newtons), measured from the generated distance-time profile.  
 
Figure 4.2: Typical force-distance profile obtained for the calculation of BHN for the compressed 
polymeric discs exposed to simulated CSF. 
 
4.2.6  Evaluation of Conductivity Changes Following Disc Gelation 
An OAKTON® TDS TestrTM Kit (Model WD-35661-70) (Solon, OH, USA) was employed to 
measure the conductivity of the PBS (0.1M; pH 7.4) solution containing the polymeric discs at 
predetermined intervals of time over a period of 30 days. Samples were extracted from the 
solutions and diluted 1:10 in double deionised water. The electrode was immersed in the diluted 
polymer-PBS solution and conductivity (µSiemens) was read. 
 
Distance (mm) 
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4.2.7  Evaluation of Matrix Erosion of Compressed Polymeric Discs Following Hydration 
Pre-weighed hydrated discs were removed from simulated CSF at predetermined intervals and 
dried under ambient conditions (21ºC) for 7 days. The dried discs were re-weighed and the 
percentage weight loss (% WL) calculated employing Equation 2.1 (Chapter 2).  
 
4.2.8  Evaluation of Changes in Disc Porosity Following Hydration  
Scanning Electron Microscopy (SEM) was employed to assess the changes in the porosity of the 
polymer matrices following hydration. Dried samples of the discs were cross-sectioned and coated 
with a thin layer of colloidal graphite. Thereafter they were mounted onto aluminium stubs and 
coated with a thin layer of gold-palladium under an electrical potential of 20keV. Samples were 
viewed in the FE-SEM (JEOL JSM-840, Tokyo, Japan) at magnification of 65 and probe current of 
30 nanoamps. 
 
4.2.9 Kinetic Modelling of Release Kinetics from Compressed Polymeric Discs  
Kinetic models represent the molecular interactions that occur when chemical bonds are broken 
and reformed into new chemical compounds. Such kinetic models are sometimes referred to as 
micro-kinetic models. A reaction mechanism consists of a set of reaction pathways, rate 
coefficients for each reaction pathway and either reverse rate coefficients or the thermodynamic 
properties necessary for calculating reverse rate coefficients. FDA-recommended f1 and f2 
similarity and difference factors were employed to compare profiles generated from drug release 
studies. This approach has been shown to be superior to conventional statistical methods such as 
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the t-test or the ANOVA, due to its ability to account for pharmaceutical variability rather than 
statistical ‘over-sensitivity’ (FDA guidelines, 1997). 
 
The Power Law equation (Equation 4.6) is employed to describe drug release from polymeric 
systems. 
Mt/M∞= k1tn                                                                                                                       Equation 4.6 
Here, Mt and M∞ are the absolute cumulative amount of drug released at time t and overall drug 
released, during the study respectively; k is a constant incorporating structural and the geometric 
dimensions of the device, and n is the release exponent, indicative of the mechanism of drug 
release. It is an equation which assumes that the two apparently independent mechanisms of drug 
transport namely, Fickian diffusion and Case II transport occur simultaneously. Thus it describes 
the dynamic interaction between the swelling of and drug release from glassy polymers. It is 
independent of the form of the constitutive equation and the nature of coupling of polymeric 
relaxation and drug diffusion. However it must be noted that the classic equation stated above is 
applicable primarily for ‘moderately swellable systems’ (in other words, the equilibrium swelling 
ratio (ratio between the hydrated and unhydrated polymeric matrix) of the polymeric system does 
not exceed 1.33) (Pillay and Fassihi, 1999). 
 
Thus Equation 4.6 has two distinct physical implications, when n=0.5, this indicates the occurrence 
of diffusion-controlled drug release or Fickian release kinetics, while, when n=1.0, it indicates 
swelling-controlled drug release, or Case II transport kinetics. Values of n which lie between 0.5 
and 1.0 are regarded as an indicator for the occurrence of anomalous transport kinetics 
(superposition of both phenomena). From Equation 4.6 it can be observed that when the value of 
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the exponent n = 1.0, the rate of drug release from the polymeric matrix is independent of time. 
This corresponds to zero-order release kinetics. For slabs, the mechanism that creates the zero-
order release is known as Case II transport. Here the relaxation process of the macromolecules 
occurring upon water imbibed into the system is the rate-controlling step. Water acts as a 
plasticizer and decreases the glass transition temperature (Tg) of the polymer, which allows the 
polymeric chains to undergo the transformation from glassy to the rubbery state, with increasing 
mobility of the macromolecules and volume expansion (i.e. swelling and subsequent polymeric 
disentanglement).  
 
Peppas and Sahlin (1989) developed the following geometry-independent equation (Equation 4.7) 
which consolidates the contributions of both Fickian and Case II transport mechanisms in drug 
release kinetics: 
Mt/M∞= k1tn +k2t2n                                                                                                              Equation 4.7 
Here, k1 is the Fickian kinetic constant and k2 is the relaxational/dissolution rate constant (i.e. 
anomalous transport). 
 
The Hopfenberg equation (Hopfenberg, 1976) is employed to compare the release rates of a drug 
within different batches produced under different conditions (Equation 4.9).  
Mt/M∞= 1-[1- k1t]n                                                                                                              Equation 4.9 
Where, k1 is the overall erosion rate constant and n is dependant on the geometry of the polymeric 
matrix i.e. it is a geometry-dependent equation. Hopfenberg proposed a model applicable to either 
a slab, cylinder or sphere showing heterogeneous erosion (Table 4.3). The model assumes that drug 
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release is not influenced by internal or external time-dependent resistance to diffusion in the 
eroding polymeric matrix (Pillay and Fassihi, 1999). It takes into account the fact that the surface 
area of the polymeric matrices change over time as a result of polymeric erosion and degradation. 
It correlates drug release with the change in surface area of the matrix (Pillay and Fassihi, 1999; 
Pillay and Fassihi, 2000). 
 
Table 4.3: The relationship between the geometry of the polymeric matrix and mechanism of drug 
release. (Source: Siepmann and Peppas, 2001). 
Exponent ‘n’ 
Slab Cylinder Sphere 
Drug Release 
Mechanism 
0.5 0.45 0.43 Fickian Diffusion 
0.5<n<1 0.4<n<0.81 0.43<n<0.85 Anomalous Transport 
1 0.89 0.85 Case II Transport 
 
This model was designed specifically for evaluating drug release from a planar surface of for 
instance, a tablet which follows zero-order kinetics from an erodible device maintaining constant 
surface area over a period of time. This model assumes heterogeneous erosion with a kinetic 
constant,  
k1=k0/C0r0                                                                                                                           Equation 4.8 
Where, 
k0 is the erosion rate constant,  
C0 is the uniform initial concentration of drug in matrix and  
r0 is the initial radius.  
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When numerous parameters are being evaluated when conducting time series analysis, it is 
possible to generate several widely different models. Thus objective criteria such as the Akaike 
Information Criterion (AIC) and the Schwartz’s Bayesian Criterion (SBC) can be employed to 
attenuate this pitfall (Akaike, 1974; Schwarz, 1978). Both are a measure of the goodness of fit of a 
particular model based on the maximum likelihood. For a given mode, the lower the AIC and SBC 
scores, the better the model. Furthermore, correlation between the predicted and experimental 
dissolution data is an additional tool which was employed to establish the reliability of the 
mathematical model. Superior correlation is suggested when the value of correlation approaches 
one. 
 
In a review by Siepmann and Peppas (2001) a comprehensive discussion on various theories based 
on drug release from a cylindrical geometry is given, whereby mass transfer is considered in three 
dimensions. However it was established that while, in most cases, simple empirical models are 
adequate to establish the basic mechanism(s) of drug release kinetics from a compressed polymeric 
matrix. However, when more reliable and detailed information is required, more complex, 
mechanistic theories need be applied and/or developed. For the purposes of our study the validity 
(‘goodness of fit’) of the abovementioned theories was evaluated for the optimised systems 
developed.  
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4.3 Results and Discussion 
4.3.1  Powder Flow and Compressibility of Polymers Employed to Formulate 
Compressed Discs 
4.3.1.1 Carr’s Compressibility Index (CCI) of Polymers Employed to Formulate 
Compressed Discs: Evaluating Powder Compressibility 
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Figure 4.3: Carr’s Compressibility Index (%) of polymers employed to formulate compressed 
discs. 
 
 
The porosity and apparent density of a powder are inversely proportional (Hui et al., 1989). PLGA 
demonstrated the most significant degree of compressibility. After the first 6 taps, PEO achieved 
an equilibrium tapped density and little change was observed upon the application of further 
mechanical stress. Powders such as HPMC and PLGA demonstrated that the small size of their 
particles (in comparison to those of PEO, which had a slightly more granular texture) indicated that 
application of further mechanical stress increased the propensity for particles to be in contact with 
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one another and thus form inter-particle bonds i.e. increased cohesion (Führer, 1996). Furthermore, 
the smaller particle size implied a higher surface area for contact between adjacent particles. Thus 
they demonstrated significantly enhanced compressibility characteristics. The incorporation of 
HPMC with PLGA demonstrated excellent compressibility and subsequently allowed for the 
formulation of compact discs. The relevance of these results indicated the degree to which the 
compressibility of the polymers and thus indicated their ability to prevent solvent penetration to 
their core containing drug-loaded gelispheres. This data allowed us to predict that polymers, such 
as PLGA with superior compression characteristics would generate more dense matrices that 
demonstrated greater endurance to the influence of the surrounding aqueous medium.    
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4.3.1.2 Angle of Repose (φ) of Polymers Employed to Formulate Compressed External 
Matrices: Evaluating Powder Flowability 
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Figure 4.4: Angle of Repose (degrees) of polymers employed to formulate compressed discs. 
 
 
The results (Figure 4.4) indicated that PLGA had the greatest degree of inter-particle interaction 
(cohesion). Hence it’s high angle of repose (AR) (40.40º) indicated that it had poor flow properties. 
When combined with HPMC, their mutually attractive interaction was indicated by the highest AR 
of 52.41º which implies that the combination had the potential for producing highly dense 
compressed discs. PEO on the other hand indicated excellent flow properties, as it demonstrated a 
lower AR of 13.49º. This can be explained in terms of the fact that it was predominately composed 
of spherical granular particles. These particles had a smaller surface area per particle to interact 
with each other, as compared to PLGA and HPMC. Its incorporation with PLGA and HPMC 
resulted in a significant decline in AR (11.46º and 12.74º respectively) and improved overall 
flowability, thus it negatively impacted on the cohesive tendency of the particles, which implied 
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that matrices generated with the aforementioned combinations would generate less compact 
matrices. From a manufacturing process point of view, improved flowability permits easier 
processing conditions. However this implies that additional substances (such as binders) may need 
to be added to enhance powder compressibility to generate discs. 
 
4.3.2  Evaluation of In Vitro Drug Release from Optimised Alg-HEC-PAA Gelispheres 
Incorporated within Compressed Polymeric Discs  
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Figure 4.5: % Drug released from optimised gelispheres (Chapter 3) compressed into polymeric 
discs following exposure to simulated CSF over a period of 50 days (N = 3; SD<0.59%). 
 
 
In vitro drug release studies in simulated CSF indicated that optimised gelispheres incorporated 
into PLGA discs demonstrated zero-order release kinetic, that were able to provide controlled and 
prolonged release for approximately 50 days. Drug release kinetics indicated a rapid burst in drug 
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release after day 35, whereafter a first-order release profile was obtained. An additional 40% of 
entrapped nicotine was released between days 35 and 40. In retrospect it was observed that PLGA 
had the maximum cohesive tendency between its particles and has the ability to be most 
compressible. Being a hydrophobic polymer, its main degradative mechanisms are though the 
hydrolytic cleavage of its polymeric backbone. Consequently, these discs underwent minimal 
matrix degradation.  
 
The rapid release rates observed from PEO and HPMC matrices allowed us to conclude that drug 
release occurred primarily by Fickian diffusion. The presence of PEO in matrices enhanced the rate 
of drug release from the compressed discs. Its hydrophilic character allowed rapid disentanglement 
and degradation of the compressed matrices. Its tendency was therefore to undergo comparatively 
rapid bulk erosion when it came in contact with the alkaline hydrating medium (Figure 4.5). 
HPMC is a hydrogel, hence it has the capacity to imbibe a significant amount of water before is 
begins to degrade. Furthermore, as observed from previous results, its particles were sufficiently 
cohesive to generate compact discs that are able to provide zero-order release following the 
achievement of an equilibrium hydrated state (discussed under later sections). Between days 3 and 
18, a linear drug release profile was observed from HPMC discs. Prior to this a burst release was 
observed, whereby approximately 33.25% of the entrapped nicotine was released within the first 
24 hours. Combining HPMC and PLGA had a unique effect on drug release. While in this case 
zero-order release was also observed, they exceeded those observed with the individual polymers.  
A burst effect was observed until day 6, by which time 54.31% of the drug had been released. 
Thereafter drug release followed a linear zero-order release profile until day 32. Release kinetics 
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for all other combinations exhibited rapid burst rates of drug release and predominately first-order 
release.    
 
4.3.3 Friability of Compressed External Polymeric Matrices 
According to the United States Pharmacopoeia (USP 23), conventional compressed tablets that 
incur a loss in weight after 100 revolutions (which is the equivalent of 4 minutes in the frabilator at 
25rpm) in a friabilator of less than 0.5% - 1.0% are considered acceptable.  
 
Table 4.4: Friability results for polymeric matrices expressed as % weight loss (% WL) after 4 and 
20 minutes in a friabilator at a rotation 25rpm. 
Formulation % WL4  % WL20   
HPMC 0.081428 0.306921 
PEO 0.101458 0.133164 
PLGA 0.000000 0.025974 
HPMC-PEO 0.050232 0.106744 
HPMC-PLGA 0.051463 0.064329 
PEO-PLGA 0.038346 0.102256 
HPMC-PEO-PLGA 0.025410 0.050819 
 
The results indicated that the discs generated were well within the predetermined limits. PLGA 
discs were exceedingly well compressed and underwent negligible loss in weight following 500 
revolutions (i.e. 20 minutes at 25rpm). Furthermore, the incorporation of PLGA with HPMC and 
PEO into the disc resulted in an enhanced robustness imparted into the matrix, while the addition 
of PEO has the reverse effect, indicated by the greater friability.  
4.3.4 Changes in Brinell Hardness Number (BHN) of Compressed External Polymeric 
Matrices Following Hydration 
Evaluating changes in the Brinell Hardness Number (BHN) of the discs allowed us to establish the 
rate at which water penetrated the surface of the discs and lead to their subsequent hydration and 
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erosion. The faster this occurred, the more quickly the incorporated gelispheres became exposed to 
the surrounding aqueous medium and released the entrapped nicotine.  
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Figure 4.6: Changes in the Brinell Hardness Number (BHN) (N/mm2) of compressed polymeric 
discs following exposure to simulated CSF over a period of 30 days (N=3; SD<23.67N/mm2). 
 
The results demonstrated that the most significant changes in BHN occurred within the first 1 day 
of exposure to simulated CSF. Discs composed of PEO in particular experienced a significant 
decline in BHN value within the first 24 hours. Due to the fact that both PEO and HPMC 
hydrogels imbibed and retained a substantial amount of water from the surrounding buffer media 
to become hydrated and subsequently undergo polymeric relaxation and generated a gel front on 
the surface of the disc. Subsequent to the initial 24 hour decline, the discs underwent gelation to the 
core of their compressed matrices rapidly. Furthermore, the presence of PEO impeded cohesion 
between the HPMC and PLGA powder particles it consequently generated matrices that were more 
prone to degradation upon exposure to hydration and mechanical stress. Due to the more complex 
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nature of the HPMC polymer in comparison to PEO, it did not undergo polymeric relaxation as 
rapidly. Thus the BHN value for HPMC declined most significantly between days 1-6. PLGA 
proved to be the exception to this rule. It demonstrated a steady decline in BHN over the 30 days. 
The combination of PLGA-HPMC also depicted a gradual, albeit more rapid decline in BHN 
indicating that the presence of PLGA with the HPMC generated sufficient cohesion between the 
polymers to restrict the diffusion of water molecules into the compressed polymeric matrix. 
4.3.5 Evaluation of Erosion of Compressed External Polymeric Matrix 
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Figure 4.7: Matrix erosion (%) of compressed polymeric discs following exposure to simulated 
CSF over a period of 30 days. (N=3; SD<0.05%). 
 
When hydrophilic polymers such as HPMC and PEO come in contact with dissolution medium (in 
this case simulated CSF) they can either swell and generate a continuous gel layer or undergo 
erosion or undergo combination of the two processes. Their swelling behaviour is controlled by 
their rate of hydration in the dissolution medium (Wan et al., 1993). ‘The extent of polymer 
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swelling, relative mobilities of dissolution medium and drug, and matrix erosion dictate the 
kinetics as well as mechanism of drug release from the polymeric matrices.’ (Roy and Rohera, 
2002).  
 
As indicated by previous results, PEO discs demonstrated lower gel strength, greater water uptake, 
and therefore demonstrated greater matrix erosion. HPMC discs on the other hand demonstrated 
greater matrix swelling with negligible matrix erosion. However, from the results it was observed 
that the rate of drug release by far superseded the rate of matrix degradation; hence it was 
concluded that the rate of drug release in this case was predominately as a result of the diffusion of 
the drug from the matrices.  
 
As mentioned previously, PLGA is a hydrophobic bioerodible polymer. Thus the mechanics of 
polymeric degradation and matrix erosion therefore occur via two main mechanisms, namely bulk 
erosion and surface erosion (Heller, 1987). The degradation of such polymers is based on the 
conversion of the macromolecule into its water soluble monomers via the hydrolytic cleavage of 
the ester bonds that constitute the backbone of the polymer. While bulk erosion does occur, a 
second mechanism that of surface erosion also takes place concurrently. This refers to the 
occurrence of hydrolytic breakdown of the polymer confined to the surface of the polymeric 
matrix. This was reflected by the steady decline in its BHN value over time following hydration. 
Drug release was therefore involves complex combination of both the drug diffusion from the 
surface and as a result of bulk erosion. This is discussed further under Section 4.3.7 which 
evaluates the results obtained for kinetic modelling of drug release data.  
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Scanning electron micrographs of the discs demonstrated the progression of pore formation and 
enlargement, formation of a trabeculated network of channels within the structure followed by 
erosion, and loss of integrity (Figure 4.8). PLGA discs demonstrated the most intact matrices in 
comparison to other systems. Figure 4.8a indicates the formation of a porous structure within the 
matrix at day 21 following exposure to simulated CSF. Larger pores (diameter of approximately 
300µm) were limited to the periphery of the discs, while the core of the matrix was relatively intact 
(where pores have a diameter of approximately 50µm). This matrix did not expand significantly, 
nor did it undergo any significant erosion. In contrast by day 21, HPMC-PLGA discs (Figure 4.8b) 
had a significantly more patent network, with pore sizes in the core of the matrix having 
comparatively larger diameters.  The disc expanded in width and cross-sectional diameter due to 
the tendency of HPMC to ‘swell’.  PEO-PLGA discs (Figure 4.8c) demonstrated a significant 
degree of erosion within the matrix while simultaneously indicating a greater degree of swelling 
and erosion. By day 21, the entire network, including the core of the matrix was extremely patent 
and highly trabeculated. The majority of the matrix appeared to be composed of PLGA. 
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Figure 4.8: Scanning electron micrographs (Magnification 65x) of compressed (a) PLGA, (b) 
HPMC-PLGA and (c) PEO-PLGA discs following exposure to simulated CSF after 21 days. 
(c) 
(a) 
(b) 
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4.3.6  Changes in Conductivity of Compressed External Polymeric Matrices Following 
Hydration 
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Figure 4.9: Changes in conductivity (µSiemens) of compressed polymeric discs following 
exposure to simulated CSF over a period of 30 days. (N=3; SD<16.34µS). 
 
 
These results inversely correlated with those observed for matrix erosion (Section 4.4.6) i.e. the 
greater the matrix erosion, the lower the observed conductivity of the solution. This indicated a 
greater degree of interaction between the untangling polymeric chains and the ions in solution. As 
greater quantities of the polymer unravelled from the disc i.e. matrix eroded, it ionized and 
interacted with ions in the surrounding PBS.  Hence we observed a decline in the conductivity of 
the solution over the 30 days. The greatest decline was observed for PEO, not surprisingly since it 
undergoes the most rapid rates of matrix degradation. Since the most significant phase of 
degradation of the PEO discs occurred within the first 12 days of exposure to simulated CSF, 
conductivity declines exponentially until this point, after which equilibrium was attained. HPMC 
demonstrated a steady, almost linear decline in conductivity until day 21 after which a significant 
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amount of the matrix had degraded to interact with surrounding counter-ionic species. As expected, 
PLGA expressed the least change in electrical conductivity, since it demonstrated the minimal 
change in weight (matrix erosion) over time following hydration. 
 
4.3.7 Kinetic Modelling of Release Kinetics from Compressed Polymeric Discs 
From model fitting, using WinNonlin Professional Edition, Version 5 (Pharsight, USA), the 
following data was generated from drug release data obtained for PLGA compressed polymeric 
discs incorporating optimised gelispheres. As observed previously from Figure 4.5, PLGA discs 
incorporating optimised gelispheres demonstrated zero-order release. 
 
 
Table 4.5: Release kinetics obtained from the various diffusion, relaxation and erosion models for 
compressed PLGA discs incorporating optimised gelispheres (Chapter 3). 
Model 
Mt/M∞= 
k1 k2 n 2AIC 3SBC 4Correlation 
k1tn  0.33 - 0.91 47.97 37.76 0.91 
k1tn+k2t2n 0.11 0.29 0.95 54.79 55.09 0.93 
1-[1- k1t]n 0.41 - 2 19.21 19.85 0.96 
2Akaike Information Criterion 
3Schwartz’s Bayesian Criterion 
4Correlation between experimental and predicted dissolution data 
 
Statistically, the large value of k2 (0.29) indicates substantial polymeric relaxation for the PLGA 
discs as compared to the k1 value (0.11) (Table 4.5) and only confirms that erosion is not the only 
release mechanism occurring when the formulation is exposed to simulated CSF. As mentioned 
previously, PLGA undergoes a combination of surface and bulk erosion (Section 4.3.5). The 
results obtained concur with this since it is demonstrated that drug release was a combination of 
diffusion (Fickian transport) and polymeric swelling and disentanglement (Case II transport).  
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High correlation and k1 values obtained for the Hopfenberg equation indicated that matrix erosion 
predominated polymeric swelling. While PLGA discs imbibed water into the matrix, since they 
retained their integrity substantially over time following exposure to simulated CSF, since they are 
hydrophobic in their chemical constitution, they do not swell significantly (as discussed 
previously). Furthermore, the lower AIC and SBC values for this model (AIC = 19.21 and SBC = 
19.85) indicated that this model most aptly described the mechanism of drug release kinetics from 
the system. The correlation for this model was also the highest (0.96). Hence it was concluded that 
drug release was a primary function of matrix erosion, rather than polymeric relaxation (matrix 
swelling). 
 
4.4 Concluding Remarks 
The intended drug delivery system this study sought to develop was one that could provide 
sustained zero-order release of a nicotine from a crosslinked polyspheric system. This would allow 
for the attainment of constant drug levels at the site of action and minimize adverse effects 
associated with fluctuating drug levels, as well as optimising patient therapy and compliance. 
PLGA matrices incorporating calcium-barium-crosslinked alginate-hydroxyethylcellulose 
(optimised system formulated) gelispheres offered minimal rates of matrix degradation and 
successfully retarded nicotine release which achieved zero-order release for 50 days following 
exposure to simulated CSF. Kinetic modelling demonstrated that drug release occurred primarily 
as a result of PLGA erosion following exposure to simulated CSF. 
 
Two alternative approaches to further modify nicotine release from the proposed delivery system 
were also investigated. It was proposed that coating HPMC and HPMC-PEO compressed discs 
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with PLGA would be investigated to establish an alternative method to retard drug release. The 
results from the study conducted are discussed in Chapter 5. In Chapter 6, a polyspheric drug 
delivery system was developed to deliver PLA-PLGA microparticles incorporating nicotine.   
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Chapter 5  
Alternative Approach to Modify Nicotine Release: (I) PLGA-Coated Polymeric 
Discs Incorporating Crosslinked Calcium-Alg-HEC Gelispheres 
 
5.1 Introduction 
Dissolution is often the rate limiting step for the rate of release of highly soluble drugs from 
compressed polymeric matrices. Sustained release of such medicaments can be achieved by a 
variety of means, one of which involves the coating of drug particles or granules with various 
materials. Drug release is generally a function of the solubility of the drug and the porosity and 
physiochemical properties of the coating membrane. Biopolymers such as celluloses, polyethylene 
glycol (PEG), various polysaccharides, fatty bases and waxes have been employed to coat 
numerous oral drug delivery systems with this goal. Release can be modulated to provide for site-
specific, targeted and pH and/or enzymatic-controlled release systems through the use of various 
materials. The majority of these systems have been applied for controlled drug delivery in oral 
dosage forms (Conrad and Robinson, 1982). In fact reservoir devices employ polymeric coats as 
their primary means of restricting drug release. The various categories of coatings investigated are 
listed below with a brief summary of their properties. 
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Table 5.1: Various categories of coatings investigated are listed below with a brief summary of 
their properties (Source: Adapted from Hui et al., 1989). 
Type of Coating Properties 
1. Barrier coating This mechanism employs the use of various hydrophobic 
polymers and is applicable to provide film-coatings for 
tablets and granules as well as compressed tablets. Release 
mechanisms can be compromised due to disintegration and 
fracture during compression.  
2. Embedment into a fatty 
coating 
This applies to the formulation of a various compressed and 
multilayer tablets. Such formulations allow for modulated 
release such that portions of the medicament can be 
released more rapidly than others. However it is often 
difficult to control release since release is often pH and/or 
enzymatic hydrolysis dependant.  
3. Repeat action coatings While these are not regarded as ‘true’ sustained release 
forms and has the same limitations and properties of barrier 
coating. 
 
4. Coated plastic matrix The majority of the dosage forms employing this 
mechanism to retard drug release involves the use of non-
biodegradable polymeric materials to formulate the device. 
Hence the plastic matrix after drug release must be 
eliminated or removed from the body.  
5. Coated hydrophilic matrix Drug release is significantly dependant on the nature of 
coating polymer employed. The rate of drug release is more 
dependant on the properties (primarily the solubility) of the 
drug entity delivered.  
 
The entrapped drug partitions into the surrounding membrane prior to release. Depending on the 
nature of the coating material, the drug can be released either via diffusion or dissolution. For coats 
composed of hydrophilic polymers, release is dependant on the formation of a viscous gelatinous 
layer of polymer as it becomes hydrated and undergoes a transition between the glassy and rubbery 
phase. Hence release in such systems is controlled provided the hydrated gelatinous layer remains 
intact. On the other hand, for hydrophobic polymers, release is more dependant on the porosity of 
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the coating membrane developed.  Drug release in such cases is expected to follow Fickian 
diffusion kinetics. Equation 5.1 describes Fick's First Law of diffusion from a plane surface, with a 
position-dependent diffusion coefficient is, 
δc = DA(Cs – Cb) 
                                                                  δt               q 
Equation 5.1 
Where, 
the rate of change in molar drug concentration (the equivalent of the rate of  drug release  
 
D      the diffusion coefficient, a macroscopic measurable quantity 
A      the cross-sectional surface area of the polymeric matrix 
Cs     the aqueous saturation concentration of the drug 
Cb   the concentration of the drug in the bulk solution (this is usually neglected, due to the presence 
of sink conditions in the body) 
q       the thickness of the stagnant diffusion layer 
Fick’s Law describes the presence of a direct and linear relationship between the rate of drug 
release (diffusion) and the concentration gradient, the surface area, the diffusion coefficient of the 
drug molecule (a factor dependant upon the chemical nature molecule and its molecular weight) 
and an inverse relationship between the thickness of the stagnant diffusion layer, a region around 
the drug delivery systems that is saturated with dissolved drug (Burnette, 1987).  
 
However if the coating materials are insoluble and non-biodegradable, this can result in problems 
regarding device elimination from the body. In the case of implants this scenario is not ideal as it 
δc 
δt 
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necessitates a second surgical procedure to remove the implant, resulting in great risk, 
inconvenience and expense to the patient. 
 
Apart from the nature of the coating agents employed, the thickness of the coat is directly related to 
the degree of control on drug release kinetics. In other words, the thicker the coating, the greater 
the provision to achieve sustained drug release from the delivery system (Rosen, 1989). 
 
From Chapter 4 it was observed that the presence of hydrophobic PLGA within the compressed 
polymeric matrices allowed for reduced rates of drug release. It was proposed that the presence of 
a hydrophobic coat of the polymer around HPMC and a combination of HPMC and PEO may also 
impact the rate of drug release. 
 
Calcium-crosslinked Alg-HEC (Ca-Alg-HEC) gelispheres generated previously (Chapter 3) were 
incorporated into external polymeric discs coated with PLGA. A comparison was conducted on 
uncoated discs also to establish the degree to which drug release could be retarded.  
 
The purpose of this study is to use the beneficial properties of coating to control the rate of drug 
release from the gelispheres. A biopolymeric barrier coating on compressed polymeric matrices 
is employed. From Chapter 4 it was observed that the porosity of PLGA matrices changed little 
over time, hence offer a suitable material for coating hydrophilic matrices. By employing high 
compression forces on this highly compressible hydrophobic polymer, we were able to employ a 
simple manufacturing strategy to develop a dense resistive coat around the matrices. The results 
from this study are presented in the following sections. 
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5.2 Materials and Methods 
The materials employed to generate the Ca-Alg-HEC gelispheres were the same as previously 
stated in Chapter 3 and those employed to formulate the external polymeric matrices were as those 
stated in Chapter 4. 
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Figure 5.1: X-ray diffraction (XRD) profile observed for the calcium-crosslinked Alg-HEC 
gelispheres selected for incorporation into external polymeric discs coated with PLGA. 
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5.2.1 Formulation of PLGA-Coated (PC) Polymeric Matrices 
Briefly, 500mg of the dry polymer(s) blended was mixed with the Ca-Alg-HEC 100mg gelispheres  
and subsequently compressed into discs using a Beckman® Hydraulic Press (Beckman 
Instruments, Inc., Fullerton, USA) applying a pressure of 8 tons. Flat-faced punches with a 10mm 
diameter were employed to compress the polymeric discs. The coated matrices were generated by 
compressing the discs with 100mg PLGA in a larger punch diameter (11.5mm in diameter) 
employing the same compression parameters as previously mentioned. Based on the results from 
Chapter 4, two formulations were selected for coating with a layer of PLGA to assess its effect on 
retarding drug release from these matrices. Table 5.2 summarizes the investigated disc 
compositions. In order to establish the impact of coating on drug release, native uncoated discs 
were also formulated.  
 
Table 5.2: Investigated polymer compositions for the external compressed polymeric matrix 
incorporating Ca-Alg-HEC gelispheres.  
Formulation Number Polymer Composition 
1 *PC-HPMC 
2 *PC-HPMC-PEO 
3 HPMC-PEO 
4 HPMC 
5 PLGA 
(*PC = PLGA-coated) 
5.2.2 Determination of In Vitro Drug Release Characteristics 
In vitro drug release studies were performed in triplicate the discs formulated were as described in 
Chapter 3, Section 3.2.8 over a period of 21 days for each disc. 
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5.2.3 Kinetic Modelling of Drug Release from Compressed Polymeric Discs 
In order to elucidate the kinetic mechanisms involved in nicotine release from the compressed 
polymeric matrices, drug release data was employed to generate mathematical models as discussed 
in Section 4.2.10 (Chapter 4).  
5.3 Results and Discussion 
5.3.1 Evaluating In Vitro Drug Release from PLGA-Coated (PC) Polymeric Matrices 
A brief summary of the properties of the gelispheres highlights the rapid release rates observed for 
the system.  Figure 5.2 and Table 5.3 indicate the release profile obtained for the Ca-Alg-HEC 
gelispheres selected for incorporation into external polymeric discs over a period of 50 hours, 
whereby 100% of the drug was released. Values exceeding 100% drug release after 50 hour 
indicated the presence of residual nicotine on the surface of the gelispheres following curing.  
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Figure 5.2: % Drug released from Ca-Alg-HEC gelispheres over a period of 50 hours after 
exposure to simulated CSF (N=3; SD<0.56%).  
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In comparison to the HCl-exposed Alg-HEC-PAA gelispheres incorporated into discs form the 
Chapter 4, it should be noted that there was a significant discrepancy between the rates of drug 
release from the two types of gelispheres. While drug release for Ca-Alg-HEC gelispheres was 
completed within 50 hours, the duration of release was far exceeded for HCL-exposed optimised 
gelispheres (Chapter 3). This therefore impacted upon the degree to which the external matrices 
retarded drug release.  
 
Coating the hydrophilic compressed matrices with the hydrophobic PLGA significantly retarded 
drug release. In particular a substantial difference was observed for HPMC-PEO matrices, which 
demonstrated zero-order kinetics following approximately 15 days exposure to simulated CSF. 
PLGA demonstrated predictable release kinetics with phasic (or pulsatile) first and zero-order 
release that continued to release the drug past the 21 day test period. This was a dramatic 
improvement from the release profiles obtained from native Ca-Alg-HEC gelispheres prior to 
incorporation, which degraded to release the entrapped drug within a space of less than 50 hours. 
 212
Time (hours)
0 100 200 300 400 500
D
ru
g 
R
el
ea
se
 (%
)
0
20
40
60
80
100
PC-HPMC
PC-HPMC-PEO
HPMC-PEO
HPMC 
PLGA 
 
Figure 5.3: % Drug released over a period of 500 hours (or 21 days) from the gelispheres 
compressed into native PLGA and PLGA coated (PC) polymeric discs following exposure to 
simulated CSF (N=3; SD<3.10%). 
Approximately 80% drug was released within the first 24 hours from uncoated HPMC and HPMC-
PEO formulations, indicating a significant burst effect. Native PLGA discs had a significantly 
attenuated burst effect, whereby a mere 8.53% of the incorporated drug was released during the 
same period of time. The most promising results were obtained with the coated discs, whereby 
drug release was 6.44% and 5.40% for HPMC and HPMC-PEO coated discs, respectively within 
the first 24 hours. Approximately 100% of the drug was released from uncoated HPMC and 
HPMC-PEO discs by day 6. The PLGA coating provided a significant barrier to penetrating 
solvent molecules into the matrices. While initially when the PLGA coating is intact, drug release 
is controlled by diffusion, indicated by the pseudo-zero-order release, subsequent to PLGA 
hydrolysis, drug release more rapid. 
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5.3.2 Kinetic Modelling of Drug Release from PLGA-Coated Compressed Polymeric 
Discs 
The results obtained from model fitting, (WinNonlin, Professional Edition, Version 5 (Pharsight, 
USA)) the following data was generated: 
 
Table 5.3: Drug release kinetics obtained from the various diffusion, relaxation and erosion 
models for PLGA-coated compressed HPMC-PEO discs incorporating Ca-Alg-HEC gelispheres.  
Model 
Mt/M∞= 
k1 k2 n 2AIC 3SBC 4Correlation 
k1tn  0.92 - 0.90 47.16 38.98 0.89 
k1tn+k2t2n 0.15 0.87 0.95 16.02 26.54 0.94 
1-[1- k1t]n 0.55 - 2 39.96 59.08 0.87 
2Akaike Information Criterion 
3Schwartz’s Bayesian Criterion 
4Correlation between experimental and predicted dissolution data 
 
 
A significantly large value for k2 (0.87) was observed which, indicated that matrix swelling and 
polymeric disentanglement contributed substantially towards the drug release mechanism form the 
compressed polymeric discs. This is further proven by the significant correlation value (0.94) 
obtained for experimental and predicted dissolution data. From previous studies (Chapter 4) it was 
observed that the contribution of Fickian diffusion mediated drug release kinetics from native 
PLGA discs to a comparatively greater degree (where, k1 = 0.11 and k2 = 0.29) verses Case II 
transport. This implies that despite PLGA coating the HPMC-PEO compressed discs, the system as 
a whole experienced a significant degree of polymeric swelling in the interior of the matrix from 
the HPMC-PEO core when exposed to simulated CSF. It is proposed that Fickian diffusion 
predominates (indicated by the high k1 value for Power Law) drug release kinetics, which may be 
as a result of a greater drug load in the Ca-Alg-HEC gelispheres (as opposed to the optimised 
system from Chapter 3, which was incorporated within native PLGA discs in Chapter 4). 
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Furthermore, gelisphere swelling cannot be ignored in this case, since these gelispheres were not 
exposed to dilute HCl post-curing, hence undergo substantial increase in volume subsequent to 
simulated CSF exposure. This theory is further supported by the low values obtained for AIC and 
SBC for this model (AIC = 16.02 and SBC = 26.54). The model also demonstrated the highest 
correlation value of 0.94.  
 
5.4 Concluding Remarks 
PLGA is a unique polymer with many properties that makes it an ideal agent for developing 
controlled and sustained release drug delivery devices.  This study has demonstrated that it 
imparted a significant impact on the nature and kinetics of drug release. We achieved zero-order 
release from the developed gelispheric system by incorporating PLGA as an external matrix as 
well as a coating agent to hydrophilic polymer systems composed of HPMC and PEO.  
 
Coating the HPMC-PEO matrices with PLGA significantly retarded drug release and allowed the 
achievement of constant zero-order release following 15 days exposure to simulated CSF. The 
presence of PLGA as a coating agent retarded the rate of drug release and allowed the achievement 
of phasic or pulsatile release.  
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Chapter 6  
Alternative Approach to Modify Nicotine Release: (II) Application of Novel 
Crosslinked Alginate-Pectinate Double-Encapsulated Approach for Delivering 
a PLA-PLGA Microparticulate System  
6.1 Introduction 
The comparative merits of multiple-unit dosage forms (e.g., in terms of bioavailability, more 
consistent blood levels and greater product safety) over single-unit products are well established. 
Analysis of release data indicates that a zero-order mechanism can be obtained (Pillay and Fassihi, 
1999; Efentakis and Koutlis, 2001). The dose dumping phenomenon that is a real risk factor with 
single-unit systems is a limitation that multiple-unit devices can very effectively overcome 
(Shivakumar et al., 2002). Failure of a single entity does not compromise the efficacy of the entire 
device. 
 
The aim of the study was to formulate and to optimise a novel drug delivery system for nicotine 
through double entrapment, finally with the biodegradable hydrophobic polymers PLA-PLGA and 
then a crosslinked zinc-alginate-pectinate polyspheric matrix. The physiochemical and 
physicomechanical characteristics that would optimise this formulation for its use as a possible 
brain implant to prevent the progression of PD were evaluated.  
 216
 
H O C H 
O
O 
C H 3 
yx
y = number of glycolic acid units
x = number of lactic acid units 
H O CH
O CH2
O
H
O 
O
CH3
CH2
O
H 
O
x y 
Polylactic acid (PLA) Polyglycolic acid (PGA)   
Polylactic-co-glycolic acid (PLGA) 
 
Figure 6.1: Chemical structure of polylactic acid (PLA), polyglycolic acid (PGA) and poly(lactic-
co-glycolic) acid (PLGA). 
 
Biodegradable polyesters, such as polylactic acid (PLA), polyglycolic acid (PGA), and poly(lactic-
co-glycolic acid) (PLGA) (Figure 6.1), have been extensively studied for a variety of 
pharmaceutical and biomedical applications. They offer unique advantages by enabling 
controllable biodegradability, displaying excellent biocompatibility, and a high degree of safety. 
The general properties and typical applications of PGA, PLA, and PLGA are summarized in Table 
6.1. 
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Table 6.1: General properties and typical applications of the biodegradable polyester polymers 
polyglycolic acid (PGA), polylactic acid (PLA) and their copolymer poly(lactic-co-glycolic) acid 
(PLGA). 
Polyester Crystallinity 
Glass 
Transition 
Temperature 
(Tg) ( ºC) 
Degradation 
Rate 
Typical 
Pharmaceutical 
and Biomedical 
Applications 
PGA 
 
Highly crystalline 35-40 2-3 months Sutures 
PLA Semi-crystalline-
Amorphous 
(depending on D/L 
ratio) 
65-55 1-2 years Fracture fixation, 
ligament 
augmentation and 
drug delivery 
systems  
 
PLGA Amorphous 
(depending on 
PLA/PGA ratio) 
45-55 1-6 months Fracture fixation, 
ligament 
augmentation, grafts, 
prosthetic devices 
and potentially 
implantable and oral 
drug delivery 
systems.  
 
PGA is a highly crystalline polymer and the most hydrophilic among them. It has an extremely 
high melting point (224°C to 226°C), and a significantly prolonged degradation rate. During 
polymerization, successive monomeric units (of glycolic or lactic acid) are linked together in 
PLGA by ester linkages, thus yielding a linear, aliphatic polyester as a product. Unlike the 
homopolymers of lactic acid (PLA) and glycolic acid (PGA) which show poor solubilities, PLGA 
can be dissolved by a wide range of common solvents, including chlorinated solvents, 
tetrahydrofuran, acetone or ethyl acetate. PLGA degrades by hydrolysis of its ester linkages in the 
presence of water. It has been shown that the time required for degradation of PLGA is related to 
the ratio of its constituent monomer ratio. More specifically, the higher the glycolide content the 
greater the rate of polymeric degradation. PLGA copolymers with varying ratios of lactide (LA) 
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and glycolide (GA) monomeric units can exhibit variable degradation rates, and therefore can be 
‘custom-made’ for specific applications requiring specific degradation kinetics. 
 
Microparticles have been proven to be efficient systems for delivery of a wide range of 
chemotherapeutic drugs to the brain (Ike et al., 1992; Menei et al., 1999). One of the most 
significant advantages they offer is that they can be injected safely as a suspension, thus permitting 
site-specific drug delivery to virtually any region in the brain (Emerich et al., 1999). PLGA is 
considered to be biocompatible with brain tissue (Menei et al., 1996; Emerich et al., 1999; Veziers 
et al., 2001) and has been employed to deliver a range of anti-neoplastic agents such as 5-
fluorouracil, BCNU, carmustine, taxol, and carboplatin by entrapping them into polymeric 
microspheres for sustained drug release treat brain tumours (Menei et al., 1996; Emerich et al., 
2000; Walter et al., 1994; Olivi et al., 1996; Chen et al., 1998). PLGA has been employed to 
formulate microparticles to deliver drugs such as levodopa (with and without a decarboxylase 
inhibitor), dopamine, norepinephrine and the neurotrophic factor, GDNF to the brain via striatal 
implants (Popovic and Brundin, 2006). 
 
The present study is aimed at understanding the incorporation of nicotine into polylactic acid 
(PLA) and poly(D,L-lactic-co-glycolic) acid (PLGA) microparticles which are then re-
incorporated into a cross-linked zinc-alginate-pectinate polyspheric multi-particulate system to 
be employed as a possible brain implant for the treatment of PD. A Box–Behnken design is 
employed to prepare 15 PLA-PLGA formulations, which are tested for their drug incorporation 
efficiency and release potential and subsequently optimised using multiple regression and an 
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artificial neural network generalized feed-forward model. Based on the rapid burst effect from 
the microparticles, further incorporation is conducted in a zinc-alginate-pectinate system using 
ionotropic gelation 
 
6.2 Materials and Methods 
A mixture of low molecular weight poly(lactic-co-glycolic) acid (85/15) (PLGA) with an inherent 
viscosity 0.65dL/g in CHCl3 at 30°C) and low molecular weight polylactic acid (PLA) with an 
inherent viscosity 0.66dL/g in CHCl3 at 30°C was purchased from Burmingham Polymers Inc. 
(Bioabsorbabale polymers, MA, USA). Nicotine ((-)-1-methyl-2-(3-pyridyl)-pyrolidine) was 
purchased from Sigma Pharmaceuticals (Sigma Pharmaceutical Group; M.A., USA). Acetonitrile 
was purchased from Merck Laboratory Supplies (Pty) Ltd. (Gauteng, South Africa), Liquid 
paraffin with a distillation range 40–60°C was purchased from Merck Laboratory Supplies (Pty) 
Ltd. (Gauteng, South Africa). Span 80 was purchased from Rochelle Chemicals (South Africa). 
Petroleum ether, Dimethylformide (DMF), both of which were 99.5 % pure, were purchased from 
Rochelle Chemicals (Gauteng, South Africa). Pectin was donated by Herbstreith and Fox KG 
(Neuenbürg/Württ., Germany), Sodium Alginate was donated by FMC BioPolymer (Drammen, 
Norway) and Zinc gluconate was purchased from Merck – Schudart (Hohenbrunn, Germany). 
 
6.2.1 Preparation of PLA-PLGA Microparticles 
In order to produce the correct formulations to optimise the release profile of nicotine and the 
entrapment efficiency of the drug, the Box-Behnken design was used. This is an independent 
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quadratic approach, which does not contain an embedded factorial or fractional factorial, was 
employed to generate a statistical matrix.  
 
The formulation input factors that were evaluated at 3-levels included: 
¾ Polymer type: PLA (1), PLGA (2) and their combination in a 1:1 ratio (3);  
¾ Stirring time: 3, 9 and 15 hours; and 
¾ Concentration of emulsifying agent Span 80: 0.5% w/v, 1.25% w/v and 2% w/v.  
 
The 15 combinations of PLA-PLGA microparticles were prepared using an oil-in-oil (O/O) phase 
separation process in accordance with the Box-Behnken design (Table 6.2). 
Table 6.2: Independent variables evaluated using the Box-Behnken Design. 
Formulation 
Number 
Polymer  
Type 
Stirring Time 
(hours) 
[Span 80] 
(%w/v) 
1 1 15 1.25 
2 2 3 0.50 
3 3 9 2.00 
4 3 15 1.25 
5 2 9 1.25 
6 1 3 1.25 
7 2 3 2.00 
8 2 9 0.50 
9 2 15 2.00 
10 1 9 0.50 
11 3 9 0.50 
12 2 15 0.50 
13 2 9 2.00 
14 3 3 1.25 
15 1 9 2.00 
 
440 mg of polymer (PLA, PLGA or combination) was added to 10mL of acetonitrile and left for 
12 hours to dissolve without stirring. Upon complete dissolution of the polymers, 300mg of 
nicotine was added and mixed by means of a magnetic stirrer. Using a 10mL pipette, the polymer-
 221
nicotine dispersion was added in a dropwise manner to 50mL of liquid paraffin containing the 
appropriate concentration of Span 80. This was conducted under agitation using a Hiedolph stirrer 
(Labotec®, Gauteng, South Africa) at 500rpm. The stirring speed was decreased to 400rpm after 
the addition was completed and for the remainder of the process with different stirring times as 
indicated in the Box-Behnken design (Table 6.2). 
 
Upon completion of the required stirring time, hardening of the microparticles was achieved by the 
addition of 25mL of petroleum ether.  This mixture was then stirred for an additional 10 minutes at 
400rpm. An Erlenmeyer flask containing a Bucchner funnel equipped with Whatman® filter paper 
(0.45μm pore size) was utilized in order to collect the microparticles via vacuum filtration.  An 
additional 25mL of petroleum ether was then added to the residual mixture in the beaker to wash 
out the remaining microparticles. 
 
The filter paper containing the microparticles was placed under an extractor for 48 hours, to 
facilitate evaporation of the residual solvent.  Subsequently the microparticles, ready for 
analysis, were stored in glass vials at -5°C. 
 
6.2.2 Determination of Drug Entrapment Efficiency 
The drug entrapment efficiency of the microparticles was determined in dimethylformide (DMF) 
since both nicotine and the polymers were soluble in this solvent. 20mg of nicotine-loaded 
microparticles was dissolved in 100mL of DMF and thereafter agitated at room temperature with 
the aid of a homogenizer (VELP® Scientifica Microstirrer, Italy).  In order to remove any 
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contaminants or residual polymer that may have not coated the nicotine, the samples were 
filtered through a Millipore® filter (0.45 μm pore size).  The absorbance values of the samples 
were read at a wavelength of 260nm and converted to drug concentration by means of a standard 
curve (obtained using concentrations of nicotine varying from 1 to 3%). Drug entrapment 
efficiency (DEE) (%) was calculated using Equation 3.2 (Section 3.2.6, Chapter 3). 
 
6.2.3 Determination of In Vitro Drug Release Characteristics  
Nicotine-loaded particles of each formulation equivalent to 20mg of pure nicotine were placed in 
100mL phosphate buffered saline of pH 7.4 (PBS) in sealed 200mL glass jars.  These jars were 
then placed in a shaker bath (Labotec®, Gauteng, South Africa) set at 37°C and agitated at 50 rpm.  
At 30-minute intervals 1mL samples of the solution were removed, appropriately diluted with PBS 
and analysed by UV at 260nm. An equal volume of drug-free PBS was added to the glass jars to 
maintain sink conditions. 
 
6.2.4 Optimisation of the PLA-PLGA Microparticles 
Optimisation of the PLA-PLGA microparticles was based on drug entrapment efficiency and drug 
release. Two different methods were considered to optimise the formulation. The first consisted of 
the application of Design of Experiments response optimiser function in Minitab (Release 14, 
Minitab Inc., USA) employing simultaneous optimisation of the responses. The second approach 
involved the application of Artificial Neural Networks (ANN) (NeuroSolutions V4.32, 
NeuroDimension Inc., USA) using a Generalized Feed Forward algorithm, also employing a 
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simultaneous optimisation technique. The employment of two methods enabled a comparison to be 
obtained between formulations that were prepared.  
 
Multiple regression of the response outputs generated from the Box-Behnken design and pattern 
recognition and prediction from artificial neural networks were used to optimise the drug 
entrapment efficiency and release of nicotine from the microparticles. 
 
6.2.5 Double Entrapment of PLA-PLGA Microparticles into Crosslinked Alginate-
Pectinate Polyspheres 
Due to the fact that entrapment of nicotine into different PLA and PLGA combinations caused the 
drug to be released within the first 30 minutes, a double entrapment approach was attempted. To 
accomplish this, pectin, sodium alginate and then a 1:1 combination thereof was used as the second 
coating.  Three 2%w/v polymer solutions composed of pectin, sodium alginate and a 1:1 
combination (2%w/v each) was dissolved in 80mL of de-ionized water. Upon complete dissolution 
of the polymer solutions, they were made up to 100mL with de-ionized water. Three 2%w/v 
solutions of zinc gluconate (200mL) were prepared as the crosslinking agents. Approximately 
24mg of the optimised nicotine-incorporated microparticles (≈ to 2mg pure nicotine) was added to 
20mL of each of the three polymer solutions and stirred for 30 minutes.  Each of these 3 polymer 
dispersions, using a 20mL syringe were then added dropwise into 3 separate beakers containing the 
crosslinking solution. This dropwise addition allowed for the formation of either PLA-PLGA-zinc-
alginate, PLA-PLGA-zinc-pectinate or PLA-PLGA-zinc-alginate-pectinate polyspheres (i.e. 
polyspheres incorporated with PLA-PLGA microparticles). These resultant polyspheric 
formulations were agitated for an additional 30 minutes in the crosslinking solution and thereafter 
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left to cure in a dark area at room temperature for 3 hours.  After 3 hours the polyspheres were 
washed with 3x500mL de-ionized water and allowed to air dry over 4 days, under ambient 
conditions. Following this, dissolution studies were conducted in a similar manner as described 
above. 
 
6.2.6 Elucidating Surface Morphology of the Developed Systems  
The shape and surface morphology of the microparticles and polyspheres was examined using a 
JEOL 6400 scanning electron microscope (JEOL, Japan).  
 
6.3 Results and Discussion 
6.3.1 Yield of Microparticles  
Varying yields of microparticles were found among the different formulations, ranging from 
83.30mg to 1164.00mg (Table 4.3). In the case of 83.30mg, the conditions were PLGA as the 
polymer, 3 hours stirring time and 0.5%w/v Span 80. This low yield may be attributed to a low 
stirring time as well as the use of minimal concentration of emulsifying agent. Conversely, the 
highest yield was seen in the formulation that employed PLGA, had a stirring time of 9 hours and 
used a Span 80 concentration of 1.25%w/v. The results thus revealed that the polymer employed is 
not the only deciding factor for microparticle yield. Rather, the stirring time and emulsifying agent 
combine in their effects. Prolonged stirring (>9 hours) may have led to poorer yields due to 
excessive shearing forces on the polymer, consequently leading to fragmentation of the 
microparticles. Figure 6.2a and 6.2b show the scanning electron micrographs (SEM) of fragmented 
and optimal microparticles respectively. 
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Figure 6.2: Scanning electron micrographs of (a) fragmented microparticles and (b) optimal 
spherical microparticles.  
 
 
(a) 
(b) 
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6.3.2 Evaluation of Drug Entrapment Efficiency 
Overall, the results demonstrated that optimal entrapment efficiency was observed from the 
following formulations (in order of increasing entrapment efficiency) (Table 6.3): 
 
¾ Formulation 2 (PLGA, 3 hours, [Span 80] 0.5 %w/v); 
¾ Formulation 14 (PLA + PLGA, 3 hours, [Span 80] 1.25 %w/v); and 
¾ Formulation 7 (PLGA, 3 hours, [Span 80] 2 %w/v) 
  
The overall trend observed is that the formulation comprising only PLGA or a combination of the 
two polymers with a stirring time of 3 hours provided the high entrapment efficiency. The presence 
of PLA in the formulation yielded a lower entrapment efficiency as it may have decreased the 
amorphous character of the polymer.   
 
6.3.3 Evaluation of In Vitro Release of Nicotine from the Microparticles  
The in vitro dissolution profiles for all formulations demonstrated near 100% release within the 
first 30 minutes (Table 6.3). This is due to the fact that the polymers are too porous, probably due 
to a lack of sufficient consolidation and therefore the ability to restrict the diffusion of nicotine via 
the pores. A typical scanning electron micrograph reveals the highly porous nature of a 
microparticle (Figure 6.3), hence leading to rapid drug diffusion. 
 
These profiles were not optimal since our aim was to formulate a controlled and prolonged release 
implant. These results therefore demonstrated the need to double-incorporate the PLA-PLGA 
microparticles, to further restrict the release rate of nicotine.  
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Table 6.3: Values of responses obtained from the formulation of nicotine-loaded PLA-PLGA 
microparticles.  
Formulation 
Number 
Yield of 
Microparticles 
(mg) 
Drug Entrapment 
Efficiency 
(%w/w) 
Drug Release 
(%) after 0.5 
hours 
1 486.90 44.78 85.12 
2 83.30 83.66 94.22 
3 1040.40 42.16 66.65 
4 981.60 35.88 77.12 
5 1164.00 39.62 82.45 
6 279.00 16.41 98.44 
7 604.20 74.39 94.08 
8 858.70 39.9 95.56 
9 1441.10 29.53 69.76 
10 932.30 28.71 94.23 
11 881.80 44.41 80.34 
12 431.20 31.42 80.51 
13 1139.00 32.57 99.12 
14 810.60 82.83 93.26 
15 818.90 51.16 98.01 
 
 
 
Figure 6.3: Typical scanning electron micrograph of a highly porous PLA-PLGA microparticle. 
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6.3.4 Statistical Optimisation Studies   
The output parameters for the optimisation and the results are provided in Table 6.5. Table 6.4 
provides the optimised input parameters generated through stepwise forward and backward 
regression.  
 
Table 6.4: Optimised parameters used to generate experimental values. 
Input Parameters Box-Behnken ANN 
Polymer Type 3 1.7 
Stirring Time (hours) 3 6.7 
[Span 80] (%w/v) 0.5 1.4 
 
Table 6.5: Comparison between desired and experimental output parameters with respect to 
selected data-modelling tools. 
Box-Behnken Artificial Neural Network Output 
Parameters Desired Exp.* Desired Exp.* 
Drug 
Entrapment 
Efficiency 
 
90% 81.29% 90% 89.81% 
Drug Release 
(%) after 1 hour 
100.02 106.32 100.00 103.33 
*see Table 6.4 
 
The regression and ANN algorithmic analysis predicted two formulations which still provided 
unfavourable results, since both reflected poorer entrapment efficiencies in comparison to those 
seen in earlier formulations and possessed release characteristics that were inconsistent and 
unpredictable (Figure 6.4). Drug was once again almost completely released from the “optimised” 
microparticles within the first 30 minutes. Since both the Box-Behnken and the ANN formulations 
showed similar behaviour, we opted to choose only one method for re-entrapment, namely the 
ANN formulation. 
 229
Time (hours)
0.0 0.5 1.0 1.5 2.0
D
ru
g 
R
el
ea
se
 (%
)
0
20
40
60
80
100
Box-Behnken
ANN
 
Figure 6.4: % Drug released from optimised PLA-PLGA microparticles as per Box-Behnken 
design and ANN algorithm (N=3; SD <0.03). 
 
 
6.3.5 Statistical Inferences between the Experimental and Predicted Values for Responses 
Measured  
Both drug release after 0.5 hours and drug entrapment efficiency (Figure 6.5a-b) reflected a close 
linear relationship between the experimental and predicted values (R2=0.89 and R2=0.80 for drug 
release and drug entrapment efficiency respectively).  Using a t-test, it was also confirmed that no 
statistical differences (p>0.05) existed between the experimental and predicted values for both 
responses. 
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Figure 6.5: Linear relationship between the experimentally-derived and Box-Behnken predicted 
values for (a) Drug release (fractional) after 0.5 hours, and (b) Drug entrapment efficiency (N=3; 
SD<0.27). 
 
Equation 6.1 below is the quadratic equation describing the Box-Behnken design: 
 
Response = b0 + b1* polymer type + b2* stirring time + b3* [Span 80] + b4 polymer type + b5 
stirring time*stirring time + b6*[Span 80]*[Span 80] + b7*polymer type*stirring time + 
b8*polymer type*[Span 80] + b9*stirring time*[Span 80] 
Equation 6.1 
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In all cases of model-fitting, the Normal Plot of the Residuals showed that the data points formed a 
straight line indicating that the residuals were normally distributed (Figure 6.6a).  Furthermore, the 
plot of the Residuals versus Fits showed a random pattern of the residuals on both sides of zero 
(Figure 6.6b).  Typical plots of these indicators are shown in Figure 6.6a and 6.6b. 
 
The adjusted Andersoñ-Darling statistic, a measure of how far the plot points fall from the fitted 
line in a probability plot produced a value of <0.2 in all cases. In general, a smaller Andersoñ-
Darling statistic indicates that the distribution fits the data better.  Essentially, the statistic is a 
weighted squared distance from the plot points to the fitted line with larger weights in the tails of 
the distribution.  In addition, the p-values (0.302 - 0.417) were obtained for the normal residual 
plots were higher than the chosen α-level of 0.05, indicating that the data followed a normal 
distribution. 
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Figure 6.6: Typical profiles for (a) the normal probability plot of the residuals, and (b) the 
residuals versus the fitted values. 
   
 
Table 6.6 shows the salient statistical parameters that were used to assess the goodness-of-fit of the 
models for the respective responses.  Note that a p-value higher than 0.05 for the lack-of-fit 
parameter also indicates better model-fitting.  R2 values above 0.80 were considered as acceptable, 
based on complexity of the design. 
 
Table 6.6: Salient Parameters employed according to Andersoñ-Darling statistic. 
Response R2 Lack-of-Fit (p-value) 
Drug Release after 0.5 hours 0.89 0.302 
Drug Entrapment Efficiency 0.82 0.417 
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6.3.6 Main Effects on the Responses  
The main effect indicates the influence of a single factor on a dependent variable averaged across 
the levels of the other factors.  Figure 6.7a and 6.7b are typical main effects plots. 
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Figure 6.7: (a) Main effects plots (data means) for Drug Entrapment (%), and (b) % Drug release 
at 0.5 hours. 
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(b) 
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As observed in Figure 6.7a, the quantity of nicotine incorporated within the microparticles 
increased with the concentration of PLGA incorporated within its matrix. This may be attributed to 
the fact that PLGA may impart greater strength around the incorporating matrix and hence 
allowing for more drug to be entrapped. Stirring time demonstrated an inverse relationship with the 
entrapment ability and may be attributed to the fragmentation of microparticles as they were 
exposed to prolonged agitation (see Figure 6.2a). The concentration of emulsifying agent, Span 80, 
did not appear to show any particular or well-defined trend. However it was observed that 
entrapment was greatest (25%) at the highest concentration of Span 80 used, i.e. 2%w/v. This may 
be due to reduced interfacial tension between the external solution system and the periphery of the 
microparticles. 
 
From Figure 6.7b, it was observed that drug release was as expected. Faster release was observed 
from microparticles that possessed a predominately PLA component in the incorporating material. 
As stated previously the comparatively more fragile nature imparted into the incorporating matrix 
by the presence of a greater amount of PLA allowed for more rapid release of nicotine. 
 
The central limit value of each factor (Polymer type – 2 [PLA-PLGA combination], Stirring time – 
7.5 hours and Span 80 concentration – 1.25%w/v) produced a focal point for significant changes 
(p<0.05) in the drug entrapment and drug release behaviour.     
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6.3.7 Response Surface Behaviour of Microparticulate System  
Surface plots demonstrating the most significant changes for each response are depicted in Figure 
6.8a and 6.8b. 
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Figure 6.8: Response Surface Plots for (a) Drug encapsulation vs. Polymer type and [Span 80]; 
and (b) Drug release in 0.5 hours vs. Stirring time (hours) and Polymer type (1 – PLA; 2 – PLA 
and PLGA and 3 – PLGA). 
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Figure 6.8a indicated that as the concentration of PLGA was increased, the drug entrapment also 
increased. The concentration of Span 80 in the presence of a changing polymer composition did 
not affect the entrapment ability of the microparticles. 
 
Figure 6.8b indicated that a decrease in the stirring time increased drug release. This may be 
attributed to possible clumping of microparticles, the aggregates of which attracted drug to the 
surface, due to inadequate stirring.    
 
6.3.8 Double-Entrapment of PLA-PLGA Microparticles within an Alginate-Pectinate 
Platform  
From the above, we have validated the need for re-entrapment of the microparticles to ensure that 
drug release can be significantly reduced to a rate that can be extended over a period of at least one 
month and to ensure that PD patients do not need to be implanted on a continuous basis, as this 
would negate patient compliance. To double-incorporate we needed to select a polymer that could 
attain this objective and interact favourably with the drug-PLGA matrix. To ensure this, a 
crosslinking agent was required to allow for the formation of bonds between the two polymers to 
form stable polyspheric structures. 
 
The two polymers selected as the re-incorporating agents were the polyanionic polymers pectin 
and sodium alginate. The two polymers, when combined, are thought to interact through a 
combination of hydrogen bonding, Van der Waals forces and a significant effect is played by the 
crosslinking agent in the entire process. Both polymers have been extensively studied for their 
ability to form drug delivery systems that are capable of providing controlled and prolonged drug 
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delivery (Liu and Krishnan, 1999; Pillay et al., 2002; Walkenström, 2003). In a previous study (Liu 
and Krishnan, 1999), the use of pectin in particular was shown to produce extremely robust 
microspheres, which were resistant to degradation in acidic pH and demonstrated modulated 
release profiles of the incorporated model drugs at an alkaline pH. In combination with alginate it 
also plays a significant role in influencing the density of the 3-dimensional network of the 
combined structure. On the other hand, the homogeneity of the microstructure is a direct function 
of the concentration of the alginate in the mixture (Walkenström, 2003). Studies have shown that a 
combination of these polymers leads to the development of a synergistic interaction between the 
two and the subsequent formation of a 3-dimensional structure that has the capacity to incorporate 
even insoluble materials and not significantly influenced by the surrounding medium/environment 
(Pillay and Fassihi, 1999). In the present study, it was found that there was a close relationship 
between the degree of crosslinking and the yield of crosslinked polyspheres (Table 6.7).  Zinc 
gluconate was selected as the crosslinking agent.  
 
6.3.9 Yield of Crosslinked Polyspheres 
The degree of crosslinking (η) was approximated using Equation 6.2, 
 
η ≈ (Experimental polymer yield) – (Theoretical polymer yield)  x 100 
(Theoretical polymer yield) 
 
Equation 6.2 
 
Where η is the comparative degree of crosslinking between the polymer and zinc ions. 
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Table 6.7: Responses obtained for re-incorporated microparticles. 
Crosslinked 
Polyspheric 
Matrices 
Polysphere Yield 
(mg) 
Drug Entrapment 
Efficiency (%) 
Comparative Degree 
of Crosslinking (%) 
Zinc-alginate 492.00 123.00 23.00 
Zinc-pectinate 572.50 143.13 43.13 
Zinc-alginate-
pectinate 
896.60 112.08 12.08 
 
The following characteristics of the double-incorporated polyspheres were observed: 
6.3.9.1 Zinc-Alginate Platform  
Discrete spherical polyspheres were formed. The theoretical weight of polymer expected was 
400mg; however an experimental value of 492.00mg was attained (Table 6.7).  This may be 
attributed to the surface adherence of salt from the crosslinking solution.  The close correlation 
between the theoretical and experimental value suggested that the degree of polymeric crosslinking 
was close to 100%.  
6.3.9.2 Zinc-Pectinate Platform  
As a double-incorporated polymer, on visual inspection they did not appear to be uniform, since 
aggregation and clumping of polyspheres was predominant. The polyspheres also formed 
significant ‘tails’ i.e. the polyspheres lost their spherical shape within the solution under the 
influence of stirring to form elongated/oblong structures. The increased weight (Table 6.7), can be 
attributed to the absorption of a large number of zinc ions within the pectinate platform. In 
comparison to zinc-alginate, it appears that the zinc-pectinate underwent a greater degree of 
crosslinking with zinc ions.  The greater the number of ions within the matrix, the greater the 
bridging between the chains and the said ions. This may decrease polymer solubility, 
disentanglement and relaxation, thus leading to decreased polymer mobility. 
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6.3.9.3 Combined Zinc-Alginate-Pectinate Platform  
Spherical polyspheres without tails were formed. The zinc-alginate-pectinate combination 
displayed the lowest degree of crosslinking compared to the other polymer types (Table 6.7). This 
may be attributed to the fact that a larger concentration of polymer, without a comparatively higher 
concentration of crosslinking agent was employed. Figure 6.9 is a typical scan of a zinc-alginate 
polysphere, which is incorporated with PLA-PLGA microparticles.  
 
 
Figure 6.9: High resolution scan of PLA-PLGA microparticles double-incorporated within a zinc-
alginate polysphere. 
 
6.3.10 Evaluation of Drug Release from Polyspheres  
It has been previously observed that significant sequestration occurs between the zinc ions, 
polymeric matrix and phosphate ions within the buffer solution (Pillay et al., 1999). This was once 
again observed, which led to the development of turbid solution due to the precipitation of zinc 
Microparticles 
Polysphere 
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phosphate within the dissolution medium. Figure 6.10 depicts the release profiles obtained from 
the three crosslinked polyionic systems.     
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Figure 6.10: Drug release studies of double-encapsulated microparticles from multiparticulate 
polyspheres. (Insert clearly shows the second phase of drug release). 
 
In all three cases it was noted that a high initial burst effect was obtained, followed by a plateau 
after a 2 hour period. The second phase of drug release appeared to occur from 6 hours onwards. 
The addition of pectin into the matrix appeared to significantly reduce drug release in comparison 
to the zinc-alginate system. 
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6.4 Concluding Remarks 
The need for double entrapment of PLA-PLGA microparticles is warranted in order to allow for 
the development of a formulation that demonstrates prolonged and controlled release. It was 
concluded that zinc-pectinate polyspheres were optimal for re-entrapment. The zinc-pectinate 
platform had a significantly greater degree of crosslinking (43.125%) leading to greater drug 
entrapment and slower drug release, thus explaining the attenuated burst effect as a result of 
surface drug followed by slower drug release (Figure 6.10).  Zinc-alginate-pectinate polyspheres 
did not appear to offer any significant advantage over zinc-pectinate polyspheres with respect to 
drug release and in fact possessed a smaller capacity to re-incorporate the PLA-PLGA 
microparticles. 
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Chapter 7  
Conclusions and Recommendations 
 
7.1 Conclusions 
According to a recent study conducted by Dorsey et al (2007) the number of patients afflicted with 
PD worldwide in 2005 was approximately 4.1 million. It is projected that as a result of increased 
average life expectancy the number of individuals affected with this chronic progressive and 
severely debilitating disease will double by 2030 (Dorsey et al., 2007). 
 
The present study developed a crosslinked multiple-unit multi-polymeric drug delivery device to 
deliver the model neuroprotectant nicotine with potential for implantation into the substantia nigra 
pars compacta to provide site-specific drug delivery provided zero-order prolonged release of the 
drug over a period of 1-2 months for the management of PD. This was achieved through the 
formulation of a novel reinforced ionotropically crosslinked reinforced alginate gelispheres which 
were compressed into release-rate modulating polymeric discs. This study has enabled the 
establishment of the elucidation of factors which influence the ability reinforced polymeric systems 
to entrap drug (drug entrapment efficiency), modulate drug release and induce changes in the 
physicomechanical properties and viscoelastic behaviour of the novel polymeric device following 
exposure to simulated CSF. Extensive tests including textural analyses, enthalpic studies and 
qualitative analyses through the use of FTIR enabled deductions regarding molecular interactions 
and configuration to correlate drug release studies. This study indicated that the reinforced system 
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far exceeds existing crosslinked polysaccharide systems of this nature with respect to its erosional 
and degradation behaviour. Furthermore, the fact that drug release of a low molecular weight and 
extremely hydrophilic model drug such as the model neuroprotectant, nicotine could be attenuated 
in the observed manner indicated the versatile platform that the device represents in terms of drug 
delivery. 
 
A comprehensive investigation of the influence of the physicomechanical properties of various 
alginates crosslinked with various combinations of the three crosslinking agents, namely, zinc, 
calcium and barium revealed their influence on its erosional and textural properties following 
hydration. Overall textural analysis of the crosslinked gelisphere matrices indicated that the ratio of 
the constituent monomers of alginate guluronic (G) and mannuronic (M) acid had a profound 
influence on the nature of the crosslinked gelispheres generated. The divalent cations employed to 
crosslink alginate during the study demonstrated varying affinity to the monomers, which 
consequently impacted on the density and erosional behaviour of the matrix. Barium generated 
densely compact polymeric crosslinked matrices, while zinc-crosslinked gelispheres possessed 
porous networks.  In terms of matrix erosion it was observed that zinc-crosslinked gelispheres 
demonstrated the most rapid rates of erosion due to the presence of porous matrices which 
permitted easier diffusion of water molecules into the polymeric network. Calcium-crosslinked 
gelispheres remained most intact over time following hydration.  
 
Statistical optimisation of hydroxyethylcellulose (HEC) and polyacrylic acid (PAA) reinforced 
crosslinked alginate gelispheres indicated the following: 
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 While all formulations demonstrated first-order drug release kinetics, it was observed that 
high alginate and high HEC formulations attenuated the burst effect.  
 High drug entrapment efficiencies (DEE) were observed with formulations with a high 
alginate and high HEC component. Formulations composed of high alginate and high HEC 
concentration and crosslinked with both crosslinking ions and high PAA concentrations 
demonstrated high DEE and slow drug release with a minimal burst effect.  
 Textural analysis indicated that the alginate and Ba2+ concentrations had the most 
significant impact on the formation of compact and robust gelispheres.  
 Finally it was observed that post-curing exposure to dilute HCl significantly attenuated 
matrix swelling and degradation as a result of precipitation of alginic acid within the 
crosslinked matrix. 
 
Alternative approaches investigated the use of PLGA coatings over compressed polymeric 
matrices incorporating reinforced gelispheres with high drug-loads and succeeded in sustaining 
zero-order drug for 21 days.  It was concluded that: 
 The presence of hydrophobic PLGA mediates drug release kinetics through matrix erosion, 
rather than polymeric relaxation.    
 The presence of hydrogels such as HPMC and PEO in the external matrix induced drug 
release to be mediated through polymer relaxation on the movement of molecules in the 
matrix. 
 
Formulation of nicotine-loaded PLA-PLGA microparticles incorporated into zinc-crosslinked-
pectinate gelispheres through double-entrapment attained prolonged and sustained release. The 
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factors which influenced drug release from the microparticulate system were optimised to establish 
that a combination of PLA and PLGA generated reinforced microparticles demonstrated high DEE 
and slower drug release. Furthermore it was concluded that employing exessive stirring times 
during formulation resulted in ruptured microparticles.  
 
The primary goal of this study conducted was to develop a reinforced biopolymeric drug delivery 
system which has the capacity to provide prolonged release of neuroprotective agents through ideal 
zero-order kinetics in a site-specific manner to the brain.  The study aimed to optimise PD patient 
therapy with respect to compliance and therapeutic efficacy. Extremely promising results were 
observed from the developed drug delivery systems investigated during this study. Formulation of 
compressed PLGA discs incorporating nicotine-loaded crosslinked alginate gelispheres reinforced 
with a combination of polymers (HEC and PAA) and crosslinked agents, namely barium and 
calcium succeeded in achieving zero-order release kinetics for 50 days.  
 
7.2 Recommendations  
The many neuroprotective agents investigated offer exciting opportunities for the development of 
future treatments. The challenge with many of these agents lies in the development of similar or 
modified versions that are both, more selective and potent. Furthermore, the development of drug 
delivery systems that can effectively deliver these molecules through site-specific mechanisms is 
vital to optimize their use.  
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The National Institute of Neurological Disorders and Stroke (NINDS) at the National Institute of 
Health (NIH) in the United States of America has created the Neuroprotection Exploratory Trials 
in PD (NET-PD), a large scale clinical trial network designed to assess potential neuroprotective 
agents for use in PD. Of the several compounds that were initially identified by scientists and 
clinicians in government, academia and industry for evaluation but only a few were promising 
enough to qualify for further study in neuroprotection clinical trials. According to an update on the 
investigations conducted by the Committee to Identify Neuroprotective Agents for Parkinson’s 
disease or (CINAPS) to identify suitable potential neuroprotective agents in treating PD in 
February 2005, four compounds, namely, creatine, coenzyme Q10, minocycline and GM-1 
ganglioside were chosen to evaluate in larger, Phase III Clinical Trials.  
 
The developed devices offer a unique platform to deliver a range of the aforementioned 
neuroprotective agents. Since most of these agents possess higher molecular weights and decreased 
propensity to become soluble in aqueous media (such as physiological fluid or CSF), it is 
postulated that drug release would be further attenuated and demonstrate release kinetics which are 
further prolonged (as opposed to the studied nicotine-loaded systems). Further studies employing 
neuroactives with larger molecular weights and lower hydrophilicity (than the model drug, 
nicotine) should be conducted to confirm and establish the versatility and efficacy of the device in 
providing prolonged zero-order release. 
 
Due to the fact that the device employs simple and mild formulation conditions, the multi-
polymeric multi-unit systems developed provide a versatile means of adapting the developed 
system not only for alternative neuroprotectant agents, but could also be expanded to serve as a 
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means to deliver other bioactives such as genes, cells and even peptides. Studies employing some 
of the aforementioned bioactives should be performed to establish their viability following 
formulation, in vitro and in vivo analyses.   
 
The geometry of the gelispheres developed during the study is significantly conducive towards 
drug release. This is due to the fact that spherical particles have the largest surface area available 
for interaction with physiological fluid. Thus it is proposed that the development of reinforced 
crosslinked polymeric particles with geometry which is less conducive towards drug release be 
developed.  
 
It is also proposed that formulating of nano- or microparticulate barium-calcium-HEC-PAA 
reinforced crosslinked alginate gelispheres such as those developed from the optimised systems be 
conducted.  This can be achieved through the use of processes such as ionotropic pre-gelation. In 
vitro analyses would enable a comparison of drug release kinetics. It is postulated that drug release 
may occur more rapidly due to the fact that such particles would provide increased surface areas 
available for surrounding physiological fluids to interact with. However, it is more feasible to 
incorporate such particles into external compressed polymeric matrices (discs). Furthermore, it 
would enable the formulation of discs with smaller dimensions, which would be more suitable for 
implantation.  
 
Due to significant developments in the arena of PD genetics and cell biology, recent studies have 
indicated an explosive development of improved animal models of PD. In addition the creation of 
genetic animal models based on genes implicated in PD, investigators have also employed 
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environmental toxins in novel ways to produce more chronic and gradually progressive models of 
PD. It is proposed that further in vivo studies employing suitable animal models be conducted to 
establish the viability of the proposed devices. Ideally, the conditions for drug release in vivo, in 
the living brain tissue, need to be simulated. Fundamental aspects to be addressed include an 
appropriate replication of cerebrospinal fluid (CSF) in terms of pH and osmotic pressure, as well as 
the degree of agitation and temperature. The overall mass transport mechanisms on a physical and 
chemical into living brain tissue are not yet fully understood. In addition to this due to the complex 
morphology of the brain, range of processes can be involved in the transport of the drug following 
its released from the dosage form to its target site (brain). To date no standardised animal models 
exist for the evaluation of drug delivery systems which provide site-specific delivery to the brain, 
CNS or for the delivery of pharmaceutical agents and devices for PD. It is proposed therefore that 
further research be conducted to establish such a system to standardise and regulate in vivo studies 
conducted for the diseases and develop models which can serve as a more robust reflection of the 
disease in human subjects, to establish meaningful in vitro–in vivo correlations. 
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